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ABSTRACT
Proteins are capable of an astounding array of functions using only the 20
canonical amino acids; however, the ability to add new functional groups to the
genetic code through the utilization of unnatural amino acids (UAAs) has greatly
expanded our ability to study and manipulate proteins. By expanding the diversity
of functional groups within proteins, a wide variety of applications in industry as
well as in fields such as diagnostics, biochemistry, and materials science are now
possible. These applications have further been expanded through the
development and optimization of bioorthogonal reactions which can occur under
physiological conditions with a high degree of specificity, allowing modulation of
the structure and function of proteins within their natural state. Several
applications of UAA technology involving bioorthogonal reactions will be explored
in this thesis. Optimization of a previously developed bioorthogonal Glaser-Hay
reaction between a protein and a fluorophore will be discussed. A further
application of the Glaser-Hay reaction involving natural product synthesis will
also be explored. The utilization of UAA technology to form trivalent conjugates
containing multiple functionalities will be described. Furthermore, the
development and optimization of organic reactions leading to the formation of
trivalent structures will be explored with the intention of translating these
reactions to biological systems. The ability to site-specifically immobilize a
hyperthermophilic carboxylesterase enzyme onto a stabilizing resin will also be
discussed and the benefits of protein immobilization will be demonstrated.
Finally, the synthesis and development of novel TMS and aldehyde UAAs will be
described and their applications will be explored. The applications highlighted in
each chapter demonstrate some of the numerous possibilities that can be
explored through modulation of the building blocks of proteins.
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Chapter 1: Introduction
Proteins are an essential part of living organisms’ ability to carry out
routine functions required for their survival and proper function. They are found in
all living organisms from unicellular organisms to plants and animals. 1 Proteins
are capable of performing countless biological functions including converting light
energy to chemical energy in photosynthesis, serving as a means to store and
transport molecules such as oxygen throughout the body, and providing a
mechanism to combat disease.1 In addition, proteins serve a vital role as
catalysts, allowing chemical reactions to occur at substantially higher rates,
making them feasible under the mild conditions required for most biological
reactions.2 This ability makes proteins valuable not only from a metabolic
standpoint, but also adds to their industrial value. Consequently, much of current
research in this field is centered around developing new ways to harness the
power of proteins for use in therapeutic, diagnostic, and industrial purposes. 3 An
increased understanding of the structure and function of these biomolecules has
allowed for significant development in these areas. This knowledge has also
provided researchers with the tools to develop methods for manipulating proteins
to serve novel functions using their own biological machinery. 3 As a result,
proteins are now able to function in ways previously thought impossible, allowing
for exciting advances in several fields including medicinal chemistry, cell biology,
and materials science.4 The foundation of this research is the ability to modify the
basic building blocks of proteins.3
1

I. The Building Blocks of Proteins
While proteins vary greatly in their structure function, they are unified in
that they all share the same basic building
blocks, amino acids. Proteins are comprised of
linear

chains

of

amino

acids

known

as

polypeptides, with some proteins containing
multiple chains of polypeptides.2 It is the
unique

sequence

of

amino

acids

that

Figure 1.1: The general structure of
an amino acid (in zwitterionic form).

determines a protein’s size, shape, and function.1,2 Αmino acids consist of an αcarbon as the central atom (Figure 1.1).2 Three important components surround

Figure 1.2: The 20 canonical amino acids.5

2

the central carbon: an amino group, a carboxylic acid group, and an R group
(side chain).2 As a result, all amino acids, with the exception of glycine, are chiral,
meaning that they are present as both L and D stereoisomers; however, only the
L isomers are found in proteins.2 Amino acids are differentiated by their unique
side chains. There are 20 amino acids which occur naturally in living organisms.
Each of these 20 amino acids varies in size, shape, reactivity, hydrophobicity,
and hydrogen bond capability allowing them to be grouped in several different
manners (Figure 1.2).2 Depending on the pH of the surrounding environment,
certain amino acids may become charged, based on their acidic or basic
character, while others contain biologically unique elements, such as sulfur,
allowing them to form covalent bonds.2 Typically proteins are formed by chains
containing an average of 50 to 2000 amino acid residues. 2
Amino acids form linear polymers through the creation of peptide bonds
between the amine group of one amino acid and the carboxyl group of the
neighboring amino acid, which is accompanied by the loss of water (Figure 1.3). 2
Peptide

bonds

have

several

properties that contribute to protein
stability

including

resistance

to

hydrolysis, a planar shape owing to
the double bond character of the CN bond, the presence of both a
Figure 1.3: The formation of a peptide bond (new
bond shown in red).

hydrogen bond donor (NH) and a
hydrogen bond acceptor (CO), and

3

finally, their lack of charge, allowing for the formation of tightly packed globular
protein structures.2
Protein structure is divided into four levels; however, some proteins only
contain the first three levels. A protein’s primary structure is defined by the
specific linear arrangement and sequence of the 20 amino acids. 2 The secondary
structure of a protein is determined by structures that form as a result of
hydrogen bonding between the backbone atoms. There are two primary
elements of secondary structure: the alpha helix and beta sheet. The α-helix is
rod-shaped and is formed when the carboxyl group of each amino acid in the
chain forms a hydrogen bond with the amino group on the amino acid four
residues down the chain.2 β-sheets are comprised of multiple segments of
polypeptide chains that line up next to each other and form hydrogen bonds
between the NH and CO groups.2 β-sheets can either be parallel or antiparallel.
Proteins may contain one, both, or neither of these secondary structures.
Secondary structure is also characterized by loops and turns. The R-groups of
amino acids play a key role in determining the tertiary level of structure, the
protein’s three-dimensional asymmetric structure.2 Several types of interactions
determine the folding patterns and overall shape of a protein. Hydrophobic
interactions

between

non-polar

amino

acids

such

as

alanine,

valine,

phenylalanine, leucine, isoleucine, methionine, and proline cluster into the center
of a protein away from water leaving the polar, hydrophilic amino acids on the
exterior surface.2 Polar R-groups can form hydrogen bonds or dipole
interactions.2 Ionic interactions can occur between R-groups with opposite
4

charges while R-groups with the same charge will repel one another. 2 Cysteines,
which contain sulfur, form a strong covalent bond known as a disulfide bond. 2
Proteins which contain multiple polypeptide chains linked together possess
quaternary structure. Quaternary structure is characterized by the same
interactions as in tertiary structure.2 Environmental factors such as temperature
and pH must be maintained in order to ensure proper protein folding. 2 The
identity of the R-group of an amino acid plays a significant role in determining the
structure and function of a protein. Further manipulating these R-groups can lead
to proteins with novel structures and functions.3
II. The Central Dogma of Molecular Biology
All the information required to make a functional protein is stored in an
organism’s genetic material. The “central dogma” of molecular biology, a term
coined by Francis Crick in 1957,
describes the flow of information
from

DNA

to

protein.1

The

central dogma describes that the
information found in DNA is

Figure 1.4: The central dogma of molecular biology.6

used to make RNA, which is then used to make proteins (Figure 1.4). 1 DNA is a
double stranded helix composed of repeating units called nucleotides. Each
nucleotide is composed of the sugar deoxyribose, a phosphate, and one of four
nitrogenous bases, adenine (A), thymine (T), guanine (G), or cytosine (C). 1 DNA
is composed of segments called genes, which are expressed to make functional
products for cells. Genes primarily encode the information needed to make
5

polypeptides; however, they can also be used to construct certain types of RNA,
such as transfer RNA (tRNA) or ribosomal RNA (rRNA), both of which are used
in the process of polypeptide synthesis.1 RNA resembles DNA; however, RNA
contains the sugar ribose and the nitrogenous base thymine is replaced with
uracil (U).1 Gene expression occurs in two sequential steps, transcription and
translation, which occur through slightly different mechanisms in prokaryotes and
eukaryotes.
Transcription is the first step of gene expression and involves the
conversion of the information in DNA into messenger RNA (mRNA). The process
involves

the

binding

of

RNA

polymerase and the transcription
factors to a specific location on
DNA known as a promoter to
initiate transcription (Figure 1.5).1
In

bacteria,

RNA

polymerase

contains 5 subunits and one
Figure 1.5: An overview of the process of
prokaryotic transcription.7

transcription factor, σ.1 Binding of

the σ factor allows for specific binding of RNA polymerase and formation of a
closed structure. Eventually some domains of σ dissociate, forming an open
structure, which allows transcription to begin.1 In eukaryotes, there are multiple
types of RNA polymerase containing additional subunits as well as multiple
transcription factors.1 Transcription initiation is controlled by the specific binding
of each of these transcription factors to RNA polymerase. Once transcription has
6

been initiated, RNA polymerase unwinds the double-stranded DNA by breaking
hydrogen bonds between DNA nucleotides.1 A transcription bubble forms and
RNA polymerase adds complementary RNA nucleotides in the 5’ to 3’ direction. 1
The growing mRNA chain shares an identical sequence to one strand of DNA
known as the coding strand, with the exception that the nitrogenous base
thymine is replaced with uracil. The other strand of DNA serves as the template
strand, which provides the sequence for complementary bases to be added.1 In
bacteria, transcription is terminated by either a rho-dependent or rhoindependent mechanism. Rho-dependent termination involves the use of a
protein, rho, to form a stem-loop structure that terminates transcription by
causing the dissociation of RNA polymerase.1 In rho-independent termination,
the formation of the stem-loop structure is caused by terminator sequences.1
Eukaryotic termination is less understood. In prokaryotes, mRNA can be used
directly for polypeptide synthesis as the processes of transcription and translation
occur simultaneously within the nucleus.1 In eukaryotes, RNA must be processed
and certain portions called introns are removed to form mature mRNA. 1 The
mRNA is then exported out of the nucleus into the cytoplasm, where protein
synthesis occurs.
Translation involves the conversion of the information encoded in mRNA
into the amino acid sequence of a protein. Transfer RNA (tRNA) serves as the
link between mRNA and the amino sequence of a polypeptide (Figure 1.6).1
tRNA is a clover shaped adapter molecule. The structure of tRNA is specifically
suited to this role as it has two distinct ends, a 3’ end serving as the site of amino
7

acid

attachment

and

the

opposite

end

containing a three-nucleotide sequence known
as an anticodon. mRNA nucleotides are read in
the 5’ to 3’ direction in triplets of three
nucleotides known as codons. The anticodon of
the tRNA forms complementary base pairs with
the mRNA codons. Since there are 4 possible
nucleotides, there are a total of 64 possible
combinations of codon triplets (Figure 1.7).1 Of

Figure 1.6: The general secondary
structure of tRNA.8

these, 61 codons are recognized by tRNAs and used to signal for the
incorporation of an amino
acid.

Each

codon

is

specific only to one of the
20 amino acids.1 One of
the codons, AUG, which
codes for the amino acid
methionine, is recognized
as

the

codon.1

universal
The

start

remaining

three codons, UAA, UAG,
Figure 1.7: The codon table.9

and UGA in mRNA (or

TAA, TAG, and TGA in DNA), are known as “stop” codons, which signal the
termination of translation.1 These codons are also called ochre, amber, and opal,
8

respectively.9 The genetic code is degenerate, meaning that tRNAs specific for a
certain amino acid can respond to several different codon triplets which differ in
the third letter.1 In other words, the same amino acid may be encoded by several
different codon triplets.
Translation is a highly specific process, which can be attributed to the
ability of tRNAs to become “charged” with the correct amino acid so that it can be
placed in the appropriate
position

on

the

growing

peptide chain.1 Amino acids
are attached to tRNAs in a
two-step enzymatic process.
The key enzymes involved in
Figure 1.8: The two-step enzymatic process involved in
“charging” a tRNA with an amino acid.10

this process are known as

aminoacyl-tRNA synthetases (aaRSs). The first step involves binding of both an
amino acid and a molecule of ATP to the active site of the aminoacyl-tRNA
synthetase enzyme (Figure 1.8).1 At this stage, the amino acid becomes
adenylated through reaction with ATP leading to the addition of AMP to the
amino acid and the release of a pyrophosphate. 1 This creates a high energy
ester bond between the phosphoryl group of AMP and the carboxyl group. 1 The
next step involves the release of AMP and the transfer of the amino acid to the 3’
end of tRNA using either the 2’-OH or the 3’-OH depending on the class of
enzyme involved.1 Aminoacyl-tRNA synthetases specifically match an amino acid
with the tRNA containing the corresponding anticodon with a remarkably low
9

error rate, which is achieved through several means. One mechanism is through
specific contacts that occur between the enzymes and the amino acid and tRNA
substrates in their active site to ensure that the proper substrates are present. 1 In
addition, the enzymes possess editing pockets with specific shapes that are able
to accommodate specific amino acid side chains, giving them the ability to locate
and hydrolyze mismatched amino acids before and after transfer to tRNA. 1
Translation ultimately involves the formation of a chain of amino acids
connected by peptide bonds (Figure 1.9). The process takes place on ribosomes,
which are composed of a large (50S) and
small (30S) subunit in prokaryotes.1 The
small subunit of the ribosome contains
three binding sites for transfer RNAs
(tRNAs), the acceptor (A), peptidyl (P), and
exit (E).1 The A site serves as the site of
binding for amino acids, the P site contains
the growing polypeptide chain, and the E
site serves as the exit where “uncharged”
tRNAs leave the ribosome.1 Translation

Figure 1.9: The process of translation.11

itself can be divided into three major steps: initiation, elongation and termination.
mRNA contains a region at the 5’ end known as the untranslated region (UTR). 1
This region serves as the ribosome-binding site. It contains a site known as the
Shine-Dalgarno box in bacteria and the Kozak box in eukaryotes. 1 During the
initiation phase, an uncharged tRNA is charged with the amino acid methionine
10

by a methionyl aaRS.1 Several initiation factors bind to the small subunit of the
ribosome forming a preinitiation complex. This complex and the methioninecarrying tRNA bind at the ribosome binding site on the mRNA.1 The small subunit
then scans the mRNA until it reaches a start codon (AUG). Once the methioninecarrying tRNA has bound to the start codon, the large ribosomal subunit joins the
complex, causing the release of the initiation factors.1 The methionine-carrying
tRNA possesses the unique ability to bind to the P site, leaving the adjacent A
site empty.1 During the elongation stage, the ribosome translocates in the 5’ to 3’
direction on the mRNA using elongation factor G (EF-G).1 Using elongation
factors (EF-Tu and EF-Ts) and energy from GTP, a tRNA charged with the next
amino acid to be added to the polypeptide chains binds to the A site based off of
its anticodon sequence which is complementary to the codon sequence in the A
site.1 Once the tRNA has bound to the A site, GTP is cleaved to GDP and EF-Tu
is released.1 A peptide bond then forms between the two adjacent amino acids
by peptidyl transferase.1 Amino acids are added to the C-terminus of the growing
polypeptide chain. Once the peptide bond has formed, the tRNA in the P site
releases the amino acid chain into the A site. 1 The ribosome then translocates
and a new tRNA carrying the next amino acid to be added to the growing
polypeptide chain is brought into the now empty A site. 1 Simultaneously, the
“uncharged” tRNA from the P site moves into the E site, where it exits the
ribosome into the cytoplasm.1 The polypeptide chain held in the P site continues
to grow in length as the process continues. Termination occurs when one of the
three stop codons, which do not carry tRNAs, reaches the A site.1 Release
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factors enter the P site, initiating the hydrolysis of the polypeptide chain. The
ribosomal subunits then dissociate from each other as well as from the mRNA.
They are then recycled and used in subsequent cycles of translation.1 The
process of gene expression is both highly efficient and specific, making it of great
use to biochemists exploring UAA technology. Researchers have been able to
harness the biological tools utilized in the process of gene expression to
incorporate UAAs in proteins.
III. Expanding the Genetic Code
While proteins are able to carry out a remarkable number of functions
using the 20 canonical amino acids, proteins are often required to serve functions
beyond those afforded by the standard amino acids. In order to function, many
proteins

require

posttranslational

modifications

including

methylation,

phosphorylation, glycosylation, and sulfation or cofactors such as metal ions or
flavins.3 Classic attempts have been made to modify proteins using modifications
of the standard amino acids including the thiol group of cysteine and the primary
amine group of lysine.12 Novel methods for protein modification involving the Nterminus as well as metal-mediated transformations involving cysteine, lysine,
tyrosine, and tryptophan have been developed. 12 However, in most cases,
residue-specific modification is not possible unless the residue is engineered on
the protein’s surface.12 In addition, several issues may result from unwanted
dimerization and solubility.12 Researchers have also examined the impact of
altering the amino acid residue at a specific location by switching one amino acid
for one of the other 19 natural amino acids. 13 This method is limited; however as
12

very few substitutions are sterically or functionally equivalent.13 Despite these
drawbacks, characterization of the mutant proteins has allowed for a better
understanding of the processes of catalysis and recognition in biological
systems.13 As a result, researchers have shifted their attention toward the
development of non-standard amino acids. Several archaea and eubacteria have
previously been found to encode amino acids other than the canonical 20 amino
acids, giving them additional functions.3 This led to the discovery of the 21st and
22nd amino acids, selenocysteine and pyrrolysine.3 Both of these amino acids are
not encoded by the typical genetic code, but are instead encoded using stop
codons during the process of translation.3 The existence of these amino acids
underscores the appeal of using an organism’s own biological machinery to
provide additional functions beyond those provided by the 20 natural amino
acids.3 The development of organisms with expanded genetic codes such as
these, provides a variety of possibilities for developing proteins with novel
functions, opening the door for an exciting avenue of research.
The process of expanding the genetic code involves a combination of both
biological and chemical knowledge. Unnatural amino acids (UAAs) which
possess novel functional groups and structures that can participate in reactions
not permitted by the 20 canonical amino acids have been synthesized organically
or by the engineering new biosynthetic pathways within the organism of
interest.13 Chemists must ensure that these new amino acids are stable, nontoxic, and able to be efficiently transported into the cell. 14 In order to utilize these
new amino acids; however, a standard method for incorporating these novel
13

amino acids into proteins at
specific

sites

organism’s

using

own

the

biological

machinery was essential (Figure
1.10).13 Several methods have
been employed to incorporate
UAAs

into

proteins

including

chemical modification to solvent-

Figure 1.10: Incorporation of standard and unnatural
amino acids.15

exposed reactive side chains, the use of functional analogues of tRNAs, peptide
synthesis, and semisynthetic methods.13 Each of these methods are limited
either by non-selective incorporation of the UAA or size restrictions on the
protein.13 Researchers have found that the answer to developing a method with
greater efficiency and selectivity lies in the central dogma of molecular biology.
IV. Current Methodology for the Site-Specific Incorporation of UAAs
In order to explore the implications of UAA technology, researchers
needed to develop a method to express mutant proteins using a model organism
that provides speed, simplicity, and cost-efficiency for protein expression. E. coli
is commonly used for large-scale protein production as it has several advantages
over eukaryotic and mammalian protein expression methodologies, which are
more prone to contamination, require special growth media, and are genetically
more complex.15 In addition, E. coli is both cheaper and more susceptible to
genetic modification.15 E. coli grow and divide rapidly making the process of
expressing proteins and introducing genetic modifications highly efficient as they
14

undergo a period of exponential growth that is ideal for inducing protein
expression (Figure 1.11).15 E. coli
is limited in its therapeutic utility;
however, as it is unable to facilitate
post-translational
required

by

proteins

such

enzymes,

Figure 1.11: A typical E. coli growth curve.16

modifications

most

therapeutic

as

antibodies,

and

cytokines.15

Despite this limitation, the benefits of the E. coli protein expression system have
made it a promising test organism for research involving UAA incorporation.
As previously described, during translation amino acids are added in a
specific order to the growing polypeptide chain through the action of tRNAs,
which are “charged” with the correct amino acid by aaRSs.1 There are 61 codons
which direct the incorporation of a specific amino acid and three codons, TAA,
TAG, and TGA, serve as stop codons that signal the termination of translation. 1
In E. coli, the TAG codon is only used 7% of the time and is rarely used to signal
the termination of vital genes.15 Attempts were first made to develop orthogonal
aaRS/tRNA pairs in E. coli, meaning that they would react with each other but not
the endogenous translational machinery in the cell. 14 These attempts were
unsuccessful due to misaminoacylation of native tRNAs by the evolved aaRS.14
Instead, orthogonal pairs with distinct tRNA elements from other organisms were
tested.14 The first successful attempt was achieved using a tRNA and aaRS from
the archaea Methanococcus jannaschii to express a UAA-containing protein in E.
15

coli.14,17 Several considerations were needed when implementing this technique.
As described previously, the introduced translation machinery needed to be
orthogonal to the endogenous translational machinery to avoid cross-charging of
natural amino acids.14,15 Thus, the evolved tRNA could not be a substrate for E.
coli aaRSs nor could the evolved aaRS aminoacylate E. coli tRNA.14 In addition,
the tRNA and corresponding aaRS must selectively recognize the selected UAA
as opposed to a natural amino acid.14 High expression levels were achieved
utilizing this aaRS/tRNA pair and it was found that there is a lack of an editing
mechanism which would deacylate the UAA and replace it with the proper natural
amino acid, making this a promising technique for UAA incorporation in E. coli.14
Using the principles of the central dogma, researchers were able to successfully
utilize an exogenous aaRS/tRNA pair from M. jannaschii in order to incorporate
unnatural amino acids at TAG codons in E. coli.
In order to utilize an orthogonal aaRS/tRNA pair in E. coli, a series of
steps must be taken to ensure that the orthogonal tRNA is able to bind the
orthogonal aaRS and that the aaRS is able to aminoacylate the orthogonal tRNA
with the selected UAA.14,15,17,18 In order to perform these steps, a mutation on the
gene of interest is made in order to insert a TAG codon, which will serve as the
location for site-specific incorporation of the selected UAA if an orthogonal
aaRS/tRNA pair is successfully evolved.15,17 In cases, where the aaRS/tRNA pair
is successful, the cell is able to “read-though” the inserted TAG codon and
produce a functional protein by inserting the UAA at the location of the TAG
codon.15,17 This process has become known as amber suppression. 15 If the
16

orthogonal aaRS/tRNA pair is not successfully evolved, suppression of the TAG
codon will not occur and translation will stop at the location of the inserted stop
codon, yielding a non-functional, truncated protein.15,17 Various reporter genes
are used throughout the evolution of the orthogonal tRNA/aaRS pair to determine
whether or not orthogonality has been achieved.15,17
In order to alter the specificity of the M. jannaschii aaRS for the desired
UAA, a large library of greater than 108 active-site mutants is constructed, which
then undergoes a double-sieve selection (Figure 1.12).15,17 The first round of
selection

involves

the use of a mutated
aaRS

along

orthogonal

with
tRNA

from M. jannaschii
to screen for the
ability of aaRS to
Figure 1.12: Evolving an
orthogonal aaRS.15

aminoacylate tRNA

with either the UAA or an endogenous amino acid.15,17 In this step, an amber
mutation is placed at a permissive site on the chloramphenicol acetyltransferase
gene and cells are grown in the presence of both chloramphenicol and the
selected unnatural amino acid.15,17 The chloramphenicol acetyltransferase gene
is responsible for antibiotic resistance in E. coli; therefore, successful
incorporation of any amino acid (natural or unnatural) at the amber mutation site
will allow the gene to be expressed, conferring survival in the presence of
17

chloramphenicol.15,17 The survivors of this positive selection encode aaRS
mutants which can aminoacylate orthogonal tRNA with either an endogenous
amino acid or the desired UAA. The second selection step involves a negative
selection to eliminate mutants which aminoacylate endogenous amino acids. 15,17
This step involves the insertion of three TAG mutations into the barnase gene.
The barnase gene encodes a toxic protein that kills E. coli cells; therefore, cells
grown in the absence of UAA will survive in cases when the aaRS cannot
recognize the natural amino acids, resulting in truncated cytotoxic protein that
lacks function.15,17 As a result of the positive and negative selection process, only
those aaRSs which charge the tRNAs with the selected UAA remain.15,17 These
synthetases are then subjected to multiple rounds of positive and negative
selection, providing the most selective synthetases for that specific UAA. 15,17
In order to design an orthogonal tRNA, a suppressor tyrosine-tRNA from
M. jannaschii was randomly mutated in the anticodon loop. 18 Mutant tRNAs were
subject to negative selection by transforming them into E. coli cells containing the
toxic

barnase

gene

and

genetically
inserted amber
codons (Figure
1.13).18

Cells

that grew were
unable to read

Figure 1.13: Evolving an orthogonal tRNA.15

18

through the TAG codons and did not express the toxic barnase gene, meaning
these tRNAs could not bind endogenous synthetases. 18 In cases where no
growth occurred, the tRNA were then subject to positive selection. These tRNAs
were transformed into E. coli cells containing the evolved orthogonal aaRS as
well as a β-lactamase gene containing a genetically inserted amber codon. 18
These cells were grown in the presence of ampicillin; therefore, growth will only
occur in cases where the β-lactamase gene, which is responsible for ampicillin
resistance, is expressed.18 Cells that survive this round of positive selection
contain tRNAs that are aminoacylated by the mutated orthogonal aaRS. 18
With an orthogonal tRNA/aaRS pair in hand, the expression of a protein
containing the selected unnatural amino
acid through amber suppression is now
feasible (Figure 1.14).4,8 In this process, a
protein

plasmid

is

mutated

to

site-

specifically introduce a TAG codon, which
will

serve

as

the

site

for

future

incorporation of the selected UAA.4 This
mutated plasmid is transformed with
plasmids

containing

the

orthogonal

tRNA/aaRS genes into electrocompetent
E. coli cells.4 In a typical case, the protein
plasmid gene is controlled by a β-D-1-

Figure 1.14: Incorporation of a selected
UAA into green fluorescent protein
(GFP).4

thiogalactopyranoside (IPTG) promoter harboring an ampicillin resistance gene
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while the tRNA/aaRS genes are under the control of an arabinose promoter
harboring a chloramphenicol resistance gene.4 Growth in the presence of both
antibiotics, induction using IPTG and arabinose, and the addition of the selected
unnatural amino acid will allow for the “charging” of the orthogonal tRNA with the
desired UAA by the corresponding aaRS.4 The UAA will be inserted at a specific
site corresponding to the location of the genetically inserted TAG codon. 4 In this
manner, a full-length, functional protein harboring a site-specifically inserted UAA
can be produced. Glycosylated amino acids as well as those with novel chemical
and photochemical functionalities in addition to fluorescence, metal-binding, and
redox activity have been successfully incorporated using this methodology. 17 This
technique has allowed for the incorporation of over 100 novel amino acids into
bacteria, yeast, and mammalian cells.3
Ongoing research has led to numerous improvements in the techniques
used for UAA incorporation. New methods have been used to improve upon the
cumbersome selection process for designing orthogonal aaRS/tRNA pairs
previously described.15 One method involves the use of a single genetic
construct carrying the genes for both the aaRS and tRNA from M.
jannaschii along with a chloramphenicol resistance tag, allowing aaRS variants to
be selected in one step.15,19 The system utilizes a T7 RNA polymerase with an
amber codon and green fluorescent protein (GFP) reporter protein. 18 Only
mutants possessing orthogonal aaRS/tRNA pairs yielded protein. 19 Another
method utilizing a dual positive/negative selection system for the evolution of
aaRSs has been proposed.20 The system involved utilizes a chloramphenicol
20

acetyltransferase-uracil phosphoribosyltransferase (UPRT) fusion gene with an
amber codon in the chloramphenicol transferase segment. 20 UPRT is an enzyme
that converts 5-fluorouracil to 5-fluorouracil monophosphate, which inhibits
thymidylate synthase.15 This enzyme synthesizes thymidine monophosphate,
which is then phosphorylated to thymidine triphosphate for use DNA synthesis. 20
In the positive selection step, E. coli was grown in the presence of both
chloramphenicol and a UAA to test for amber supression.20 Negative selection
was then performed using 5-fluorouracil to determine whether or not DNA
synthesis is permitted.20 Additional research is focused on overcoming the
limitations imposed by amber codon suppression, such as low protein yields and
the fact that only one type UAA can be incorporated into proteins. 15 Low protein
yields can be attributed to the presence of amber-recognizing release factor
protein 1 (RF1), which is involved the termination of translation.15 RF1 competes
with tRNA during UAA incorporation and cannot be removed through knockout as
it encodes essential genes.15 Researchers have developed methods to overcome
this problem through the creation of an RF1 knockout strain that could be
complimented with the orthogonal tRNA plus seven essential genes on an
additional plasmid.21 An RF1-independent E. coli strain JX33, which utilized a
wild type RF2 and did not require additional genes has also been developed.22
The use of orthogonal aaRS and tRNA pairs which recognize four codons can be
used to incorporate multiple UAAs. This has been applied in the development of
an orthogonal ribosome, Ribo-X, which has increased the efficiency of UAA
incorporation as well as provided the ability to incorporate multiple UAAs.23,24
21

Recent advances have allowed for the development of synthetases with
improved yields and other import attributes. The pEVOL vector makes use of
both a constitutive and an arabinose inducible promoter to make two copies of
the M. jannaschii aaRS gene.15,25 As a result, a basal level of aaRS is always
present, which is then supplemented by induction of the second promoter. 25 The
use of this vector has provided protein expression levels as high as 100 mg/L.25
Further advances have been made though the development of the pUltra plasmid
system which can be used for single and multiple UAA incorporation. 15,26 The
pUltra system utilizes an amber M. jannaschii tyrosyl tRNA/aaRS pair as well as
an ochre M. barkeri pyrrolysyl tRNA/aaRS pair.26 It can be used in combination
with pEVOL synthetases as it contains a spectinomycin antibiotic resistance
marker.26 Expression levels as high as 30% of the level of wild type protein have
been reported using this system. Other methods have been developed to
eliminate the need for timely selection protocols when developing orthogonal
aaRS/tRNA pairs.27 During selection of an aaRS, there is no selective pressure
against other UAAs; therefore, it is possible that evolved aaRSs may recognize
multiple UAAs while remaining orthogonal to endogenous amino acids, a
phenomenon referred to as promiscuity.27 This promiscuity is not problematic as
growth media is typically only supplemented with one UAA during protein
expression.27 As a result of this promiscuity, one orthogonal aaRS/tRNA pair may
be used to incorporate several UAAs without the need for timely selection
protocols.27

For

example,

p-cyanophenylalanine

specific

aminoacyl-tRNA

synthetase (pCNF-RS) is capable of incorporating at least 18 different UAAs
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while remaining orthogonal to endogenous amino acids. 27 The continued
development and improvements in the technique for incorporating UAAs into
proteins with high specificity and efficiency has made UAA technology a
promising tool for use in a vast number of applications.
V. Applications of UAA Technology
The ability to modify proteins through the addition of novel functional
groups can lead to proteins with exciting physicochemical, biological, and
pharmacological properties.3 The ability to site-specifically incorporate UAAs has
allowed for vast improvements in the process of protein immobilization to be
made. Protein immobilization has several industrial and therapeutic benefits
including the use of immobilized enzymes in microarrays, imaging probes, and
biosensors.28 Immobilized proteins are stable in non-aqueous environments,
adding to their industrial utility and are also capable of being recycled, making
them economically beneficial.28 Current methodologies are limited by their lack of
specificity, which can lead to a reduction in protein activity. 28,29 The use of UAAs
has been shown to solve this specificity problem, allowing site-specific
immobilization of proteins onto solid supports.28 UAAs created by posttranslationally modifying cysteine have been used for the regio- and
chemoselective covalent immobilization of soluble proteins onto glass surfaces
through Click reactions and Staudinger ligations.29 Site-specific incorporation of
UAAs has been used to immobilize green fluorescent protein (GFP) onto a
sepharose resin in high yields with remarkable stability in the presence of several
organic solvents (Figure 1.15).28 In addition, oriented immobilization of the
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pathogenic DrrA protein has been achieved
through site-specific UAA incorporation and
has been used to analyze interactions with
its binding partner, Rab1.30 The ability to
site-specifically immobilize proteins is also of
value in developing protein biochips. Protein
biochips are a collection of miniaturized
spots which allow high-throughput protein
Figure 1.15: Site-specific
immobilization of GFP onto a solid
support resin.28

screenings of thousands of protein samples
through enzyme activity analysis.31 The

development of protein biochips has key implications in diagnostics, allowing
quick, reliable, and quantitative comparisons of the expression profiles of patients
and healthy individuals to be made.31 The ability to covalently immobilize proteins
in a uniform orientation that allows binding sites to be exposed to sample
solutions while maintaining high protein yield and activity is key to the
development of these biochips.28,31
Understanding complex cellular processes and reactions involving
proteins, such as those involved in the development and combat of certain
diseases, is crucial to the development of novel biomedical and therapeutic
applications.32,33 This understanding is highly dependent on the ability to
selectively label and modify proteins within their native environment through
highly specific chemical reactions.32 Examining proteins in their purified and
isolated forms limits the ability to understand their interactions with other
24

molecules within the body, such as biopolymers, ions, and metabolites. 32 GFP is
a commonly used reporter protein due to its fluorescence ability; however, its
large size may cause structural perturbation, negatively impacting the expression
and function of the protein of interest.32 In addition, GFP cannot be used to
visualize metabolites, glycans, lipids, or nucleic acids.32 Antibodies are commonly
used for binding specific epitopes of proteins for visualization purposes as well as
in drug delivery.32,34 Antibodies can be generated for any epitope, making them
useful for imaging and drug attachment purposes.32 Nevertheless, their large size
and the lack of selectivity in drug delivery methods has limited their use.32,34
Small molecule reporters, such as those with fluorescent properties, are a
promising method for labeling proteins; however, a means to specifically deliver
them to proteins was necessary.32 As a result, researchers have employed UAAs
to develop reactions for protein labeling and drug delivery using small molecules
that possess a high degree of specificity.
The

development

of

bioorthogonal

reactions

using

UAAs

has

revolutionized the ability to label proteins in their native context as well as to
selectively deliver drugs to specific targets.32-34 In this method a UAA containing
the desired nonnative chemical
reporter is sitespecifically
Figure 1.16: Examples of bioorthogonal reactions including protein
labeling using a bioorthogonal probe (a) and the addition/removal of a
protecting group (b).33
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incorporated into
the protein and

reacted with an exogenously delivered probe, forming a bioconjugate (Figure
1.16).4,32,33 Bioconjugates are defined as the association of a biomacromolecule,
such as a protein, DNA, or RNA, with a secondary molecule, such as labeled
probe, other biomacromolecule, or small molecule. 4 To be successful, these
reactions must occur efficiently in aqueous environments under physiological
conditions at a temperature near 37 °C and a pH near 7.2.4,32 The reaction must
be orthogonal, meaning that it does not cross-react with any endogenous
functionalities, so as not to interfere with natural cell processes. The reporter,
probe, and resulting bioconjugate should be metabolically stable and no harmful
byproducts should be produced. This technology has been used recently in the
development of antibody-drug conjugates for the targeting of cancer cells
presenting tumor-associated surface-markers by cytotoxic drugs.34 Bioorthogonal
reactions have been used in the creation of a bioluminescent assay for
interferon-γ, which is used to detect bacterial and viral infections, through
bioorthogonal conjugation of Gaussia luciferase with an anti-interferon-γ
antibody.35 Recently, a bioorthogonal tetrazine cycloaddition reaction has been
used in the site-specific glycoconjugation of a protein, which has important
biological and therapeutic applications.36
Organic chemists have devised several bioorthogonal conjugation
reactions between UAA-containing proteins and small molecules, which have
been used for a variety of purposes. Several UAAs containing a variety of
functional groups such as thioesters, acetylenes, aldehydes, ketones, azides,
and alkenes have been utilized.33 Aldehydes and ketones can react with
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hydrazides and alkoxyamides to make hydrazones and oximes. 33 Staudinger
ligations

involving

the

reduction

of

azide-containing

UAAs

with

triphenylphosphine have been utilized to form stable amide bonds. 33 Certain
phosphine reagents containing an acyl group attached to the phosphine group
with a cleavable linker can undergo “traceless Staudinger ligations” in which the
final bioconjugate does not contain the phosphine oxide moiety. 33 The ability to
incorporate UAAs containing terminal alkynes has allowed for the implementation
of biological Glaser-Hay reactions involving the coupling of two terminal alkynes. 4
In addition, azides can undergo [3+2] cycloadditions with alkynes to produce
triazoles.33 To avoid constraints imposed by temperature and pressure on yields,
copper (I) may be used as a catalyst in the copper catalyzed azide-alkyne
cycloaddition (CuAAC) reaction.33 Ring strain can also be introduced in the
strain-promoted alkyne-azide cycloaddition (SPAAC).33 Alkynes can also
undergo a [3+2] cycloaddition with nitrones known as the strain-promoted alkynenitrone cycloaddition (SPANC), which are up to 30 times faster than the SPAAC
reaction.37 Proteins containing 1,2-aminothiol moieties can undergo condensation
reactions with 2-cyanobenzothiazole (CBT).37 Photoinduced organic reactions
between tetrazole derivatives and terminal alkynes have also been explored. 33
These 1,3-dipolar cycloaddition reactions can be induced by UV light. 33 Efficient
protein bioconjugations can also occur using Diels-Alder reactions between a
tetrazine-containing compound and a strained alkene or alkyne group, such as
norbornenes (Nor), cyclopropenes (Cyp), bicyclononynes (BCN), or transcyclooctenes (TCO).32 Olefin metathesis involving alkenes can be used to
27

construct new carbon-carbon bonds. A final type reaction involves the use of
palladium catalysts such as the Suzuki-Miyaura cross-coupling reaction with
Pd(OAc)2(ADHP)2 and the Sonogashira cross-coupling reaction using an
aminopyrimidine–palladium(II) complex.32
A final application of UAA technology is the exploration and modification of
the structure and function in proteins. Proteins containing UAAs incorporated at
specific sites have been used in mechanistic and biophysical studies. 38 For
example UAAs have been used as NMR probes to locate the binding site of a
small molecule inhibitor and monitor changes in protein structure as a result of
inhibitor binding.38,39 IR and X-ray active UAAs have also proven useful in the
study of protein structure.38,40 Fluorescent UAAs can be incorporated on the
surface of proteins and viewed via fluorescence microscopy. 38,41 These can be
used to study protein interactions as well as folding and conformational
changes.41 Phage-based systems are being implemented to determine if there is
an evolutionary advantage to UAA incorporation.38 Protein activity can be
controlled using site-specific incorporation of caging groups on residues, such as
cysteine, tyrosine, and serine, that are key to protein function. 14,38,42 Non-invasive
light irradiation can then be used to restore protein function through removal of
the caging group.14,38,42 Redox-active UAAs can be used to probe and manipulate
electron transfer processes in proteins.43,44 The continued development and
incorporation of novel UAAs will further enhance the realm of possibilities for
exploring and manipulating protein structure and function, allowing the number of
applications possible using UAAs to continue to expand.
28
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Chapter 2: Optimization of the GlaserHay Bioconjugation Reaction
I. Introduction
With widespread applications in the fields of medicine, materials, and
pharmaceuticals, bioconjugate chemistry is a rapidly growing area of chemical
research. Bioconjugates are comprised of a biological macromolecule linked to a
second molecule, often a surface, probe, nanoparticle, or another biomolecule. 1,2
Protein bioconjugates, wherein at least one of the conjugate partners is a protein,
have been utilized to enhance drug delivery and cellular imaging through the use
of antibodies conjugated to cytotoxic drug molecules and luminescent quantum
dots, in addition to numerous other applications.3-9
The preparation of covalently-linked protein bioconjugates is often
accomplished through reaction of a protein’s native nucleophilic residues, such
as lysine, cysteine, and serine.10 However, through this method, bioconjugation
can occur at multiple residues within the protein, resulting in non-specific
conjugation at a varying number of positions.10,11 To overcome this lack of
selectivity, unnatural amino acids (UAAs) can be site-specifically introduced into
proteins via suppression of the amber stop codon (TAG) by an evolved
orthogonal amino acyl synthetase (aaRS)/tRNA pair.12-14 The incorporation of a
UAA bearing a chemical moiety not found within the twenty naturally occurring
amino acids not only provides a specific site for conjugation of the protein, but
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also allows access to several useful conjugation methods previously unavailable
for bioconjugation reactions involving proteins.15-16
The Glaser-Hay coupling of two terminal alkynes is among these nowaccessible protein bioconjugation reactions due to the preparation of a terminal
alkyne containing UAA, ppropargyloxyphenylalanine
(pPrF, 1).17 This coupling
reaction

affords

a

well-

defined, linear 1,3-diyne via
a copper (I) catalyst and
bidentate

nitrogenous

ligand (Figure 2.1), most
Figure 2.1: Glaser-Hay reactions. (A) Structure of alkynyl
amino acid pPrF incorporated into proteins. (B) General
Glaser-Hay reaction linking two terminal alkynes. (C) GlaserHay bioconjugation of a protein.

often

N,N,N′,N′-

tetramethylethylenediamine

(TMEDA, 2).18-21 Moreover, this generates a new carbon-carbon bond that is
highly stable and unreactive under typical physiological conditions. 18 Diynes and
other conjugated acetylenic structures generated from the Glaser-Hay coupling
reaction have many useful applications. Such diynes are the starting point for
many cycloaddition reactions yielding carbo- and heterocycles that display
interesting

biological,

optoelectronic,

and

photochemical

properties. 22-26

Additionally, the Glaser-Hay reaction can be utilized to generate diacetylenes
employed in crystal-forming polymerization reactions,27 or to prepare classes of
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macrocyclic compounds with diverse applications in supramolecular chemistry
and nanotechnology.28,29
II. Results and Discussion
Transferring the Glaser-Hay coupling to a biological setting for use in
bioconjugations necessitates relatively mild reaction conditions that are
compatible with physiological systems, namely a moderate temperature,
aqueous environment, and short reaction time. Several past experiments have
successfully employed the Glaser-Hay reaction on biologically relevant
molecules, though not necessarily under mild conditions. In 2015, oxidative
coupling of terminal alkynes was reported with the formation of peptoid dimers at
90 °C in DMSO, and again with macrocyclization of tetrapeptides at 60 °C using
Cu(OAc2) and NiCl2 catalysts.30,31
Our previous work demonstrated the first successful biological Glaser-Hay
coupling

in

a

full-length

protein

and

under

mild

reaction

conditions

(Figure 2.1C).32-34 With incorporation of pPrF into green fluorescent protein
(GFP), a protein-fluorophore bioconjugate was generated at 4 °C after 4 hours.
Despite having successfully employed the Glaser-Hay coupling in a biological
context, noticeable protein degradation after about 6 hours was observed. It has
been proposed that this degradation was potentially due to hydroxyl radicals
generated from the copper (II)-hydroxyl intermediate in the catalytic cycle of the
Glaser-Hay reaction, which is known to be deleterious to living systems. 19,35 This
protein oxidation was characterized by MS analysis, ultimately resulting in loss of
protein product (Figure 3.2). To avoid protein degradation, we became interested
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in developing means to
circumvent

the

production of harmful
radical

species

generating
internal

the

while
same

1,3-diyne

structure.

One

such

method

that

we

developed implemented
the Cadiot-Chodkiewicz
Figure 2.2: MS analysis of protein damage. A) pPrF-GFP when
subjected optimized conditions at pH 6.0 in the presence of
CuI/TMEDA. B) When reaction time of the pPrF-GFP is extended to
10 h at 30 oC, significant oxidative damage to the protein is
observed. C) Expanded MS of C, indicating +16 repeat units
resulting from protein oxidation.

coupling of a terminal
alkyne and halo-alkyne

to afford a protein-fluorophore bioconjugate.36 Because the Cadiot-Chodkiewicz
mechanism is thought to cycle between the copper (I) and copper (III) states
while avoiding the harmful copper (II) state, reaction times could be extended
with minimal protein degradation.37 Furthermore, under the Cadiot-Chodkiewicz
mechanism, we were able to reduce the amount of catalytic copper ten-fold from
that required by the Glaser-Hay mechanism and achieve satisfactory coupling.
While the Cadiot-Chodkiewicz coupling occurred with less protein degradation, it
did require additional synthetic steps to access bromo-alkyne amino acids or
brominated coupling partners. Because the terminal alkyne amino acid is
commercially available, and an orthogonal aaRS/tRNA pair has specifically been
evolved to incorporate it, the Glaser-Hay coupling is more easily accessible.
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Thus, we aimed to systematically optimize the traditional Glaser-Hay reaction to
increase coupling efficiency and preserve protein from degradation, allowing it to
find more widespread utility.
In order to further optimize the biological Glaser-Hay reaction, a 250 mL
expression of GFP harboring pPrF in position 151 was performed to ensure that
all reactions were conducted on the same protein batch (1.0 mg/mL) to remove
variability between expressions. With the pPrF-GFP in hand, a range of
experimental variables was examined in a systematic fashion when reacting the
mutant GFP with an Alexa Fluor-488 alkyne dye. Due to the production of
biologically deleterious Cu(II) in the catalytic cycle, we examined the addition of
both reducing agents and radical scavengers to the reaction as a mechanism to
mitigate the potential damage caused by the radicals initiated by the Cu(II)
species. Additionally, we examined the effects of a wide variety of copper
sources and ligands to further activate the copper center. The impact of reaction
temperature as well as buffers at varying pH was also investigated. Each variable
was independently varied based on the previously reported conditions, and
optimized conditions were then screened in combination to elucidate the best
Glaser-Hay bioconjugation conditions.
Initial studies examined the addition of reducing agents to the reaction to
reduce harmful Cu(II) back to the Cu(I) species. Based on their biological
compatibility,

β-mercaptoethanol,

tris(2-carboxyethyl)phosphine

(TCEP),

dithiothreitol (DTT), and nicotinamide adenine dinucleotide (NADH) were
selected for analysis. Glaser-Hay reactions were conducted with the pPrF-GFP
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and Alexa Fluor-488 alkyne in the presence of a reducing agent (500 mM),
TMEDA and CuI for 4 hours at 4 °C. Control reactions were also performed in the
absence of reducing agent, or in the absence of the CuI/TMEDA. After
purification and buffer exchange, the reactions were analyzed by SDS-PAGE for
protein degradation and coupling efficiency. Fluorescence intensity indicated the
effectiveness of the coupling reaction as the GFP is denatured and no longer
fluorescent, while the coupling to the fluorophore re-establishes a fluorescent
signal. Coomassie staining was also performed to indicate protein presence and
relative degradation. Unfortunately, no reducing agent afforded better coupling
conditions than the original conditions, and DTT dramatically inhibited efficient
coupling. Similar results were observed when radical scavengers were employed
including cysteine, oleic acid, and ascorbic acid. Ascorbic acid also hindered the
Glaser-Hay reaction from occurring and increased the level of protein
degradation.
Based on the literature, a variety of copper sources have been utilized in
the Glaser-Hay reaction; therefore, several of these copper sources were
investigated to determine if any
were more advantageous than the
previously reported copper iodide.
Reactions were performed using
copper(I) iodide, copper(I) chloride,
copper(II)chloride,

and

copper(II)

sulfate. Reactions were additionally

Figure 2.3: Effect of copper source on coupling.
Ratios indicate that the previously published
conditions (lane 1) are superior.
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performed using copper(II) chloride with nicotinamide adenine dinucleotide and
copper(II) sulfate with nicotinamide adenine dinucleotide to test whether a
copper(II) catalyst reduced to copper(I) would be advantageous for the reaction.
None of these copper sources were able to outperform the previously established
CuI, as determined by SDS-PAGE (Figure 2.3).
Literature studies involving the synthesis of diyne-containing peptide
macrocycles have suggested that the addition of a nickel-containing co-catalyst
may improve coupling efficiencies and increase reaction rates. 38 Therefore,
Ni(NO3)2•6H2O (500 mM, 5 µL) was added to the catalyst system in conjunction
with CuI. The addition of Ni(NO3)2•6H2O to the catalyst system was tested with
each of the previously described copper sources and was compared to a control
reaction which contained no added Ni(NO3)2•6H2O. Unfortunately, the addition of
Ni(NO3)2•6H2O caused complete degradation of protein for each copper source
tested. As a result, additional studies involving the addition Ni(NO 3)2•6H2O with
various radical scavengers and reducing agents were not warranted.
The next factor to be investigated was the effect of the ligand on the
Glaser-Hay

bioconjugation.

attempts

with

Early

nitrogenous

monodentate ligands (TEA, pyrrolidine,
etc.)

did

coupling,

not
and

lead
a

to

substantial

more

thorough

investigation of bidentate nitrogenous
ligands

followed

(Figure

2.4).

Figure 2.4: Structures of ligands employed in
Glaser-Hay bioconjugation optimization.

41

Ligands 3 and 4 were selected to investigate the optimal chelation ring size,
and 5, 6, and 7 were employed to probe the substitution of the nitrogen atom.
Finally, 8 and 9 were selected to alter the electronic environment of the nitrogen
atoms, while simultaneously testing
the necessity of chelation. Each
ligand was tested in the presence
and absence of a reducing agent,
tris(2-carboxyethyl)phosphine
Figure 2.5: Comparison of dipyridyl nitrogenous
ligands. Ratios indicate that 8 and 10 result in
increased coupling over the previously published
conditions (lane 1), though poor solubility of 10
resulted in protein degradation and non-optimal
coupling.

or

nicotinamide adenine dinucleotide,
to determine whether or not the
combination of a different ligand and

a copper(II) catalyst reduced to copper(I) would provide an improvement off of
the

previously

published

conditions. These experiments
indicated that both the 2,2bipyridyl ligand (8) and the
diaminopropane ligand (3), to a
much lesser extent, were as
good as or better than 2, with 4fold and 0.8–1.2-fold increases

Figure 2.6: Comparison of dipyridyl nitrogenous ligands,
with and without addition of reducing agent TCEP.
Results indicate that in the absence of TCEP, ligands 8
and 10 show increased coupling over the previously
published conditions (lane 2). Furthermore, by fully
solubilizing ligand 10, coupling is enhanced and
degradation is reduced.

in coupling efficiency, respectively. Because the results using 8 were dramatically
better than those using 3, only 8 was tested in future experiments. Despite the
fact that coupling efficiencies were drastically improved using 8, it had limited
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solubility in aqueous media, so the commercially available 10 was explored to
overcome these issues (Figure 2.5). After overcoming initial solubility
issues, 10 afforded a coupling efficiency nearly 7 times greater than that of 2,
also surpassing the coupling efficiencies achieved using the less soluble 8. It was
hypothesized that the combination of the electronic effects of the bipyridyl ligand
coupled with the rigidity of the ligand aided in the chelation and activation of the
copper center to improve the reaction.
After elucidating that ligand 10 resulted in superior coupling, we explored
whether other copper sources, radical scavengers, or reducing agents would
further increase the coupling efficiency with these ligands. Varying these other
conditions did not afford enhanced results, as copper(I) iodide with no added
agents remained the best condition using either 2 or 10 (Figure 2.6).
The next variable examined was the effect of solution pH on the reaction.
GFP was buffer exchanged into PBS at pH 6.0, pH 7.4, pH 8.0, and pH 9.0. Both
the original ligand (2) and 10 were used for Glaser-Hay couplings in each pH
solution. Interestingly, reactions employing 2 exhibited higher coupling ratios at

Figure 2.7: Effect of pH with ligand 2 on
coupling. Results indicate that optimal coupling
occurs at pH 6 when ligand 2 is used, which
represents an increase over the previously
published conditions (lane 2).

Figure 2.8: Effect of pH with ligand 10 on coupling.
Results indicate that optimal coupling occurs at pH
8.0 when ligand 10 is used. Ligand 10 at all pH
points represents an increase in coupling over
previously published conditions (lane 1).
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pH 6.0, and reactions using 10 had the highest Glaser-Hay coupling at pH 8.0
(Figures 2.7 and 2.8). It was hypothesized that 10 functioned best at pH 8.0 due
to solubility factors. Because the solubility of 10 was increased upon the addition
of base, a greater amount was available for reaction at higher pH values as the
ligand was more completely dissolved. At a pH of 9.0; however, the pH was
increased to the point where protein degradation became significant and coupling
efficiencies were reduced. Less degradation of protein was observed under both
of these new conditions, as observed by comparable amounts of protein on the
gels as the control reactions, and minimized oxidative damage by MS.
Due to the decreased oxidative damage, these conditions were then
employed at different temperatures to see if coupling ratios could be increased
further, as the previously published conditions were performed at 4 °C to
minimize

degradation.

Identical

reactions with both ligands were
conducted at 4, 22, 30, and 37 °C for
4 hours. After quantitation by SDSPAGE, the most effective coupling
Figure 2.9: Effect of reaction temperature on
coupling. Results indicate that room
temperature (22°C, lane 2) affords an
increase in coupling over the previously
published conditions (lane 1). The same trend
was observed when 10 was used.

condition with the least amount of
protein degradation was found to be
room temperature (22 °C) for both

ligands (Figure 2.9). As a final optimization, the two ligands were employed at
their appropriate pH and at room temperature over a timespan of 24 hours. The
results indicate that for both conditions, protein degradation begins to become a
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factor after approximately 8 hours, leading to a subsequent decrease in GlaserHay bioconjugations. The timecourse experiments also reveal that the
conjugations employing 10 result in less overall protein degradation relative to
conditions using 2 (Figure 2.10). This decreased degradation allows for
increased reaction times, which facilitates higher levels of coupling. In the case
of 2, lowering the pH to 6.0 appears to accelerate the reaction rate, improving
coupling prior to degradation.

Fig. 2.10: Timecourse data for optimized Glaser-Hay bioconjugations demonstrating coupling
efficiency (lines) in combination with protein degradation (bars). (A) Timecourse of the GlaserHay bioconjugation with ligand 10, pH 8. (B) Timecourse of the Glaser-Hay bioconjugation with
ligand 2, pH 6. All reactions were conducted in triplicate to establish appropriate standard
deviations.
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Ultimately, two optimized conditions were elucidated that improved
coupling efficiency and/or minimized protein degradation, resulting in yields of
∼95% or greater as determined by absorbance spectroscopy. For ligand 2,
reactions performed at 22 °C, pH 6.0, for 4 hours afforded the best results,
while 10 functioned best at 22 °C, pH 8.0, for 8 hours (Figure 2.11). Each of these
conditions facilitates substantial improvement over the previously published
conditions of 2, 4 °C, pH 7.4, for 4 hours. Selection of appropriate ligand is most
likely application dependent, as 2 affords shorter reaction times to obtain the
bioconjugate, while 10 provides slower couplings, but with less protein
degradation.

Figure 2.11: Optimized Glaser-Hay Bioconjugations. (A) SDS-PAGE analysis of the best
conditions for the bioconjugation compared to a negative control (lane 1) and the previously
reported conditions (lane 2). The fluorescence (bottom gel) indicates degree of fluorophore
coupling and the Coomassie stain (top gel) indicates relative protein concentrations. Ultimately 2,
pH 6, 4 h (lane 3) and ligand 10, pH 8, 8 h (lane 4) afforded the highest bioconjugate yields with
minimal protein degradation. (B) Graphical representation of the gel densiometry analysis
performed on three independent SDS-PAGE experiments quantifying the optimized conditions.

In conclusion, two new reaction conditions have been developed towards
optimizing Glaser-Hay bioconjugations. The ability to increase coupling
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efficiency, while simultaneously reducing harmful protein degradation, increases
the overall utility of this reaction. Expanding the chemical toolbox of
bioorthogonal bioconjugations is essential towards the preparation of various
conjugates having medical and materials based applications. The Glaser-Hay
reaction in particular is unique in its installation of a linear, carbon-carbon
covalent bond, which also facilitates secondary reactions from the diyne moiety.
Either lowering the pH with the traditional TMEDA ligand, or employing a
carboxylated biphenyl ligand generates more efficient couplings with less
degradation than the previously reported conditions.
III. Materials and Methods
General: Solvents and reagents were obtained from either Sigma Aldrich or
Fischer Scientific and used without further purification. Plasmids were provided
by the laboratory of Dr. Peter Schultz at The Scripps Research Institute. All
proteins were purified according to manufacturer’s protocols using a Qiagen NiNTA Quik Spin Kit. Reactions were performed in ambient conditions with nondistilled solvents. SDS-PAGE gels were imaged on a BioRad Molecular Imager
(Gel Doc XR+).
Synthesis of p-propargyloxyphenylalanine (pPrF): Boc-Tyrosine-OMe (114
mg, 2 eq, 0.39 mmol) was placed in a flame-dried vial. Cesium carbonate (254
mg, 3 eq, 0.58 mmol) was then added, followed by dry DMF (3 mL). This mixture
was stirred at 100 °C for 20 minutes. 5- Bromo-1-pentyne (20 μL, 1 eq, 0.19
mmol) was then added to the mixture, as well as a catalytic amount of potassium
iodide. The reaction was stirred overnight at 100 °C, then cooled to room
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temperature and washed with brine (10 mL) and diethyl ether (10 mL). The
organic layer was then washed with brine (10 mL x 3). The aqueous layer was
then back-extracted with ether (10 mL). The organic layers were combined, dried
with magnesium sulfate, filtered, and solvent was removed under reduced
pressure. Column chromatography (silica gel, 5:1 hexanes/ethyl acetate) was
performed to yield the desired product as a white crystalline solid (22 mg, 0.061
mmol, 31.6% yield). 1H NMR (400 MHz, CDCl3): δ 7.02 (d, J = 12 Hz, 2 H), 6.82
(d, J = 12 Hz, 2 H), 4.95 (d, J = 8 Hz, 1 H), 4.53 (d, J = 8 Hz, 1 H), 4.03 (t, J = 4
Hz, 2 H), 3.71 (s, 3 H), 3.02 (m, J = 8 Hz, 1 H), 2.39 (t, J = 4 Hz, 2 H), 1.97 (m, J
= 8 Hz, 2 H), 1.55 (s, 1 H), 1.41 (s, 9 H).

13C

NMR (400 MHz, CDCl3): δ 172.4,

157.9, 130.3, 127.9, 114.5, 83.5, 79.9, 68.8, 66.0, 54.5, 52.2, 37.4, 28.3, 28.2,
21.1, 15.1.
Expression of GFP containing pPrF: A pET-GFP-TAG plasmid (0.5 μL) was
co-transformed with a pEVOL-pPrF aaRS plasmid (0.5 μL) into Escherichia
coli BL21 (DE3) competent cells using an Eppendorf Eporator electroporator.
The cells were then plated (100 μL) on LB agar supplemented with ampicillin
(50 μg/mL) and chloramphenicol (34 μg/mL), then incubated for 16 hours at
37 °C. One colony was used to inoculate LB media (10 mL) containing ampicillin
and chloramphenicol. The culture was incubated overnight at 37 °C and used to
initiate

an

expression

culture

(250 mL

media,

ampicillin

50 μg/mL,

chloramphenicol 34 μg/mL) at an OD600 = 0.1. The cultures were incubated at
37 °C until an OD600 = 0.7 was reached. Protein expression was induced by the
addition

of

20%

arabinose

(250 μL),
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0.8 mM

isopropyl-β-D-1-

thiogalactopyranoside (IPTG; 250 μL), and pPrF (1) (2.5 mL, 100 mM). Cultures
were incubated at 30 °C overnight, then pelleted by centrifugation (5000 rpm,
10 minutes). Pelleted cells were stored at −80 °C until purification. The cell pellet
was resuspended with 500 μL of Bugbuster (Novagen) containing lysozyme, and
200 μL of lysis buffer and incubated for 20 minutes at 37 °C. Cellular debris was
pelleted out by centrifugation at 5000 rpm for 10 minutes and the supernatant
was added to an equilibrated Ni-NTA resin (200 μL). GFP was purified according
to manufacturer’s protocol before being analyzed by SDS-PAGE (BioRad 10%
precast gels, 150 V, 1.5 hours). Gels were stained using Coomassie Brilliant
Blue, and destained using destain solution (60% deionized water, 30% MeOH,
10% acetic acid).
Biological Glaser-Hay reaction under optimized condition 1: To a sterile
1.5 mL eppendorf tube, the following were added: 5 μL of a vigorously shaken
solution of CuI (500 mM in H2O) and 5 μL of tetramethylethylenediamine (2 in
500 mM in H2O). The two solutions were thoroughly mixed by pipetting. Next,
30 μL of GFP containing a terminal alkyne UAA (GFP/pPrF; pH = 6.0,
1.04 ± 0.03 mg/mL) and 20 μL of Alexa Fluor-488 Alkyne (1 mM in DMSO) were
added to the tube. Negative control reactions were performed containing 10 µL
1x PBS (pH 7.4) in place of the tetramethylethylenediamine ligand and CuI. The
reaction was incubated at room temperature (22 °C). After 4 hours, excess
reactants were removed by buffer exchange using Corning Spin-X UF
concentrator columns. The reaction was washed with PBS (8 × 200 μL) to a final
volume of 50 μL. The reaction was analyzed by SDS-PAGE and imaged
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immediately to analyze fluorescence. The gel was then stained for 3 hours using
Coomassie Brilliant Blue, then destained overnight using a methanol solution
(60% deionized water, 30% MeOH, 10% acetic acid). The gel was then analyzed
again after 24 hours.
Biological Glaser-Hay reaction under optimized condition 2: To a sterile
1.5 mL eppendorf tube, the following were added: 5 μL of a vigorously shaken
solution of CuI (500 mM in H2O) and 5 μL of 2,2′-Bipyridine-4,4′-dicarboxylic acid
(10, 500 mM in 1 M NaOH). The two solutions were thoroughly mixed by pipetting
until a dark brown color was achieved. Next, 30 μL of GFP containing a terminal
alkyne UAA (GFP/pPrF; pH = 8.0, 1.04 ± 0.03 mg/mL) and 20 μL of Alexa Fluor488 Alkyne (1 mM in DMSO) were added to the tube. The reaction was
incubated at room temperature (22 °C). Negative control reactions were
performed containing 10 µL 1x PBS (pH 7.4) in place of the 2,2’-Bipyridine-4,4’dicarboxylic acid ligand and CuI. After 8 hours, excess reactants were removed
by buffer exchange using Spin-X UF concentrator columns. The reaction was
washed with PBS (8 × 200 μL) to a final volume of 50 μL. The reaction was
analyzed by SDS-PAGE and imaged immediately to analyze fluorescence. The
gel was then stained for 3 hours using Coomassie Brilliant Blue, then destained
overnight using a methanol solution (60% deionized water, 30% MeOH, 10%
acetic acid). The gel was then analyzed again after 24 hours.
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Chapter 3: Toward the Development of
Trivalent Conjugates
I. Introduction
Bioconjugation is a broad term that involves the coupling of a
biomacromolecule, such a protein or DNA, to another biomacromolecule or a
smaller molecule such as a fluorophore, small molecule probe, or solid-support.1
The development and preparation of multivalent bioconjugates is a developing
field that relies on contributions from both biology and chemistry. 1 Numerous
applications in enzyme immobilization, therapeutics, diagnostics, and materials
science have benefited from the ability to prepare multivalent systems.1-3 Several
criteria must be met in order to employ bioconjugation reactions due to the
biological components involved. The reactions must be able to occur under the
mild physiological conditions required by biological systems, a pH near 7.2 and
temperatures near 37 °C, in order to prevent degradation of reaction
components.1 In addition, reactions must be orthogonal, meaning that they do
not cross-react with components within the endogenous biological system.1-3 In
order to prepare multivalent conjugates with proteins under favorable conditions,
reactions often must first be optimized under organic conditions and translated to
a physiological setting. Research into the development of novel bioorthogonal
reactions is a rapidly growing field as they have substantial applicability within
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biological chemistry, and are specifically required when constructing multivalent
bioconjugates due to the requirement for multiple reactions.
Despite the fact that bioconjugates have drawn substantial attention owing
to their numerous applications, certain limitations must be addressed in order to
expand the utility of multivalent conjugates. Most current research has focused
on the preparation of bivalent conjugates involving only the conjugation between
two reaction partners, and requiring only a single reaction. While conjugation
systems containing two functionalities have a variety of applications, there are
instances where conjugation systems may require more than two functionalities,
necessitating the need to develop additional reactions based on the functionality
introduced by the initial conjugation reaction.1 In addition, many current
methodologies for preparing bioconjugates suffer from a lack of specificity. 3
Methods to produce conjugates using reactive residues such as the amine group
of lysine or the thiol group of cysteine have been successfully implemented. 4
Nevertheless, these methods rely on the relatively limited amount of reactions
possible using the naturally occurring amino acids. In addition, these reactions
can lead to the formation of heterogenous mixtures resulting from random
coupling.4 This is problematic in protein immobilization as random binding may
lead to the active site of the enzyme being blocked by the solid support.5,6 In
addition, attempts to form antibody drug conjugates will be hindered by the fact
that some antibodies may be conjugated multiple times while others may not be
conjugated at all, leading to a conjugate mixture with varying properties such as
stability, pharmacokinetics, affinity, and efficacy.4,7 Furthermore, the non57

orthogonal nature of these reactions prevents them from being applied to
biological settings, as side reactions can occur involving other proteins within the
system aside from the protein of interest resulting from the prevalence of
cysteine and lysine residues in most proteins.3 UAA technology has been shown
to be an effective solution to address these limitations. By site-specifically
incorporating UAAs into proteins, bioorthogonal reactions between a protein and
a reactive group can be carried out in a controlled manner at the selected site.
The ability to site-specifically incorporate UAAs which can then participate
in bioorthogonal conjugation reactions has led to several exciting applications.
UAAs have been
site-specifically
incorporated into
antibodies,
which can then
Figure 3.1: Formation of an Antibody Drug Conjugate using a sitespecifically incorporated UAA.4

be

conjugated

with various small molecules allowing the formation of antibody drug conjugates
(ADCs) (Figure 3.1).4,7 Unlike previous attempts using reactive amino acid
residues, the use of site-specifically incorporated UAAs allows for the formation
of homogenous ADCs.4,7 Upon binding of the ADC to its associated antigen,
these ADCs can then be endocytosed into the cell where the antibody will be
degraded in the lysosome, allowing release of the cytotoxic drug. 4 UAAtechnology has also been implemented in enzyme immobilization, allowing for
orientated immobilization to occur using bioorthogonal coupling reactions
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between a UAA-containing enzyme and a solid-support.5,8 This serves an
important role in lowering the costs of industrial processes by allowing better
control over reactions, recyclability of enzymes, and improved enzyme stability. 5,8
Further applications of protein immobilization have arisen through the
development of protein biochips.9,10 Protein biochips have allowed for exciting
developments to be made in diagnostics. These biochips require the
immobilization of multiple proteins onto a surface.10 High-throughput screenings
can then be performed by screening thousands of samples in parallel using
microarrays.10 These biochips can ultimately be used as a more efficient and
cost-effective diagnostic tool for the identification of disease biomarkers allowing
expression profiles to be rapidly and accurately compared in patients and healthy
individuals.10 The ability to site-specifically immobilize proteins in an oriented
manner has greatly contributed to the success of this technique. Finally,
bioconjugation reactions can be utilized in the fluorescent labeling of proteins in
order to determine the localization of proteins within cells, which can be useful for
diagnostics (Figure 3.2).11-13 In addition, fluorescence labeling allows for real-time
studies
changes,

of

conformational
protein

activity,

and protein interactions.13
The

ability

to

bioorthogonal

perform
reactions

between

UAA-containing

proteins

and

reactive

Figure 3.2: Protein labeling using a site-specifically
incorporated UAA followed by a bioorthogonal coupling
reaction.14
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functionalities within biological systems is essential in order to maximize the
potential utility of multivalent conjugates. Multivalent conjugations are especially
intriguing as they have the ability to combine several of the previously mentioned
bioconjugations into a single conjugate.
Several types of bioconjugation reactions have been implemented toward
the

preparation

of

bioconjugates.

The

copper(I)-catalyzed

1,3-dipolar

cycloaddition
reaction or “Click”
reaction is one of
Scheme 3.1: The 1,3-dipolar cycloaddition yielding a 1,4-disubstituted
1,2,3-triazole.

the most commonly

utilized bioorthogonal reactions (Scheme 3.1). The reaction was first described
by Huisgen and involves coupling between a terminal alkyne and an azide to
form a highly stable 1,4-disubstituted 1,2,3-triazole.15 In separate studies,
Sharpless

and

Meldal

found that the addition of
copper

(I)

significantly

enhanced the reaction rate
while allowing the reaction
to be carried out at lower
temperatures,

making

it

suitable for bioorthogonal

Figure 3.3: A proposed mechanism for the 1,3-dipolar
cycloaddition reaction.18

reactions in physiological systems.16,17 This has allowed for its use in a wide
variety of applications including materials science, drug discovery, and organic
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synthesis.1 The reaction involves the formation of a copper acetylide to activate
terminal alkynes (Figure 3.3).1,17 The use of tetradentate ligands such as
tris(benzyltriazolylmethyl) amine (TBTA) has been shown to further enhance the
reaction rate, allowing reaction times between 2-12 hours.1 In addition, TBTA
stabilizes the oxidation state of the copper (I) catalyst, preventing it from being
oxidized into CuII or disproportionating into CuII and Cu0, which modulates and
increases the reactivity of the copper catalyst throughout the reaction. 15,19 The
addition of a reducing agent such as TCEP can also stabilize the oxidation state
of copper (I).20 Despite these benefits, the use of copper in this reaction poses
some limitations. Copper undergoes redox side-reactions that increase toxicity
and may lead to protein degradation.1 In addition, the poor solubility of certain
ligands necessitates the use of DMSO to increase solubility, which may
negatively impact the reaction.1 Despite these limitations, the development and
successful incorporation of an azide containing UAA, pAzF, has allowed this
reaction to be utilized within biological systems within the context of proteins.
Another valuable bioconjugation reaction involves the coupling of terminal
alkynes to form a linear diyne product (Scheme 3.2).21 The reaction was first
reported in 1869 by Glaser and utilized a copper salt and a base, such as
ammonia in the presence of oxygen.21,22 It is the oldest reaction involving
coupling of acetylenes.21 Improvements to the reaction were made by Hay in
1962 utilizing the bidentate tetramethylethylenediamine (TMEDA) ligand as a

Scheme 3.2: The Glaser-Hay coupling reaction between terminal alkynes.
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copper-stabilizing ligand.23 The modified reaction, termed as the Glaser-Hay
reaction, could proceed at significantly lower temperatures and higher reaction
rates, making it highly valuable to synthetic chemists due to its mild nature.23
DFT studies have suggested that the reaction involves a dicopper(III)
intermediate (Figure 3.4). These studies propose a catalytic cycle from CuI to
CuIII to CuII back to CuI with the key step being dioxygen activation.21 The
synthesis

and

incorporation of a
terminal

alkyne-

containing

UAA,

pPrF,

has

allowed

for

the

implementation of
Figure 3.4: The proposed Glaser-Hay reaction mechanism using DFT
studies.24

this

reaction

in

biological systems. Due to the lack of knowledge about its feasibility in aqueous
solvents, its use as a bioconjugation reaction remained relatively unexplored. In
fact, the Glaser-Hay reaction has only recently been applied to biological
reactions under physiological conditions. It was demonstrated that the GlaserHay reaction could be used to couple a protein to a fluorophore molecule with
minimal protein degradation and high coupling efficiency. 25 This was done at
relatively low temperatures with relatively high reaction rates. 25 Furthermore, the
reaction has been applied to the immobilization of proteins to resins. 5 The
reaction yields a stable linear diyne product through the formation of a new
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carbon-carbon bond. The product is electron rich, making it highly reactive and
susceptible to further modification.1 The reaction is beneficial over the 1,3dipolarcycloaddition reaction as there are no regioselectivity issues.1 In addition,
the reaction only relies on a Cu(I) source and TMEDA, both of which are
common biological reagents, making it a convenient choice for use in the
development of multivalent conjugates.1
While both the Glaser-Hay and 1,3-dipolar cycloaddition coupling
reactions have proven effective in the development of bivalent systems involving
two functionalities, our next goal is to utilize these systems to incorporate a third
functionality, which requires initial optimization of reactions in an organic solvent
followed by the eventual transfer to biological systems. The Glaser-Hay reaction
may be ideal for this approach due to the potential reactivity of the diyne
functionality, whereas the triazole moiety is substantially more limited in engaging
in secondary reactions. One such reaction which is relevant toward this goal is
the formation of pyrroles through the reaction of a diyne and aniline. 26 This
reaction has been successfully employed using high temperatures and metal
catalysts; however, the reaction conditions must be altered as they are not suited
for biological systems.26 This reaction serves as a model reaction which will be
optimized and utilized toward the development of trivalent conjugates under
biological conditions.
Herein, the initial stages toward the development of trivalent conjugates
are described. First, the initial stages toward the development of protein hetero
and homodimers using Green Fluorescent Protein (GFP) and Ubiquitin (Ub) are
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described to prepare relevant bivalent conjugates that can readily be employed in
subsequent conjugation reactions. The systematic optimization of both 1,3dipolarcycloaddition and Glaser-Hay couplings toward this end are described.
Upon successful synthesis of protein dimers, reaction conditions allowing the
attachment of a third group, such as DNA, proteins, fluorophores, or other small
molecules will be explored to obtain trivalent conjugates (Figure 3.5).

Figure 3.5: Organic optimization and utilization of bioorthogonal reactions for the preparation
of trivalent conjugates.

Additionally, several organic reactions are examined for their ability to add a third
functional group onto a diyne. Specifically, the utilization of various ligands
toward the synthesis of pyrrole rings using dimers of phenylacetylene or
propargyl alcohol with aniline are examined. In addition, the use of microwave
irradiation in the synthesis of pyrrole rings using these phenylacetylene and
propargyl alcohol dimers with azidoheptane and benzyl azide was investigated.
These reaction conditions will be optimized in an organic environment to assess
their ability to form the desired product, allowing the eventual application of these
reactions to biological systems.
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II. Results and Discussion
A. Toward the Development of Heterodimers via Bioorthogonal Reactions
Out of a desire to obtain trivalent conjugates of either a homo or hetero
protein dimer, we sought to develop a method to obtain protein dimers through
previously developed bioorthogonal reactions. Ideally, these protein dimers will
be joined using a diyne
linkage so that a third
group,

either

DNA,

a

fluorophore, or other small
molecule could be added
using reactions similar to
those described in the
next section (Figure 3.6).
This section describes the

Figure 3.6: Schematic representation of the targeted
homodimer (A) and heterodimer (B) structures.27,28

systematic optimization of a Glaser-Hay dimerization reaction to yield homo and
heterodimers. Reactions were also tested using 1,3-dipolar cycloaddition
reactions; however, due the stable and unreactive nature of the obtained triazole
product, these products are less likely to be used for further reactions to yield
trivalent conjugates.
Two proteins were selected for dimerization studies, ubiquitin (Ub) and
green fluorescent protein (GFP). A WT Ub and a Ub plasmid containing a
mutation at residue 45 (Ub 45) was obtained from the Cropp Lab at Virginia
Commonwealth University. Ub was selected as a viable protein for dimerization
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studies due to its small size and lack of steric bulk, which we believed would
allow it to effectively react with other proteins. Green Fluorescent Protein (GFP)
was selected as a coupling partner for dimerization expressions due to its high
expression levels, fluorescent properties, relatively small size, and the availability
of GFP containing mutations at multiple residues, 3, 133, and 151. Each of these
mutations have been shown in previous studies to be capable of successfully
undergoing biorthogonal reactions. Prior to beginning dimerization studies, the
relative efficiency of Ub to undergo
bioorthogonal reactions was tested.
The

1,3-dipolar

reaction

and

cycloaddition

the

Glaser-Hay

reaction were intended to be used
in dimerization studies; therefore,
the ability of Ub 45 to participate in
both

reactions

needed

to

be

confirmed. Ub 45 was expressed
using

both

an

azide-containing

UAA, pAzF, and a terminal alkynecontaining UAA, pPrF, allowing Ub

Figure 3.7: SDS-PAGE analysis of Glaser-Hay and
1,3-dipolar cycloaddition reactions using Ub and GFP.
Reactions between GFP 151-pPrF (Lane 1) and Ub
45-pPrF (Lane 2) and Alexa Fluor-488 Alkyne yielded
low to moderate coupling. Reactions between GFP
151-pAzF (Lane 3) and Ub 45-pAzF (Lane 4) with
Alexa Fluor-488 Alkyne yielded excellent coupling.

45 to participate in both 1,3-dipolarcycloaddition reactions or Glaser-Hay
reactions. Reactions were carried out between pAzF or pPrF-Ub 45 and Alexa
Fluor-488 Alkyne. Control 1,3-dipolarcycloaddition reactions and Glaser-Hay
reactions using GFP 151 were prepared and compared to those using Ub 45.
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The presence of fluorescent bands at approximately 8.5 kDa indicates successful
coupling of Ub 45 to the fluorophore using both 1,3-dipolar cycloadditions and
Glaser-Hay reactions at comparable levels to those seen using GFP 151 (Figure
3.7). It is evident that the 1,3-dipolar cycloaddition reactions showed greater
coupling for both proteins.
Initial attempts toward the development of heterodimers involved the
implementation of the optimized Glaser-Hay bioconjugation reaction conditions
described previously.29 These studies showed that relatively equal coupling was
achieved using CuI and TMEDA at a pH of 6 for 4 hours at room temperature (22
°C) (condition 1) or CuI and 2,2′-Bipyridine-4,4′-dicarboxylic acid at a pH of 8 for
8 hours at room temperature (condition 2).29 These conditions were utilized for
initial dimerization studies. Reactions were prepared using equal amounts (15
µL) of both Ub 45-pPrF and GFP 151-pPrF for each condition. Homodimerization
reactions were also prepared using 30 µL of Ub 45-pPrF or GFP 151-pPrF for
each

condition.

Negative

control

reactions were prepared using equal
amounts (15 µL) of the relative
proteins in PBS buffer without the
presence

of

catalyst.

SDS-PAGE

analysis did not indicate that any
Figure 3.8: SDS-PAGE analysis of dimerization
reactions using denatured protein. Lane 1: Nondenatured GFP control reaction, Lane 2:
Denatured GFP 151, Lane 3: Denatured GFP
151/Ub 45, Lane 4: Denatured Ub 45, Lane 5:
Non-denatured Ub control reaction.
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significant coupling occurred as there
were

no

apparent

shifts

in

the

molecular weight for any of the

reactions. It was hypothesized that steric hinderance was preventing protein
dimerization. Consequently, we attempted to reduce steric hinderance by
denaturing proteins prior to reaction. To carry out these reactions, purified
proteins were heated at 98 °C for 10 minutes prior to subjecting them to the
Glaser-Hay reaction conditions. As no significant difference was seen using the
two optimized conditions, only the TMEDA condition was utilized for this trial.
Hetero and homodimer reactions were prepared as previously described using
denatured protein and control reactions were prepared using non-denatured
protein. No gel shifts were
evident
analysis

via

SDS-PAGE

indicating

that

successful coupling did not
occur (Figure 3.8). We then
attempted to carry out these
reactions

using

the

TMEDA conditions at 4 °C
and 37 °C to determine

Figure
3.9:
SDS-PAGE
analysis
of
homo
and
heterodimerization reactions conducted at 4 oC and 37 oC.
Lane 1: GFP 151 control, Lane 2: GFP 151 at 4 oC, Lane 3:
GFP 151/Ub 45 at 4 oC, Lane 4: Ub 45 at 4 oC, Lane 5: GFP
151 at 37 oC, Lane 6: GFP 151/Ub 45 at 37 oC, Lane 7: Ub 45
at 37 oC.

the impact of changing reaction temperature; however, again no coupling was
evident (Figure 3.9). Additionally, we attempted to increase reaction time to 24
hours and 48 hours to allow more time for coupling to occur; however, this
resulted in significant protein degradation.
We then attempted to utilize the 1,3-dipolar cycloaddition reaction to
synthesize homo and heterodimers. Heterodimerization reactions were prepared
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using 15 µL each Ub 45-pPrF and GFP 151-pAzF and Ub 45-pAzF and GFP
151-pPrF. Homodimerization reactions were prepared using 15 µL each of GFP
151-pPrF and GFP 151-pAzF or Ub 45-pAzF and Ub 45-pPrF. A negative control
reaction was prepared by mixing 15 µL each protein in PBS in the absence of
catalyst. Reactions were conducted using CuSO4, TBTA, and TCEP as the
catalyst system at 4 °C for 14 hours. No successful coupling was observed using
SDS-PAGE analysis. Due to the lack of coupling when using both 1,3-dipolar
cycloaddition reaction and the Glaser-Hay reaction, we hypothesized that steric
hinderance was most likely preventing dimerization, necessitating the use of a
linker to enhance coupling and overcome steric hinderance.
Due to the difficulties encountered in obtaining heterodimers, we shifted
our focus to the optimization of conditions for the development of homodimers,
which could then be translated to the development of heterodimers. Therefore,
we only performed linker experiments in the context of developing homodimers.
A 5000 Da PEG Alkyne was selected as the first linker to be investigated in
homodimerization experiments due to its length, maximizing distance between
the protein dimers and minimizing steric hinderance. This linker contains terminal
alkynes, allowing either 1,3-dipolar cycloaddition reactions or Glaser-Hay
reactions to occur between the protein and the linker. Both a 1 mM and a 50 mM
solution of the PEG Alkyne was prepared in deionized water. 1-3-dipolar
cycloaddition reactions were carried out as described previously for both UbpAzF and GFP 151-pAzF with the addition of 10 µL of PEG Alkyne to the
reaction mixture. Negative controls for both Ub 45-pAzF and GFP 151-pAzF
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were prepared as described previously. No coupling was evident for either Ub or
GFP when using the 1 mM solution of PEG Alkyne. Fortunately, significant
coupling was demonstrated for GFP 151 when the 50 mM PEG Alkyne solution
was used (Figure 3.10). A gel shift
corresponding to approximately 40
kDa was obtained, indicating the
formation of dimerized protein. The
reaction appeared to be favorable as
it resulted in a 56.7% conversion to
dimerized
coupling

product.
was

No

observed

significant
for

Ub;

however, the small size of the

Figure 3.10: SDS-PAGE analysis of GFP 151
1,3-dipolarcycloaddition reactions using 50
mM PEG alkyne.

monomer makes assessment of experimental success challenging. Our next aim
was to attempt homodimerization using a Glaser-Hay reaction with the PEG
linker.
Glaser-Hay homodimerization reactions were prepared as described
previously using TMEDA and the addition of 20 µL of 50 mM PEG alkyne with
either Ub 45-pPrF and GFP 151-pPrF. Negative controls for both Ub/pPrF and
GFP 151/pPrF were prepared as described previously. A gel shift of
approximately 40 kDa, identical to that seen using the 1,3-dipolar cycloaddition
reaction, was observed for GFP 151; however, the results were less clear for Ub.
Despite the presence of a gel shift, significantly less conversion to dimerized
product was seen, indicating that the Glaser-Hay reaction conditions were less
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efficient than the 1,3-dipolar cycloaddition conditions; therefore, further
optimization was necessary. We tested the impact of using various linker sizes
on reaction efficiencies using GFP 151 as a model system. Three linkers of
varying length were explored: 1,5-hexadiyne, 1,7-octadiyne, and 1,9-decadiyne
using 50 mM solutions of each in DMSO. Each of these linkers (10 µL) were
utilized in reactions with GFP 151-pPrF using both the TMEDA and 2,2bipyridyldicarboxylic acid conditions (Figure 3.11). SDS-PAGE analysis revealed
that only slight coupling occurred using 1,5-hexadiyne with both conditions and
slight coupling occurred using 1,9-decadiyne with the bipyridyl ligand conditions.
None of these couplings
were as productive as
those using the PEG

Figure 3.11: SDS-PAGE analysis of GFP 151 Glaser-Hay reactions
using different linkers. Lane 1: GFP 151 control, Lane 2: GFP 151
with 1,5-hexadiyne using condition 1, Lane 3: GFP 151 with 1,7octadiyne using condition 1, Lane 4: GFP 151 with 1,9-decadiyne
using condition 1, Lane 5: GFP 151 with 1,5-hexadiyne with condition
2, Lane 6: GFP 151 with 1,7-octadiyne using condition 2, Lane 7:
GFP 151 with 1,9-decadiyne using condition 2.

Alkyne.

In

studies,

the

Chodkiewicz
was

shown

increased

previous
Cadiotreaction
to

have

coupling

efficiency, quicker reaction times, and less protein degradation.30 Therefore,
dibromohexadiyne and dibromodecadiyne linkers were dissolved in DMSO to
give 50 mM and 100 mM concentrations which were subsequently used in
Cadiot-Chodkiewicz reactions with 50 mM TEA and 50 mM CuI as the catalyst
system. No coupling was observed when using the Cadiot-Chodkiewicz reaction
in this context. It appears that the PEG Alkyne linker offers the best
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homodimerization reaction efficiencies for both the 1,3-dipolar cycloaddition
reaction and the Glaser-Hay reaction; however, further optimization is still
required.
After establishing that the PEG Alkyne was the most effective linker, we
then sought to investigate the impact of other variables including reaction time
and catalyst concentration. Due to the success of using GFP 151-pPrF and the
PEG Alkyne linker, we focused our attention primarily on the optimization of
homodimerization reactions using GFP 151-pPrF. We were specifically interested
in improving the coupling efficiencies for the Glaser-Hay homodimerization
reactions. We first sought to compare the two previously optimized Glaser-Hay
conditions using the 50 mM PEG Alkyne and determine if improvements could be
observed

upon

alteration of reaction
time (Figure 3.12).
Homodimerization
reactions were set
up using both the
Figure 3.12:
SDS-PAGE analysis of timecourse Glaser-Hay
dimerization reactions using each condition. Lane 1: GFP 151 control,
Lane 2: GFP 151 with condition 1 for 4 hours, Lane 3: GFP 151 with
condition 2 for 4 hours, Lane 4: GFP 151/Ub 45 with condition 1 for 4
hours, Lane 5: GFP 151/Ub 45 with condition 2 for 4 hours, Lane 6:
GFP 151 with condition 1 for 8 hours, Lane 7: GFP 151 with condition
2, for 8 hours, Lane 8: GFP 151/Ub 45 with condition 1 for 8 hours.
Lane 9: GFP 151/Ub 45 with condition 2 for 8 hrs.

TMEDA

and

2,2-

bipyridyldicarboxylic
acid conditions with

30 µL GFP 151-pPrF and 20 µl of 50 mM PEG Alkyne. Heterodimerization
reactions were also attempted using both conditions with 15 µL each of Ub 45pPrF and GFP 151-pPrF and 20 µl of 50 mM PEG Alkyne. Reactions were
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carried out for 4 and 8 hours for each condition for both homo and
heterodimerization reactions. A negative control reaction was performed as
described previously. SDS-PAGE analysis revealed that more coupling occurred
using the 2,2-bipyridyldicarboxylic acid conditions at both reaction times for the
GFP 151 homodimerization reactions. Coupling efficiencies were significantly
improved when the 2,2-bipyridyldicarboxylic acid conditions were utilized at 8
hours as coupling efficiencies near 40% were obtained; however, coupling
efficiencies were still lower than those attained using the 1,3-dipolar cycloaddition
reaction. The most significant coupling occurred at a reaction time of 4 hours for
the TMEDA condition and at a reaction time of 8 hours for the 2,2bipyridyldicarboxylic acid condition, which supports the results of previous
Glaser-Hay optimization studies.29 Heterodimerization reactions were not
effective as no new bands at the correct molecular weight as the heterodimer
were observed, indicating that Ub was not coupled to GFP. Overall it did not
appear that altering reaction time for either condition improved coupling
efficiency. It did appear; however, that the 2,2-bipyridyldicarboxylic acid
conditions were more effective than the TMEDA conditions. We next
hypothesized that the catalyst was being consumed before the reaction could go
to completion; therefore, we increased the reaction time to 6 hours using both the
TMEDA conditions and the 2,2-bipyridyldicarboxylic acid conditions and added a
second aliquot of catalyst (5 µL 500 mM TMEDA or 5 µL 500 mM 2,2bipyridyldicarboxylic acid and 5 µL 500 mM CuI) after three hours. No
improvement in coupling was evident compared to reactions in which no
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additional catalyst was added for the 2,2-bipyridyldicarboxylic acid conditions
while slight improvement was observed for the TMEDA conditions upon the
addition of more catalyst; however, coupling efficiencies still did not surpass
those

using

the

2,2-

bipyridyldicarboxylic

acid

conditions (Figure 3.13).
We then increased the
reaction time to 24 hours
and
Figure 3.13: SDS-PAGE analysis of Glaser-Hay dimerization
reactions using two additions of catalyst compared to those
with a single addition for each condition. Lane 1: GFP 151
control, Lane 2: GFP 151, TMEDA condition, Lane 3: GFP 151
TMEDA condition, double catalyst, Lane 4: GFP 151, 2,2bipyridyldicarboxylic acid condition, Lane 5: GFP 151, 2,2bipyridyldicarboxylic acid condition, double catalyst.

added

additional

catalyst (5 µL 500 mM
TMEDA or 5 µL 500 mM
2,2-bipyridyldicarboxylic

acid and 5 µL 500 mM CuI) to one reaction and additional catalyst as well as
additional PEG Alkyne (10 µL, 50 mM) to another reaction after 12 hours. No
significant increases in coupling were observed by adding additional catalyst or
additional PEG Alkyne.
We then sought to improve coupling efficiencies for the Glaser-Hay
dimerization by increasing the amounts of reactants. Doubling the initial protein
concentration in order to prevent protein degradation and increase the likelihood
of two proteins interacting was attempted. When using 50 mM PEG Alkyne,
dimerization did not increase for either the TMEDA condition or the 2,2bipyridyldicarboxylic acid condition. It was hypothesized that increasing the
concentration of PEG Alkyne may improve coupling efficiencies. PEG Alkyne
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solutions at concentrations of 75 mM, 100 mM, and 125 mM were prepared by
dissolving the PEG Alkyne in DMSO. DMSO was used to improve the solubility of
the PEG Alkyne at concentrations greater than 50 mM. Reactions were prepared
using the 2,2-bipyridyldicarboxylic acid condition and 10 µL of each concentration
of PEG Alkyne. SDS-PAGE analysis revealed that the use of larger
concentrations

of

PEG Alkyne appeared
to improve coupling
efficiencies

when

compared to 50 mM
(Figure

3.14).

Coupling efficiencies
were greatest when
using 75 mM PEG
Alkyne as opposed

Figure 3.14: SDS-PAGE analysis of Glaser-Hay dimerization reactions
using the 2,2-bipyridyldicarboxylic acid condition with different
concentrations of PEG Alkyne. Lane 1: GFP 151 control, Lane 2: GFP
151, 50 mM PEG Alkyne, Lane 3: GFP 151, 75 mM PEG Alkyne,
Lane 4: GFP 151, 100 mM PEG Alkyne, Lane 5: GFP 151, 125 mM
PEG Alkyne.

to 100 mM and 125 mM, potentially resulting from the decreased solubility of the
PEG Alkyne at higher concentrations.
Numerous other variables were tested in both 1,3-dipolar cycloaddition
reactions and Glaser-Hay reactions to see if coupling efficiencies were improved.
The impact of mutations at different residues on GFP was examined, as it was
hypothesized that these mutations may be more accessible to reaction due to
their location. Residues 3 and 133 are located within loop motifs at either end of
β-barrel while residue 151 is located at the terminus of a β-sheet within the β75

barrel (Figure 3.15).31 GFP 3 and GFP
133

were

subjected

to

homodimerization reactions as well as
heterodimerization

reactions

with

each other as well as GFP 151 using
both

1,3-dipolar

cycloaddition

reactions and Glaser-Hay reaction
conditions and the PEG linker. For the
1,3-dipolar

cycloaddition

and

Figure 3.15: The structure of GFP showing
the location of each mutation.31

the

Glaser-Hay reaction, only GFP 151 showed significant coupling as demonstrated
previously for homodimerization reactions. Reactions between GFP 3 and GFP
151 showed a gel shift and a higher coupling efficiency when compared to the
GFP 151 homodimerization reaction; however, it could not be determined if this
was

caused

by

homodimerization of
GFP

151

or

heterodimerization as
both proteins have
the same molecular
weight (Figure 3.16).
Figure 3.16: SDS-PAGE analysis of 1,3-dipolarcycloaddition
homo and heterodimerization reactions using mutations at
residues 3, 133, and 151. Lane 1: GFP 151 control, Lane 2: GFP
151, Lane 3: GFP 3, Lane 4: GFP 133, Lane 5: GFP 3/GFP 133,
Lane 6: GFP 3/151, Lane 5: GFP 133/GFP 151.

76

We believe that due
to

the

lack

of

homodimerization for

GFP 3 the weight shift resulted from GFP 151 homodimerization. Significant
degradation occurred for GFP 133; however, this protein was present in lower
concentrations initially. We attempted to resubject successful 1,3-dipolar
cycloaddition reactions and Glaser-Hay reactions to the same conditions to see if
the reaction could be pushed to completion; however, this led to significant
degradation of the product. Denaturing GFP 151 by heating at 98 °C for 15
minutes before reaction and subjecting it to either Glaser-Hay condition in the
presence of 50 mM PEG Alkyne did not lead to any coupling. We then attempted
to utilize a Cadiot-Chodkiewicz reaction involving a brominated UAA (pBrPrF) in
the presence of 10 µL of 50 mM PEG Alkyne using 50 mM TEA and 50 mM CuI
as the catalyst system; however, no significant coupling was observed.
In summary, conditions for the development of homodimers using GFP
151 have been optimized. Initial attempts to develop heterodimers using Ub and
GFP and homodimers using Ub with both 1,3-dipolar cycloaddition addition
reactions and Glaser-Hay reactions did not yield any significant coupling.
Homodimers were successfully prepared using GFP 151-pAzF through the 1,3dipolar cycloaddition reaction using 20 µL of 50 mM PEG alkyne with coupling
efficiencies near 56%. Homodimers using the Glaser-Hay reaction using 10 µL of
75 mM PEG alkyne using either CuI and TMEDA at a pH of 6 for 4 hours at room
temperature or CuI and 2,2-bipyridyldicarboxylic acid at a pH of 8 for 8 hours at
room temperature were successfully obtained; however, coupling efficiencies
were lower than those obtained using the 1,3-dipolar cycloaddition reaction. It
appeared that the 2,2-bipyridyldicarboxylic acid condition yielded better coupling;
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however,

the

lower

reaction

time

and

difficulty

solubilizing

the

2,2-

bipyridyldicarboxylic acid ligand may make the use of the TMEDA condition more
practical. Future work will involve the continued optimization of these conditions
to maximize the coupling efficiencies so that these conditions can be expanded
to the development of heterodimers. Once homo or heterodimers have been
obtained in significant yields using Glaser-Hay reactions, the diyne product can
then be subjected to further coupling reactions with other proteins, DNA,
fluorophores, or small molecules to form trivalent conjugates.
B. Organic Development of Multivalent Bioconjugation Reactions
In order to develop reactions that lead to trivalent conjugates under
physiological conditions, reactions must first be tested in organic solvents to
ensure that the desired product can be obtained in high yields under mild
conditions

with

reasonable

reaction

times.

Reactions

requiring

high

temperatures, extreme pH, harsh reagents, water incompatible catalysts, or long
reaction times are not optimal in physiological conditions as protein degradation
may result. Prior to developing these reactions, a suitable starting material must
be synthesized. The Glaser-Hay reaction has been previously shown to yield
alkyne dimers in both the organic and biological context. The electron rich diyne
linkage formed as a product of this reaction provides an adequate starting
material for use in further reactions to form trivalent conjugates. Two starting
materials, 1,4-diphenylbuta-1,3-diyne (1) and Hexa-2,4-diyne-1,6-diol (2) were
synthesized using the traditional Glaser-Hay coupling (Scheme 3.3). Both
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products were obtained in moderate yields (31-52%) and used in subsequent
reactions.

Scheme 3.3: Glaser-Hay coupling reactions used to obtain 1 and 2.

The preparation of trivalent molecules was next attempted by reacting 1
with aniline in the presence of copper chloride and a ligand. Three different
ligands, tetramethylethylenediamine (TMEDA), triethylamine (TEA), and 2,2’Bipyridine were tested to determine their effectiveness in forming a pyrrole
product (3) (Scheme 3.4). A control reaction was prepared in the absence of a
ligand. These reactions were performed on a small scale using only 10 mg of
diyne. Reactions were carried out at 40 °C overnight using THF as the solvent. A
relatively low temperature was selected for this reaction as a method to
determine their effectiveness for translation into a physiological context.
Reactions were monitored by TLC for the formation of 3. After 24 hours, the
formation of product was identified when using the 2,2’-bipyridine ligand based
on the appearance of a spot which had a differing Rf value from the starting
materials. No products were observed using the TMEDA or TEA ligands, or the
control reaction. These reactions were allowed to continue for an additional 24
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hours; however, still no product was obtained. We attempted to scale up the
reaction using the 2,2’-bipyridine ligand using 50 mg of starting material;
however, we were unable to obtain 3 in high yields and purity due the inability to
effectively separate the 2,2’-Bipyridine ligand from the reaction mixture. We then
attempted to use 50 mg of 2 to obtain pyrrole 4; however, NMR spectra did not
indicate the formation of product. Due to the difficulties encountered in obtaining
3 and 4 with a high degree of purity, alternative methods of synthesizing pyrroles
were obtained, such as the use of microwave irradiation.

Scheme 3.4: Reaction of 1 and aniline to yield pyrrole 3.

We then sought to use Microwave irradiation to produce triazoles 5 and 6
(Scheme 3.5), as microwaves have previously been demonstrated to accelerate
these types of reactions.32 These reactions were performed in the presence and
absence of copper, which can be deleterious to living systems when in the Cu(II)
state. Microwave irradiation was applied using a CEM Discover in SPS mode
with 300 W of power for 20 minutes. These reactions were also performed
thermally in the presence and absence of copper. Reactions were stirred at room
temperature for 24 hours. Pyrrole 5 was successfully obtained in moderate yields
in the presence and absence of copper using microwave irradiation. A crude
NMR spectrum indicated the presence of pyrrole 6; however, the product was
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lost during purification. Unfortunately, products were not obtained when reactions
were performed thermally, even after an additional 24 hours of reaction time.
These results indicate that microwave irradiation can be used to successfully
obtain trivalent products in the absence of copper. In order to translate these
reactions to proteins, a Coolmate system will need be utilized, meaning that
these reactions must be tested under these conditions prior to attempting these
reactions on a protein context.

Scheme 3.5: Microwave reactions yielding trivalent pyrroles 5 and 6.

In summary, multivalent reactions have been tested organically using
various ligands to obtain pyrrole products. It appeared that reactions utilizing the
2,2’-Bipyridine ligand may have given small amounts of product; however, pure
product was not obtained in high yields using either 1 or 2. Further attempts will
be made to scale up these reactions in order to better isolate product. Attempts
at subjecting internal diynes to microwave irradiation in the absence of copper
indicated that pyrrole products could be obtained in moderate yields when SPS
mode was used. Unfortunately, these reactions were unsuccessful when carried
out at room temperature over the course of two days. In order to translate these
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reactions to proteins, a Coolmate system will need be used; therefore, future
work will be aimed at optimizing these reactions using the Coolmate system.
Continued research will focus on the further development and optimization of
reactions to produce trivalent organic products.
III. Materials and Methods
General: Solvents and reagents were obtained from Sigma Aldrich, Alfa Aesar,
or Fischer Scientific and used without further purification. Reactions were
performed under ambient conditions with non-distilled solvents. Microwave
reactions were performed using CEM Discovery microwave reactors. NMR data
was acquired using a Varian Gemini 400 MHz NMR. Alkyne-PEG5000-alkyne
was purchased from JenKem Technology. All GFP and Ub proteins were purified
according to manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit.
pET-Ub and pET-Ub-TAG plasmids were obtained from the Cropp lab at Virginia
Commonwealth University.
1,4-diphenylbuta-1,3-diyne (1): A catalytic amount of CuI (160 mg, 0.04 eq.,
0.84 mmol) and tetramethylethylenediamine (TMEDA) (240 µL, 0.08 eq., 1.60
mmol) was added to a flame-dried vial. This mixture was dissolved in THF (4 mL)
and stirred at room temperature for 15 minutes to generate the catalyst system.
This mixture was then transferred to a flame-dried round-bottom flask containing
THF (30 mL). Diphenylacetylene (2.15 mL, 2 eq., 19.60 mmol) was added and
the reaction was stirred at 60 °C in an oil bath for 48 hours. The reaction was
monitored by TLC for the formation of product. After 48 hours, the reaction was
cooled and extracted four times using DCM. The organic layer was then washed
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3 times using deionized water, dried using anhydrous magnesium sulfate,
filtered, and solvent was evaporated under reduced pressure to yield a dark
brown solid. The solid was evaporated on a vacuum line for 3 hours to give 1
(972 mg, 4.81 mmol, 52.1% yield). 1H NMR (CDCl3, 400 MHz): δ 7.63-7.61 (m,
4H), 7.42-7.40 (m, 6H).

Figure 3.17: 1H NMR of 1 in CDCl3.

Hexa-2,4-diyne-1,6-diol (2): A catalytic amount of CuI (160 mg, 0.02 eq., 0.84
mmol) and tetramethylethylenediamine (TMEDA) (240 µL, 0.04 eq., 1.60 mmol)
was added to a flame-dried vial. This mixture was dissolved in THF (4 mL) and
stirred at room temperature for 15 minutes to generate the catalyst system. This
mixture was then transferred to a flame-dried round-bottom flask containing THF
(30 mL). Propargyl alcohol (2.11 mL, 2 eq., 35.70 mmol) was added and the
reaction was stirred at 60 °C in an oil bath for 48 hours. The reaction was
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monitored by TLC for the formation of product. After 48 hours, the reaction was
cooled and extracted four times using DCM. The organic layer was then washed
3 times using deionized water, dried using anhydrous magnesium sulfate,
filtered, and solvent was evaporated under reduced pressure to yield a light
brown solid (610 mg, 5.54 mmol, 31.0% yield). 1H NMR (D2O, 400 MHz): δ 4.16
(s, 4H).

Figure 3.18: 1H NMR of 2 in D2O.

1,2,5-triphenyl-1H-pyrrole (3): To a flame-dried round-bottom flask was added
1 (50 mg, 1 eq., 0.25 mmol). 1 was then dissolved in THF (3 mL). Aniline (225
µL, 10 eq., 2.47 mmol), CuCl (1 mg, 0.1 eq., 0.025 mmol), and 2,2’-Bipyridine (39
mg, 1 eq., 0.25 mmol) were added to a flame-dried vial and dissolved in THF (3
mL). This mixture was stirred at room temperature for 15 minutes to generate the
catalyst system then added to the round-bottom flask containing 1. The reaction
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was monitored by TLC for the formation of product. Solvent was evaporated
under reduced pressure to yield an oil. The reaction was purified using column
chromatography (silica gel, 7:1 hexanes:EtOAc). Yield and NMR data are not
reported as the product was not successfully obtained.
(1-phenyl-1H-pyrolle-2,5-diyl)dimethanol (4): To a flame-dried round-bottom
flask was added 2 (50 mg, 1eq, 0.45 mmol). 2 was then dissolved in THF (3 mL).
Aniline (415 µL, 10 eq., 4.54 mmol), CuCl (4.49 mg, 0.1 eq., 0.045 mmol), and
2,2’-Bipyridine (71 mg, 1 eq., 0.45 mmol) were added to a flame-dried vial and
dissolved in THF (3 mL). This mixture was stirred at room temperature for 15
minutes to generate the catalyst system. The mixture was then transferred to the
first round-bottom flask containing 2. The reaction was stirred at 40 °C overnight.
The reaction was evaporated under reduced pressure to yield an oil. The
reaction

was

purified

using

column

chromatography

(silica

gel,

1:1

hexanes:EtOAc). Yield and NMR are not reported as the product was not
successfully obtained.
2-(1-benzyl-4-(hydroxymethyl)-1H-1,2,3-triazol-5-yl)ethyn-1-ol

(5):

To

a

microwave vial was added a small stir bar, 2 (19 mg, 1 eq., 0.17 mmol), benzyl
azide (106 µL, 5 eq., 0.85 mmol), deionized water (970 μL), and tert-Butyl alcohol
(99 %, 1 mL). The solution was subjected to microwave irradiation (SPS mode,
20 minutes, 0-300 W, 168 °C, δT= 15 °C). The resulting mixture was then
quenched with chilled deionized water (10 mL, 0 °C). A rotary evaporator was
used to remove water from the reaction, and the crude product was purified using
column chromatography (silica gel, 3:1 EtOAc:hexanes) to yield 5 (10 mg, 0.041
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mmol, 24.1% yield). 1H NMR (CDCl3, 400 MHz): δ 7.36-7.33 (m, 4H), 7.24-7.21
(m, 1H), 5.64 (s, 2H).

Figure 3.19: 1H NMR of 5 in CDCl3.

1-heptyl-4-phenyl-5-(phenylethynyl)-1H-1,2,3-triazole (6): To a microwave vial
was added a small stir bar, 1 (34 mg, 1 eq., 0.17 mmol), azidoheptane (139 µL, 5
eq., 0.85 mmol), deionized water (970 μL), and tert-Butyl alcohol (99%, 1 mL).
The solution was subjected to microwave irradiation (SPS mode, 20 minutes, 0300 W, 168 °C, δT= 15 °C). The resulting mixture was then quenched with chilled
deionized water (10 mL, 0 °C). A rotary evaporator was used to remove water
from the reaction, and the crude product was analysed by NMR. Yield data could
not be obtained as product was lost during purification. 1H NMR (CDCl3, 400
MHz): δ 8.20 (d, J = 7.6 Hz, 2H), 7.57-7.18 (m, 8H), 4.51 (t, J = 7.2 Hz, 2H),
2.04-2.02 (m, 2H), 1.28-1.15 (m, 8H), 0.86-0.84 (m, 3H).
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Figure 3.20: 1H NMR of 6 in CDCl3.

Expression and Purification of Ubiquitin containing pAzF and pPrF: A Ub
plasmid (0.50 µL) was co-transformed with a pEVOL-pCNF plasmid (0.50 µL)
into Escherichia Coli BL21 (DE3) competent cells by heat shock using an
Eppendorf eporator electroporator. The cells were then plated (250 µL) on LB
agar containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) and
incubated at 37 °C overnight. One colony was then used to inoculate LB media
(10 mL) containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This
culture was then incubated and allowed to shake at 37 °C overnight. The
following day, the culture was then used to inoculate an expression culture
containing LB media (250 mL), ampicillin (50 µg/mL), and chloramphenicol (34
µg/mL) at a starting OD600 of 0.1. The cultures were incubated and allowed to
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shake at 37 °C until an OD600 of 0.7 was reached. Protein expression was then
induced by the addition of 20% arabinose (250 µL), and isopropyl β-D-1thiogalactopyranoside (IPTG, 250 µL, 0.8 mM), and pPrF or pAzF (250 mL, 100
mM). The cultures were then incubated with and allowed to shake at 30 °C for 16
hours. The cells were then pelleted by centrifugation (5,000 rpm, 10 minutes) and
stored at -80 °C until purification.
Purified Ub was obtained by resuspending the cell pellet in 500 µL of Bug
Buster (Novagen) containing lysozyme and 200 µL lysis buffer. The mixture was
incubated with shaking at 37 °C for 20 minutes. The mixture was then transferred
to an Eppendorf tube and centrifuged at 13,200 rpm for 10 minutes to pellet out
cellular debris. The supernatant was decanted into an equilibrated HisPur NiNTA spin (Qiagen) column containing Nickel resin (200 µL) and Ub was purified
according to the manufacturer’s protocol. Purified Ub was analyzed by SDSPAGE (BioRad 15% precast gels, 120V, 2 hours). Gels were stained with
Coomassie Brilliant Blue solution, and destained using a destain solution
containing 60% deionized water, 30% MeOH, and 10% glacial acetic acid. Gels
were analyzed using a BioRad Molecular Imager (Gel Doc XR+) gel imager
(Coomassie protocol) after 24 hours. Protein was then concentrated and buffer
exchanged into PBS buffer at a pH of 7.4 using Corning Spin-X UF purification
columns. Protein was used without further purification.
Expression and Purification of GFP containing pAzF and pPrF: A pET-GFPTAG plasmid (0.50 µL) was co-transformed with a pEVOL-pAzF plasmid (0.50
µL) into Escherichia Coli BL21 (DE3) competent cells by heat shock using an
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Eppendorf eporator electroporator. The cells were then plated (250 µL) on LB
agar containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) and
incubated at 37 °C overnight. One colony was then used to inoculate LB media
(10 mL) containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This
culture was then incubated and allowed to shake at 37 °C overnight. The
following day, this culture was used to inoculate an expression culture containing
LB media (250 mL), ampicillin (50 µg/mL), and chloramphenicol (34 µg/mL) at a
starting OD600 of 0.1. The cultures were incubated and allowed to shake at 37 °C
until an OD600 of 0.7 was reached. Protein expression was then induced by the
addition of 20% arabinose (250 µL), and isopropyl β-D-1-thiogalactopyranoside
(IPTG, 250 µL, 0.8 mM), and pAzF or pPrF (250 mL, 100 mM). The cultures were
then incubated with and allowed to shake at 30 °C for 16 hours. The cells were
then pelleted by centrifugation (5,000 rpm, 10 minutes) and stored at -80 °C until
purification.
Purified GFP was obtained by resuspending the cell pellet in 500 µL of
Bug Buster (Novagen) containing lysozyme and 200 µL lysis buffer. The mixture
was incubated with shaking at 37 °C for 20 minutes. The mixture was then
transferred to an Eppendorf tube and centrifuged at 13,200 rpm for 10 minutes to
pellet out cellular debris. The supernatant was decanted into an equilibrated
HisPur Ni-NTA spin (Qiagen) column containing Nickel resin (200 µL) and GFP
was purified according to the manufacturer’s protocol. Purified GFP was
analyzed by SDS-PAGE (BioRad 10% precast gels, 120V, 2 hours). Gels were
stained with Coomassie Brilliant Blue solution, and destained using a destain
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solution containing 60% deionized water, 30% MeOH, and 10% glacial acetic
acid. Gels were analyzed using a BioRad Molecular Imager (Gel Doc XR+) gel
imager (Coomassie protocol) after 24 hours. Protein was then concentrated and
buffer exchanged into PBS buffer at a pH of 6.0, 7.4, or 8.0 using Corning Spin-X
UF purification columns. Protein was used without further purification.
Optimized Click Dimerization Reaction protocol: The following reagents were
added to a sterile 1.5 mL eppendorf tube in the order listed: 2 µL CuSO 4 (50 mM
in H2O), 20 µL tris(benzyltriazolylmethyl)amine (5 mM in DMSO), 20 µL of GFP
containing an azide UAA (GFP/pAzF), 10 µL of Alkyne-PEG5000-alkyne (50 mM
in H2O), 2 µL tris(2-carboxyethyl)phosphine (50 mM in H2O), and 6 µL PBS (pH
7.4). A negative control reaction was prepared using 20 µL GFP/pAzF, 10 µL of
Alkyne-PEG5000-alkyne, and 30 µL PBS in place of the catalyst system.
Reactions were incubated for 14 hours at 4 °C. Excess reagents were removed
by buffer exchange (5 x 200 µL of PBS buffer) using Corning Spin-X UF
purification columns to obtain a final volume of approximately 50 µL. Reactions
were analyzed for successful dimerization of protein using SDS-PAGE (BioRad
10% precast gels, 120V, 2 hours). Gels were then stained with Coomassie
Brilliant Blue solution, and destained using a solution containing 60% deionized
H2O, 30% MeOH, and 10% glacial acetic acid. Gels were then imaged using a
Bio-Rad Molecular Imager (Gel Doc XR+) using the Coomassie protocol after 24
hours.
Optimized Glaser-Hay Dimerization Reaction protocol: A vigorously shaken
solution of CuI (500 mM in H2O, 5 µL) and 2,2′-Bipyridine-4,4′-dicarboxylic acid
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(500 mM, 5 µL) were added to a sterile 1.5 mL eppendorf tube and allowed to
equilibrate for 10 minutes. The two solutions were thoroughly mixed by pipetting.
Next, 30 µL of GFP containing a terminal alkyne UAA (GFP/pPrF) and 20 µL
Alkyne-PEG5000-alkyne (75 mM in H2O) were added. A control reaction was
prepared using 30 µL GFP/pPrF, 20 µL Alkyne-PEG5000-alkyne, and 10 µL PBS
buffer in place of the catalyst system. Reactions were incubated at room
temperature (22 °C). After 8 hours, excess reagents were removed by buffer
exchange (5 x 200 µL of PBS buffer) using Corning Spin-X UF purification
columns to obtain a final volume of approximately 50 µL. Reactions were
analyzed for successful protein dimerization using SDS-PAGE (BioRad 10%
precast gels, 120V, 2 hours). Gels were then stained with Coomassie Brilliant
Blue solution, and destained using a solution containing 60% deionized water,
30% MeOH, and 10% glacial acetic acid. Gels were then imaged with a with a
Bio-Rad Molecular Imager (Gel Doc XR+) using the Coomassie protocol after 24
hours.
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Chapter 4: The Application of
Microwave Irradiation for Copper-free
Alkyne/azide 1,3-dipolar Cycloadditions
I. Introduction
The alkyne/azide 1,3-dipolar cycloaddition reaction has become an
indispensable tool for scientists as a mechanism to conjugate an alkyne moiety
with an azide (Scheme 4.1).1–4 While the general class of pericyclic reactions has
proven useful to organic chemists,5,6 the robust nature of this particular
alkyne/azide “click” reaction has allowed it to become ubiquitous in a plethora of
fields such as drug

Scheme 4.1: Standard copper-free 1,3-dipolar cycloaddition.

design,

sensors,

catalysis,

materials

chemistry,

and

bioconjugations.7–14 While this specific cycloaddition was first discovered in 1963,
the copper catalyzed variant has expanded its utility by decreasing reaction times
and temperatures, while increasing regioselectivity.3 However, the addition of a
copper catalyst has some limitations within biological systems and in some
materials applications.15,16 These issues have necessitated the development of
rapid copper-free conditions, which is typically accomplished through the use of
highly strained alkynes, many of which are challenging to synthetically access. 17–
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Alternatively, heterogeneous reactions employing an immobilized catalyst, and

non-transition metal catalyzed reactions have been explored.20,21 While these
methodologies are extremely useful, we became interested in exploring other
options for rapid copper-free reaction conditions using unstrained alkynes.
Another mechanism to accelerate the reaction has been the application of
microwave irradiation, which has been primarily examined under coppercatalyzed

conditions.22–25 Previously,

a

microwave-mediated

copper-free

cycloaddition toward the preparation of a complex polymer was reported;
however, little experimental optimization of the reaction was conducted and
yields were significantly low.26 We aimed to significantly expand on this approach
by optimizing reaction conditions and broadening its utility towards biological
applications.
II. Results and Discussion
Due to the extensive number of variables associated with microwave
irradiation, initial investigations involved the optimization of reaction conditions
with a model system.27 Based on commercial availability of reagents and
spectroscopic properties, the reaction of benzyl azide (2) and phenylacetylene
(1) was selected to
explore the copperfree
Scheme 4.2: The reaction of benzyl azide (2) with phenylacetylene
(1).

microwave

mediated 1,3-dipolar
cycloaddition

of

alkynes and azides. The rapid nature of the microwave was expected to facilitate
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productive reactions in a short amount of time, without necessitating the use of a
copper catalyst, and ultimately making the reaction more useful for biological
settings or other applications where the use of copper precludes the utilization of
the reaction. Using a CEM Discover, various temperatures, microwave powers,
and microwave settings were explored (Table 1). Standard microwave conditions
involve the input of power until a specific temperature is obtained, followed by
Table 4.1: Optimization of the copper-free microwave assisted 1,3-dipolar cycloaddition.

brief bursts of power to maintain the temperature. Power mode involves the
constant input of a microwave power until a set temperature is reached, followed
by termination of reaction conditions. Finally, Pulsed Power (SPS) mode involves
power cycling to maintain the temperature within a specific range (δT). A delicate
interplay between power input and reactant decomposition was noted, as higher
product yields were observed with increased power settings (300 W); however,
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increased irradiation times began to lead to decreased yields. Thus, the SPS
setting was found to be optimal as it afforded high power inputs with reduced
times at elevated temperatures. Ultimately, maximizing power to 300 W in SPS
mode for 20 minutes afforded a 96% yield and was employed in further reactions.
As expected, a mixture of the two regioisomers (3a and 3b) was obtained under
all conditions.
In order to assess the scope of the reaction, we next examined a variety of
alkynes and azides under the optimized reaction conditions. In addition to benzyl
azide (2), azidoheptane (4) and trimethylsilyl azide (5) were examined due to
their commercial availability and chemical functionality. This set of azides was
reacted with phenylacetylene (1), 1-hexyne (6), and propargyl alcohol (7) under
the previously optimized microwave conditions. When reacting equimolar ratios
of the propargyl alcohol and any azide, very little product was recovered (<5%),
obviating the further optimization of the reaction. It was hypothesized that the
propargyl alcohol was susceptible to decomposition under the microwave
conditions as reactions typically resulted in a very dark crude mixture, which was
unobserved with other alkynes. Two remedies were examined to address the low
yields, first methyl propargyl ether (8) and trityl-protected propargyl alcohol (9)
were employed to protect the hydroxyl group, and second, excess of the alkyne
was employed to identify if decomposition was an issue. Reactions of benzyl
azide (2) and trimethylsilyl azide (5) with methyl propargyl ether (8) using 1
equivalent of alkyne continued to result in low yields of product (<5%). Therefore,
the same reactions were performed utilizing 2 equivalents of alkyne, giving
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increased yields of
approximately
for

both

20%

reactions,

indicating that alkyne
decomposition

may

indeed be a factor.
To

further

support

this, these reactions
were then performed
using 5 equivalents
of alkyne, resulting in
dramatic increases in
yields

for

both

reactions. Ultimately,
it appears that alkyne

Figure 4.1: Triazole array prepared to assess the scope of the
microwave assisted copper-free 1,3-dipolar cycloaddition.
Reactions were performed with 5 equivalents of alkyne, using
SPS mode 300 W, 20 minutes.

decomposition under microwave conditions was the primary factor contributing to
low yields in previous reactions as increasing alkyne equivalents from 1 to 5
greatly improved yields. While not ideal in the organic sense, bioconjugation
reactions typically employ extreme excess of the non-protein partner to drive
reactions, making the use of 5 equivalents relatively minimal in the context of
bioconjugation reactions. Consequently, the array of triazole products (3, 10–
23) was re-synthesized using an excess of alkyne. Conveniently, the volatility of
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the alkyne reactants allowed for easy purification under vacuum or via column
chromatography (Figure 4.1).
Overall, the reactions proceeded in moderate to excellent yield (96–47%),
with the benzyl azide being the most reactive azide (96–84%), and the
azidoheptane exhibiting lower activity (94–46%) (Figure 4.1). This may be a
result of some solubility issues, or simply the aliphatic nature of the azide. Tritylprotected propargyl alcohol reactions resulted in the lowest yields, potentially due
to decomposition. These yields could be significantly increased via alteration of
the protecting group to a methyl substituent. Additionally, reactions performed
with the TMS-azide in the microwave resulted in desilylation and yielded the free
triazole ring after column chromatography. Control reactions that mimicked the
microwave temperature profile without microwave irradiation did afford product,
albeit in markedly lower yield <20%. Thus, the dramatically increased yields
using the optimized microwave conditions demonstrate the utility of this
methodology. While these yields are sometimes comparable to previously
reported reactions, the combination of decreased reaction times and the absence
of copper suggest that the methodology may be useful in specific applications. 28
In order to further apply the microwave assisted copper-free 1,3-dipolar
cycloadditions, we next investigated their use in a biological context. This is
especially relevant due to the propensity of copper to generate radicals that
degrade proteins, and due to the general cytotoxicity of copper.15 To accomplish
this aim, an alkynyl unnatural amino acid was incorporated using the Schultz
amber suppression technology into green fluorescent protein (GFP).29–34 GFP
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was selected due to its
nascent

fluorescent

properties

and

documented

use

reporter

protein.

wellas

a

The p-

propargyloxyphenylalanine
Figure 4.2: Incorporation and cycloaddition using an
unnatural amino acid. A) Structure of ppropargyloxyphenylalanine incorporated into GFP. B)
Proposed 1,3-dipolar cycloaddition reaction between the
mutant GFP and an azide-containing fluorophore in the
microwave.

(24) unnatural amino acid
was expressed at residue
151 of GFP, which is

located within the rigid β-barrel of the protein (Figure 4.2).13,35,36 With the alkynecontaining protein in hand, we next investigated the ability to translate our
previously optimized reaction to a biological context. The mutant GFP was
reacted with Alexa Fluor-488 azide to generate a fluorescent bioconjugate that
could be analyzed via SDS-PAGE. Not surprisingly, when subjected to
microwave irradiation in the standard CEM Discover under a variety of conditions
(including the previously optimized SPS conditions), protein degradation was
observed at high temperatures, providing no observable conjugated product.
In order to prevent protein degradation, the reaction was translated to a
CEM Coolmate system, which utilizes a jacketed reaction vessel to allow
microwave transparent cooling fluid to be flowed through to significantly reduce
reaction temperatures, while still affording microwave irradiation.37 The SPS
setting previously employed is not feasible under Coolmate conditions, and thus
modulation of microwave power was the most logical variable to examine.
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Reactions containing the mutant protein and azide fluorophore were conducted
at microwave powers of 100 W, 200 W, and 300 W. The coolant was pre-chilled
to −50 °C and used to cool the reaction to −30 °C prior to microwave irradiation,
and the reaction was then irradiated until the temperature reached 40 °C.
Following irradiation, the protein was denatured and analyzed by SDSPAGE. Due to the covalent modification of the protein with a fluorophore,
successful reactions were expected to yield a fluorescent product even

Figure 4.3: Microwave-mediated 1,3-dipolar cycloadditions on GFP. A) SDS-PAGE Coomassie
stain indicating the presence of GFP both with a control reaction not utilizing the microwave
(Lane 1) and under microwave conditions in the absence of copper (Lane 2). B) SDS-PAGE
fluorescence image, demonstrating the effective coupling between the protein and the azide
fluorophore to generate a triazole linkage. The difference in protein concentration is potentially
due to some minor degradation under microwave conditions. C) Copper-free control reactions in
the absence of either microwave irradiation or the fluorescently labelled reaction partner. GFP is
present and non-degraded in both reactions when stained with Coomassie blue. D)
Fluorescence imaging indicates that no bioconjugation occurs under the two control conditions
as no fluorescence is observed.
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after denaturation of the protein fluorophore. Reaction success was determined
by first examining the fluorescence of the gel, and then staining the gel
with Coomassie blue to ascertain the presence of protein. Reactions at 300 W
displayed significant protein degradation, while reactions at 100 W did not exhibit
significant

fluorophore coupling.

significant

coupling

without

However,
protein

reactions at

degradation.

200 W

While

displayed

other

types

of bioconjugations have been performed in the microwave, we believe this to be
one of the first reported microwave-mediated bioconjugations involving full length
proteins.38 In order to further optimize the coupling, the reaction was subjected to
2 pulses of microwave irradiation at 200 W prior to purification (Figure 4.3).
Based on both absorption spectroscopy of the conjugates and densiometry
measurements of the gels,
the

coupling

yields

are

∼85%. Additionally, control
irradiations in the absence
of the fluorophore were
performed,
that

GFP

demonstrating
was

still

fluorescent after irradiation,

Figure 4.4: GFP fluorescence in the presence and absence
of microwave irradiation (Coolmate; 2x200W),
demonstrating minimal protein degradation as comparable
levels of fluorescence are maintained.

signifying that it was not denatured as a result of microwave irradiation at low
temperature (Figure 4.4). This is an important aspect when considering the utility
of these reactions within the context of the microwave. Reactions under identical
temperature profiles to the microwave yielded no observable conjugate. It is
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important to note that GFP is a relatively hearty protein and the presence of
copper does not necessarily lead to degradation; however, many other less
stable proteins may require the copper-free conditions, or the eventual
application of the protein in a biological setting may necessitate the absence of
copper to prevent cytotoxicity. Attempts were then made to translate these
Coolmate conditions to the previously optimized small molecule reactions. This
was demonstrated through the reactions of benzyl azide (2) with phenylacetylene
(1), 1-hexyne (6), propargyl alcohol (7). In each reaction, 5 equivalents of alkynes
were used in order to prevent degradation as previously described. These
reactions resulted in some coupling; however, the obtained yields were between
9-20%, a significant decrease from the previously optimized conditions. We
hypothesize this is due to the significantly higher reagent concentrations
compared to the protein system, coupled with substantially shorter reaction
times. Thus, optimal conditions for the microwave-mediated click reaction are
dependent on the nature of the reactants (proteins vs. small molecules).
In conclusion, we have demonstrated that it is feasible to conduct
alkyne/azide 1,3-dipolar cycloadditions in the microwave without the requisite of
a copper catalyst. This has far-reaching applications within the realms of both
biology and materials science where copper may be prohibitive to specific
reactions. The microwave-mediated reaction was optimized to afford high yields
of triazole products and further applied to a protein context via the utilization of
unnatural amino acids. Overall, we believe this to be one of the first reported
protein bioconjugations utilizing

microwave
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irradiation.

Moreover,

the

methodology developed facilitates an extremely rapid method to obtain
bioconjugates in the absence of potentially cytotoxic copper.
III. Materials and Methods
General. Solvents and reagents were obtained from either Sigma Aldrich or
Fischer Scientific and used without further purification. Reactions were performed
in ambient conditions with non-distilled solvents. Microwave reactions were
performed using CEM Discovery and CEM Discovery Coolmate microwave
reactors. NMR data was acquired on a Varian Gemini 400 MHz NMR. GC/MS
analysis was conducted on an Agilent Technologies 6890N GC system
interfaced with a 5973N mass selective detector. An Agilent J&W GC capillary
column (30 m length, 0.32 mm diameter, 0.25 m film) was employed with a
splitless injection (250° C inlet, 8.8 psi) with an initial 70 °C hold (2 minutes) and
ramped for 15 minutes to 230 °C. All GFP proteins were purified according to
manufacturer’s protocols using a Qiagen Ni-NTA Quik Spin Kit. NMR data is in
accordance to previously published NMR spectra of identical compounds.
General 1,3-dipolar Cycloaddition Method. To a microwave vial was added a
small stir bar, an alkyne (5.1x10-4 moles; 3 eq.), an azide (1.7x10-4 moles; 1 eq.),
deionized water (970 μL), and tert-Butyl alcohol (99 %, 1 mL). The solution was
subjected to microwave irradiation (SPS mode, 20 minutes, 0-300 W, 168 °C,
δT= 15 °C). The resulting mixture was then quenched with chilled deionized
water (10 mL, 0 °C). A rotary evaporator was used to remove water from the
reaction, and the crude product was purified using flash chromatography (3:1
hexanes:EtOAc) to yield the product.
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General GFP Expression Protocol: A pET-GFP-TAG plasmid (0.5 μL) was cotransformed with a pEVOL-tRNA synthetase plasmid (0.5 μL) into Escherichia
coli BL21(DE3) cells using an Eppendorf eporator electroporator. The cells were
then plated (100 μL) on LB agar in the presence of chloramphenicol (Chlr, 34
mg/mL) and ampicillin (Amp, 50 mg/mL) at 37° C overnight. One colony was then
used

to

inoculate

LB

media

(4

mL)

containing

both

ampicillin

and

chloramphenicol. The culture was incubated at 37 °C overnight and used to
inoculate an expression culture (10 mL LB media, 50 mg/mL Amp, 34 mg/mL
Chlr) at an OD600 0.1. The cultures were incubated at 37 °C to an OD600 between
0.7 and 0.9, and protein expression was induced by addition of the respective
unnatural amino acid (100 μL, 100 mM), 20 % arabinose (10 μL) and 0.8 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG; 10 μL). The cultures were
incubated at 30 °C for 16-20 hours then pelleted at 5,000 rpm for 10 minutes and
stored at -80° C for 3 hours. The cell pellet was re-suspended using 500 µL of
Bugbuster (Novagen) containing lysozyme, and incubated at 37° C for 20
minutes. The solution was transferred to an Eppendorf tube and centrifuged at
15,000 rpm for 10 minutes, then the supernatant was added to an equilibrated
column of Ni-NTA resin (200 µL) and the GFP was purified according to
manufacturer’s protocol.
Coolmate Click Procedure: GFP containing 24 at residue 151 (30 μL, 0.5
mg/mL), Alexa Fluor-488 dye (20 μL, 1 mM), deionized water (1 mL), in the
presence and absence of CuSO4 (32 μL, 50mM) were added to a Coolmate vial.
The Coolmate was chilled to -50 °C, and the contents of the vial were cooled to 107

30 °C and subjected to microwave irradiation (200 W) until the contents of the
vial reached a temperature of 40° C. A buffer exchange was performed with
Spin-X UF concentrator columns, and PBS buffer (8 x 200 μL) to a final volume
of 50 μL. The GFP was analyzed by SDS-PAGE (BioRad 10% precast gels,
150V, 1.5 h). Gels were imaged on a BioRad Molecular Imager (Gel Doc XR+).
The gels were then stained with Coomassie Brilliant Blue for analysis.
1-benzyl-4-phenyl-1H-1,2,3-triazole (3):39 The solvent was removed in vacuo to
give 3 as a solid (38 mg, 0.16 mmol, 96.2% yield) 1H NMR (400 MHz; CDCl3): ∂
7.80 (m, 2H), 7.74 (s, 1H), 7.45-7.37 (m, 3H), 7.33-7.24 (m, 4H), 7.09-7.06 (m,
1H), 5.58 (s, 2H);

13C

NMR (400 MHz; CDCl3): ∂ 135.5, 133.3, 129.5, 129.2,

128.9, 128.9, 128.8, 128.8, 128.1, 127.1, 125.7, 119.5, 54.2, 51.8; GCMS (R t =
12.54) calculated for C15H13N3 235.29, was found to be 235.2. Regioisomer ratio
of 1,4:1,5 adducts was found to be 1.1:1.

Ph
N

N

N

Ph
3

Figure 4.5: 1H NMR of triazole 3.
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1-heptyl-4-phenyl-1H-1,2,3-triazole (10):40 The solvent was removed in vacuo
to give a 10 as a solid (16 mg, 0.11 mmol, 19.3% yield) 1H NMR (400 MHz;
CDCl3): ∂ 7.83 (d, J=8.5 Hz, 2H), 7.74 (s, 1H), 7.50-7.37 (m, 3H), 4.40 (t, J=7.9
Hz, 2H), 4.34 (t, J=8.0 Hz, 2H), 1.95-1.91 (m, 2H), 1.82 (m, 2H), 1.37-1.17 (m;
8H), 0.90-0.82 (m, 3H);

13C

NMR (400 MHz, CDCl3): ∂ 129.4, 129.0, 128.7,

125.7, 48.3, 31.5, 30.1, 28.5, 26.3, 22.4, 13.9; GCMS (Rt = 13.77 min) calculated
for C15H21N3 243.35, was found at 243.2. Regioisomer ratio of 1,4:1,5 adducts
was found to be 2:1.
C6H13
N

N

N

Ph
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Figure 4.6: 1H NMR of triazole 10.

4-phenyl-1H-1,2,3-triazole (11):41 The solvent was removed in vacuo to give 11
as a solid (16 mg, 0.11 mmol, 64.8% yield) 1H NMR (400 MHz; CDCl3): ∂ 7.98 (s,
1H), 7.83 (d, J=8.5 Hz, 2H), 7.48-7.37 (m, 3H);

13C

NMR (400 MHz; CDCl3): ∂

129.0, 128.8, 126.1; GCMS (Rt= 8.71 min) calculated for C8H7N3 145.16, was
found at 145.1.
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Figure 4.7: 1H NMR of triazole 11.

1-benzyl-4-butyl-1H-1,2,3-triazole (12):39 The solvent was removed in vacuo to
give 12 as a solid (35 mg, 0.16 mmol, 96.8% yield) 1H NMR (400 MHz; CDCl3): ∂
7.94 (s, 1H), 7.41-7.39 (m, 2H), 7.38-7.26 (m, 3H), 5.56 (s, 2H), 3.09 (t, J=7.9
Hz, 2H), 1.77 (q, J= 7.9 Hz, 2H), 1.00-0.91 (m, 3H);

13C

NMR (400 MHz; CDCl3):

∂ 129.3, 129.2, 128., 125.2, 54.5, 41.40, 17.41, 13.8; GCMS (R t = 11.67 min)
calculated for C13H17N3 215.30, was found at 215.2. Regioisomer ratio of 1,4:1,5
adducts was found to be 1:6.
Ph
N

N

N

C 4H 9
12

Figure 4.8: 1H NMR of triazole 12.
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4-butyl-1-heptyl-1H-1,2,3-triazole (13):42 The solvent was removed in vacuo to
give 13 as a solid (33 mg, 0.15 mmol, 87.3% yield) 1H NMR (400 MHz; CDCl3): ∂
7.73-7.70 (m, 1H), 4.30 (t, 2H), 4.24 (t, J=7.9 Hz, 2H), 1.76-1.73 (m, 2H), 1.411.26 (m, 14H), 1.00-0.85 (m, 6H);

13C

NMR (400 MHz; CDCl3): ∂ 130.9, 128.8,

65.9, 29.3, 28.9, 28.5, 25.9, 25.6, 23.7, 22.5, 14.0; GCMS (Rt = 10.49 min)
calculated for C13H25N3 223.36, was found at 223.2. Regioisomer ratio of 1,4:1,5
adducts was found to be 1:1.7.

C 6H13
N
N

N
C 4H 9

13

Figure 4.9: 1H NMR of triazole 13.

4-butyl-1H-1,2,3-triazole (14):43 The solvent was removed in vacuo to give 14
as a solid (20 mg, 0.16 mmol, 94.8% yield) 1H NMR (400 MHz; CDCl3): ∂ 8.18 (s,
1H), 3.04 (t, J= 7.9 Hz, 2H), 1.84-1.68 (m, 4H), 1.01 (t, 2H); GCMS (Rt = 8.78
min) calculated for C6H11N3 125.18, was found at 125.1.
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Figure 4.10: 1H NMR of triazole 14.

(1-benzyl-1H-1,2,3-triazol-4-yl) methanol (15):44 The solvent was removed in
vacuo to give 15 as a solid (1.2 mg, 0.62 mmol, 87.0% yield). 1H NMR (400 MHz;
CDCl3): ∂ 7.41-7.24 (m, 5H), 5.66 (s, 2H), 5.53 (s, 2H), 5.31 (s, 1H), 4.75 (s, 2H),
4.61 (s, 2H);

13C

NMR (400 MHz; CDCl3): ∂ 147.3, 129.3, 129.2, 129.1, 128.7,

128.3, 127.6, 122.2, 55.3, 54.8, 53.3, 52.7, 29.7; GCMS (Rt = 10.84 min)
calculated for C10H11N3O 189.22, was found at 189.2. Regioisomer ratio of
1,4:1,5 adducts was found to be 1:1.5.
Ph
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Figure 4.11: 1H NMR of triazole 15.
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(1-heptyl-1H-1,2,3-triazol-4-yl) methanol (16):45 The solvent was removed in
vacuo to give 16 as a solid (1.3 mg, 6.65 mmol, 92.5% yield). 1H NMR (400 MHz;
CDCl3): ∂ 7.68 (s, 1H), 7.58 (s, 1H), 5.49 (s, 1H), 4.79 (d, J=4 Hz, 2H), 4.42-4.35
(m, 2H), 1.93 (m, 2H), 1.35-1.25 (m, 8H), 0.90-0.86 (m, 3H);

13C

NMR (400 MHz;

CDCl3): ∂ 122.2, 55.3, 53.2, 51.1, 31.6, 31.5, 30.1, 28.7, 28.6, 26.5, 26.3, 22.5,
13.9; GCMS (Rt = 11.72) calculated for C10H19N3O 197.28, was found at 196.2.
Regioisomer ratio of 1,4:1,5 adducts was found to be 1.6:1.
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N

N

N
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16

Figure 4.12: 1H NMR of triazole 16.

(1H-1,2,3-triazol-4-yl) methanol (17):46 The solvent was removed in vacuo to
give 17 as an oil (< 5% yield). 1H NMR (400 MHz; CDCl3): ∂ 7.64 (s, 1H), 7.52
(s, 1H), 4.80 (s, 2H); GCMS (Rt = 10.84 min) calculated for C6H13N3OSi 171.28,
was found at 171.1.
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Figure 4.13: 1H NMR of triazole 17.

1-benzyl-4-(methoxymethyl)-1H-1,2,3-triazole (18): The solvent was removed
in vacuo to give 18 as a solid (29 mg, 0.14 mmol, 84.0% yield). 1H NMR (400
MHz; CDCl3): ∂ 7.44 (s, 1H), 7.36-7.27 (m, 5H), 5.50 (s, 2H), 4.54 (s, 2H), 3.37
(s, 3H). Regioisomer ratio of 1,4:1,5 adducts was found to be 1:1.4.
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Figure 4.14: 1H NMR of triazole 18.
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1-heptyl-4-(methoxymethyl)-1H-1,2,3-triazole (19): The solvent was removed
in vacuo to give 19 as a solid (27 mg, 0.13 mmol, 75.2% yield). 1H NMR (400
MHz; CDCl3): ∂ 7.50 (s, 1H), 4.57, (s, 2H), 4.32 (t, J= 14.6 MHz, 2H), 3.40 (s,
3H), 1.91-1.86 (m, 2H), 1.33-1.24 (m, 8H), 0.87-0.84 (t, J= 7.9 Hz 3H).
Regioisomer ratio of 1,4:1,5 adducts was found to be 1:1.7.
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Figure 4.15: 1H NMR of triazole 19.

4-(methoxymethyl)-1H-1,2,3-triazole (20): The solvent was removed in vacuo
to give 20 as a solid (9 mg, 0.080 mmol, 46.9% yield). 1H NMR (400 MHz;
CDCl3): ∂ 7.72 (s, 1H), 4.63 (s, 2H), 3.42 (s, 3H), 1.67 (s, 1H).
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Figure 4.16: 1H NMR of triazole 20.

1-benzyl-4-(trityloxy)-1H-1,2,3-triazole (21):47 The solvent was removed in
vacuo to give 21 as a solid (23 mg, 0.062 mmol, 32.7% yield). 1H NMR (400
MHz; CDCl3): ∂ 7.56 (s, 1H), 7.48 (d, 4H), 7.47-7.18 (m, 16 H), 6.99-6.97 (m, 4H),
5.52 (s, 2H), 5.50 (s, 2H), 4.31 (s, 2H), 4.08 (s, 2H). Regioisomer ratio of 1,4:1,5
adducts was found to be 1:3.
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Figure 4.17: 1H NMR of triazole 21.
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1-heptyl-4-(trityloxy)-1H-1,2,3-triazole (22):47 The solvent was removed in
vacuo to give 22 as a solid (8 mg, 0.018 mmol, 10.7% yield). 1H NMR (400 MHz;
CDCl3): ∂ 7.55 (s, 1H), 7.47-7.44 (m, 5H), 7.35-7.26 (m, 10H), 4.19 (s, 2H), 4.16
(t, J=7.8 Hz, 2H), 1.77-1.75 (m, 2H), 1.25-1.20 (m, 8H), 0.85 (t, J=8.0 Hz, 3H).
Regioisomer ratio of 1,4:1,5 adducts was found to be 1:3.
C6H13
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Figure 4.18: 1H NMR of triazole 22.

4-(trityloxy)-1H-1,2,3-triazole (23):48 The solvent was removed in vacuo to give
23 as a solid (7 mg, 0.021 mmol, 12.1% yield). 1H NMR (400 MHz; CDCl3): ∂
7.61 (d, 2H), 7.59 (d, J=9.2 Hz, 2H), 7.55 (d, J=9.2 Hz, 4H), 7.34-7.23 (m, 10 H),
3.76 (s, 2H), 3.73 (s, 2H).
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Figure 4.19: 1H NMR of triazole 23.
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Chapter 5: Site-directed Immobilization
of a Carboxylesterase Enzyme onto a
Stabilizing Resin
I. Introduction
While enzymes have long been known to play an indispensable role in
biological systems, discoveries involving their utility in chemical processes have
laid the groundwork for exciting new avenues of research. With the development
of improved methods of enzyme isolation and purification, their role has been
expanded to include several areas of research including materials science,
organic chemistry, pharmaceuticals, food and beverage, detergents, textiles, and
green chemistry.1-4 Enzymes are now employed in the production of over 500
products used in as many as 50 different applications. 1 The ability to use
enzymes to catalyze chemical reactions holds significant advantages over
traditional chemical catalysts. Enzymes are derived from renewable resources
and are biodegradable, which eliminates many environmental concerns
associated with chemical catalysts and has allowed for the replacement of
several chemical catalysts in applications such as bread making and textiles. 1
Enzymes provide high reaction rates under mild reaction conditions, such as
pressure, temperature, and pH levels, permitting these processes to occur at
lower costs.2-4 In addition, enzymes may eliminate the need for organic solvents
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in certain reactions.1 Moreover, enzymes are highly specific for their substrates
and have high stereoselectivities, allowing for the production of enantiomerically
pure products, which is highly beneficial in the development of pharmaceuticals. 4
Despite the countless benefits of enzymes, there are several associated
limitations which preclude their widespread use in the industrial realm.
The ability to maintain the structural integrity and activity of enzymes
during biochemical reactions is crucial for their effective use in the industrial
realm. The conditions for enzymatic reactions must be highly controlled as minor
changes in pH and temperature can lead to denaturation and inactivation of the
enzyme.5 Nevertheless, many industrial reactions involving enzymes require high
temperatures, nonaqueous solvents, or extremely acidic/basic conditions,
reducing their utility in such processes. Furthermore, transferring the utility of
enzymes from biological to chemical settings has proven difficult resulting from
the instability of enzymes in nonaqueous environments, such as organic
solvents, which are often essential for industrially relevant reactions and
substrate solubility.2 Additionally, in order for the commercial use of enzymes to
be economically viable and gain widespread implementation, a means to recycle
and reuse enzymes must be developed in order to compensate for the potentially
high cost of enzyme production.5 Furthermore, the inability to separate enzymes
from the reaction products can lead to contamination of the reaction product.6
The ability to immobilize enzymes onto solid supports serves as a viable method
to address many of these limitations.
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Protein immobilization is the attachment of an enzyme to a phase different
from that of the products or substrates, typically a solid matrix or support.5
Several solid-supports have been utilized for protein immobilization including
glass, beads, resins, silica, aluminum, titanium, carbon, and even certain
metals.6,7 The ability to immobilize proteins greatly expands the scope of
enzymatic reactions beyond biological processes. Significant improvements in
both the cost and efficiency of industrial processes involving enzymes have been
made as a result of this technique.6 Immobilized enzymes have greater stability
in nonaqueous environments, extreme pH levels, and high temperatures, further
expanding their utility in industrial processes.2 Additionally, with enzymes
coupled to a solid-support, they are able to be recycled and reused through
simple filtration.2,6 This also allows better control over reactions by allowing
separation of the catalyst from the products.6 In this manner, continuous flow
processes are possible through the elimination of the enzyme in subsequent
reaction steps.6 Several important applications have arisen from the ability to
immobilize proteins onto solid supports including the development of protein
microarrays, biosensors, continuous flow reactors, as well as developments in
drug discovery, diagnosis, and quality control.2,8
Several methods are commonly employed for enzyme immobilization
including adsorption, cross-linking, entrapment, and membrane confinement
(Figure 5.1).5 Adsorption is the attachment of enzyme to an inert surface, such as
glass or beads, through noncovalent hydrophobic interactions, salt linkages, and
polar interactions. This method is limited by slow reaction times. In addition, this
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Figure 5.1: A visual representation of the different immobilization techniques.9

method is limited by specificity as enzymes bind heterogeneously and in random
orientations, meaning that the active site of the enzyme may be inaccessible as a
result of binding to the matrix.5 Additionally, since a new chemical bond is not
formed, enzymes may lose their attachment to the matrix, decreasing activity and
contaminating the solution phase. Entrapment (physical adsorption) involves the
implementation of an insoluble polymer network, such as silica gel, to cage the
enzyme.5,9 Enzymes are protected from the environment; however, this method
limits the accessibility of the enzyme to the substrate and the amount of product
that can be released.5 Covalent immobilization involves attachment of proteins to
solid-supports using accessible functional groups of reactive amino acid
residues, such as cysteine, lysine, serine, and glutamine.8 Attachment may also
be random in this case as there is little control over the number and location of
residues that react. In addition, many covalent reactions are caustic and may
lead to denaturation of the enzyme.11 This reaction provides the strongest bond
between the enzyme and solid support, preventing leaching of the enzyme during
the reaction. Enzyme stability and activity may be impacted during immobilization
due to the transfer of the enzyme from a soluble to insoluble state, making the
choice of immobilization methodology crucial. 10
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The use of unnatural amino acid (UAA) technology has been implemented
to overcome the limitations of current immobilization methodologies. Through the
use of the Schultz methodology for UAA incorporation, UAAs containing reactive
groups can be site-specifically incorporated into proteins. Bioorthogonal coupling
reactions between functional groups present in the UAA and a coupling partner,
such as a solid support, have previously been optimized. 13 These reactions are
specific in that coupling only occurs between the functional group of the UAA and
a complementary functional group on the surface without interfering with native
cellular processes.14 The use of bioorthogonal reactions allows enzymes to be
immobilized in a homogenously oriented fashion determined by the site of UAA
incorporation, eliminating the
production of heterogenous
mixtures on the solid support
(Figure 5.2).2 This improves
enzyme activity levels as the
accessibility of the active site
can be controlled. Previous
Figure 5.2: A comparison of random vs. controlled protein
immobilization orientation using UAAs.12

work has demonstrated that

GFP can be site-specifically immobilized onto a solid-support resin using UAAs.2
It was found that the immobilization of GFP onto the solid-support resin allowed
the structural integrity of the protein to be maintained under typically denaturing
conditions.2 While this research served as a valuable proof of concept, GFP is a
reporter protein and not an enzyme, necessitating the need for further studies
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involving enzymes. For the purpose of this study, a caboxylesterase enzyme
(SSO Est) obtained from the archaeon Sulfolobus sulfataricus will be utilized. A
carboxylesterase enzyme cleaves an ester into an alcohol and a carboxylate
through a hydrolysis reaction.15 These enzymes are found in a wide variety of
organisms including plants, animals, and microorganisms. 15 The use of SSO Est
is further step toward the eventual utilization of UAA-mediated protein
immobilization in industrially relevant hyperthermophilic enzymes.
Hyperthermophilic enzymes are a fascinating class of enzymes that
function at extremely high temperatures between 80 and 110 °C. S. sulfataricus
P1 is a hyperthermophilic archaeon capable of surviving in sulfur-rich volcanic
hot springs. These organisms thrive at high temperatures and low pH. 15,16
Enzymes from hyperthermophilic archaea have key applications in biotechnology
and industry resulting from their ability to maintain stability under extreme
conditions. This increased stability coupled with a solid support is especially
useful in multiple applications. These enzymes are highly specific and are
currently being used for a variety of industrial purposes including food, paper, oil
production, toxic waste removal, detergents, as well as pharmaceuticals. 17 In
addition, they serve as model systems for use in evolutionary studies of
enzymes, mechanisms of protein stability, and determining the upper
temperature limit for enzyme function.16 Enzymes from hyperthermophilic
organisms allow researchers to examine the relationship between structural
flexibility and catalytic function over large temperature ranges.17 Experimental
evidence has shown that at increasing temperatures, hyperthermophilic enzymes
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become less conformationally flexible in order to overcome thermally denaturing
forces.16,18 Unfortunately, this limits their catalytic functionality at physiological
temperatures due their rigidity. Various denaturants, detergents, and solvents
have been shown to activate hyperthermophilic enzymes at lower temperatures;
however, these conditions may also lead to protein denaturation. 16,18 Studies
have demonstrated that the introduction of dimethylformamide, acetonitrile, and
dioxane solvents at physiological temperatures led to a decrease in enzymatic
activity due to denaturation while DMSO allowed for an increase in enzymatic
activity due to conformational changes leading to a reduction in rigidity.18 We
believe that by immobilizing SSO Est onto a solid support, the range of
conditions, including solvents, in which the enzyme is catalytically active can be
expanded.
Herein, the initial steps toward site-specific immobilization of SSO Est onto
a stabilizing resin using UAAs are
discussed. This research expands
off of previous work involving the
immobilization of GFP onto a solid
support resin using UAAs. Unlike
GFP, SSO Est catalyzes an organic
reaction whose kinetics can be
quantified through a previously
established solution based assay.
Upon successful incorporation of

Figure
5.3:
Structures
obtained
from
immobilization of SSO Est using a Glaser-Hay
reaction (A) and 1,3-dipolar cycloaddition
bioconjugation reaction (B).
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azide

and

terminal

alkyne

containing

UAAs,

bioorthogonal

1,3-dipolar

cycloaddition or Glaser-Hay coupling between the mutated SSO Est and alcohol
derivatized sepharose resin were carried out (Figure 5.3). Comparisons were
made via assay between mutant and wild type SSO Est when subject to these
reaction conditions to demonstrate the continued activity of the enzyme despite
the insertion of a mutation. Upon optimization, this methodology can then be
extended to other hyperthermophilic proteins and eventually mesophilic
enzymes, which have greater industrial relevance. In addition, immobilized SSO
Est can be subjected to various solvents in order to demonstrate the ability of the
enzyme to function under a wider range of conditions. Immobilized SSO Est may
also have utility within microwave irradiation applications.
II. Results and Discussion
Wild type (WT) SSO Est plasmid was obtained from Robert Kelly at North
Carolina State University. The WT gene was encoded on a pQE-30 plasmid;
however, this plasmid was not independently compatible with the BL21 (DE3)
competent cells utilized by our laboratory for protein expression which utilize a T7
RNA polymerase. The pQE-30 plasmids contain a T5 promoter, which has an
extremely high transcription rate and is recognized by the T7 RNA polymerase
within the competent cells. To express proteins containing UAAs, an inducible
plasmid system is required which is orthogonal to the E. coli expression system.
This is often accomplished in our laboratory using pET plasmids which contain a
T7 promoter and BL21 (DE3) competent cells which contain a plasmid harboring
an IPTG-inducible gene for T7 RNA polymerase. IPTG binds to the lac repressor
132

and releases it from the operator, allowing the expression of lac controlled genes
only in the presence of IPTG. Consequently, expression of proteins containing
UAAs only begins after induction by the addition of IPTG. In order to allow for
inducible gene expression when using pQE-30 plasmids, the plasmids are cotransformed with a pREP4 plasmid, which contains a kanamycin resistance gene
and constitutively expresses the lac repressor protein, preventing constitutive
gene expression from occurring. In this manner, pQE-30 plasmids can be
expressed using BL21 (DE3) competent cells in an inducible system controlled
by IPTG.
Using the crystal structure of SSO Est, three sites were chosen for sitespecific insertion of UAAs through amber suppression. Because tyrosine shares
a similar structure to the UAAs to be incorporated into SSO Est, surface-exposed
tyrosines were selected as the residues to be mutated. Based off an examination
of the crystal structure, Y90TAG (SSO 90), Y116TAG (SSO 116), and Y191TAG
(SSO 191) were selected as the three sites for mutagenesis. QuickChange PCR
was carried out to
incorporate
mutation

a

TAG

at

the

selected sites (Figure
5.4).
Figure 5.4: QuickChange PCR methodology.21

QuickChange

PCR utilizes exactly

complimentary forward and reverse primers containing the TAG mutation in the
selected position to synthesize a mutant DNA strand using the parental plasmid
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(SSO Est WT) as a template. PCR was carried out using three different
concentrations of template plasmid: 24.7 ng/µL, 12.3 ng/µL, and 6.2 ng/µL.
Template plasmid is first denatured by increasing the temperature. The
temperature is then lowered, allowing the primers to anneal. The temperature is
then raised allowing DNA polymerase to extend the mutant strand. Methylated
parental DNA is then digested using DpnI, leaving only plasmid harboring the
TAG mutation. Negative control reactions in which polymerase was not added
were prepared for each site to be able to monitor digestion of template primer.
Both reactions and controls for each site transformed into E. coli cells and were
plated in the presence of ampicillin. The best differential growth between reaction
and control plates was obtained using 24.7 ng/µL, particularly for the SSO 90 and
SSO 191 mutants. Successful incorporation of the TAG mutation for each site
was confirmed by sequencing at Genewiz using primers specific for the T5
promoter in the pQE-30 backbone of the SSO Est plasmid. Sequencing results
confirmed successful incorporation of the TAG mutation in each of the three
selected sites.
With the three mutated plasmids in hand, initial attempts were made to
express both WT and mutant SSO Est enzymes and evaluate their activity via
assay. WT enzyme was expressed by co-transforming the SSO Est plasmid (0.5
µL) with a pREP4 plasmid (0.5 µL). Cells were grown in the presence of
ampicillin and kanamycin antibiotics. A 50 mL expression was prepared and
induced by the addition of a 1:1000 ratio of IPTG. The expression was grown for
16 hours at 37 °C. Because of the hyperthermophilic nature of SSO Est, purified
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enzyme was obtained by heating the cell lysate at 80 °C for 1 hour. Successful
expression of WT enzyme was confirmed through SDS-PAGE analysis as a band
was observed as 33 kDa; however, there was also a band at approximately 37
kDa indicating the overexpression of a different hyperthermophilic impurity which
was not removed by heating. To express mutant SSO Est enzyme, a triple
transformation was carried out by co-transforming a mutant SSO Est plasmid
(0.33 µL) with a pREP4 plasmid (0.33 µL) and a pEVOL-pCNF synthetase
plasmid (0.33 µL), allowing for incorporation of UAAs via an orthogonal
aaRS/tRNA pair evolved from M. jannaschii. Cells were grown in the presence of
ampicillin,

chloramphenicol,

and

kanamycin antibiotics. Expression
and purification of mutated SSO Est
at each of the three sites was
carried out in a similar manner as
WT with enzyme expression being
induced by the addition of a 1:1000
ratio of IPTG and 20% arabinose and
a 1:100 ratio of pPrF. Unfortunately,
successful expression of mutated
SSO Est was not obtained as could

Figure 5.5: SDS-PAGE analysis of WT and
mutant SSO Est enzymes. Lane 1 contains WT
enzyme. Lane 2 contains SSO 90 expressed
with pAzF. Lane 3 contains SSO 191
expressed with a pEVOL WT synthetase which
incorporates a tyrosine at the site of the TAG.
Little to no expression of SSO Est is evident for
the mutants and the impurity is overexpressed.
The WT expression contained a mixture of
SSO Est enzyme and the impurity.

be seen by the lack of the characteristic SSO Est band on SDS-PAGE gels. In
addition, the impurity was still present in large quantities despite the lack of SSO
Est enzyme expression (Figure 5.5). The lack of significant levels of mutant
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enzyme expression was further confirmed via a colorimetric esterase assay. This
assay involves the hydrolysis of 4-nitrophenyl hexanoate into an alcohol (4nitrophenol) and a carboxylic acid (hexanoic acid) through the activity of the SSO
Est enzyme (Scheme 5.1).15 The formation of 4-nitrophenol causes a yellow color
change which can be measured via absorbance measurements taken 405 nm. 15

Scheme 5.1: Carboxylesterase assay reaction.15

The formation of this product is used an indicator of SSO Est activity. 15 Assay
results indicated that the WT enzyme had significant activity when compared to
the mutants, which showed trace to no activity. We hypothesized that this lack of
activity resulted from the fact that SSO Est enzyme was present in low
concentrations, but was poorly expressed relative to the impurity, which could not
be removed through purification. As a result, we sought to optimize the
expression methodology of SSO Est to improve mutant concentrations and
reduce the amount of impurity present.
Several variables were tested to improve the expression levels of mutant
SSO Est enzymes. The first variable tested was temperature. Expressions were
incubated overnight at three different temperatures following induction: room
temperature (22 °C), 30 °C, and 37 °C. Unfortunately, expressions grown at room
temperature and 30 °C did not show any significant improvement over those
grown at 37 °C. Moreover, impurity levels were slightly higher in most cases for
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Figure 5.6: SDS-PAGE analysis of SSO Est mutants expressed at different temperatures.
These results indicate that for each of the mutants, the levels of impurity were highest at 37 oC
and lowest at 30 oC. No significant expression of SSO Est was obtained for any of the mutants
at any of the selected temperatures, which was confirmed using the esterase assay.

those expressions grown at 37 °C (Figure 5.6). It was then hypothesized that
scaling up the expression size may increase the amount of enzyme obtained.
Upon increasing expression sizes to 250 mL, the amount of impurity was
reduced; however, there was no 33 kDa band indicating the presence of SSO
Est. The purified samples also failed to display any significant activity when
subject to the esterase assay. Attempts were also made to alter the purification
method by increasing or decreasing the denaturation time. Upon decreasing the
heating time from 1 hour to 30 minutes and increasing heating time to 2 hours,
no changes in the expression level or the amount of impurity were seen.
Additional attempts to concentrate and buffer exchange SSO Est mutants into
PBS buffer did not yield successful results. Utilization of the pUltra synthetase for
unnatural amino acid incorporation also failed to yield SSO Est enzyme for any of
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the mutants. It was then hypothesized that the previously isolated pREP4
plasmid may have contained WT plasmids that were interfering with enzyme
expression. To further isolate the pREP4 plasmid, selection pressure was utilized
by growing the pREP4 plasmid in the presence of kanamycin so that only the
pREP4 plasmid was maintained within the cells. Four rounds of selection were
used to obtain pure pREP4 as confirmed via agarose gel electrophoresis.
Unfortunately, no significant SSO Est expression for any of the mutants
expressed with the purified pREP4 resulted. It was apparent that the expression
issues encountered for the mutants resulted from the introduction of the third
plasmid used for the UAA expression system. To confirm this theory, each of the
three mutated SSO Est plasmids were co-transformed with purified pREP4
plasmid and a pEVOL WT synthetase, which would incorporate a standard
tyrosine into the location of the TAG mutation using the orthogonal aaRS/tRNA
pair, making WT enzyme. The lack of SSO Est enzyme obtained from these
expressions confirmed our theory that the three-plasmid system was ineffective
for expressing the SSO Est mutants.
As a result of the difficulties encountered in the expression of mutant SSO
Est enzyme using the three-plasmid system, we sought to clone WT and mutant
SSO Est genes into pET 22(b)+ plasmids, which have been successfully used by
our lab in the expression of several different UAA-containing proteins. We first
attempted to clone SSO Est WT into a pET 22(b)+ plasmid (Figure 5.7). To clone
the SSO Est plasmid into the pET plasmid, forward and reverse primers were
designed that contained restriction sites found in both the SSO Est plasmid and
138

Figure 5.7: The general methodology for the cloning of the SSO Est gene into the pET 22(b)+
vector.22

the pET 22(b)+ plasmid. The XhoI and NdeI restriction sites were selected for
cloning and were included in the primers. First, the vector in which the SSO Est
insert was to be cloned was prepared. To do this, a pET 22(b)+ plasmid was
digested at both the XhoI and NdeI restriction sites. The plasmid was then
dephosphorylated to prevent the plasmid from recircularizing in the absence of
the SSO Est insert. The plasmid was the analyzed using agarose gel
electrophoresis (Figure 5.8). The SSO Est insert was prepared by amplifying the
SSO Est WT gene using PCR. The amplified SSO Est WT gene was then
digested in the same manner as the pET plasmid using the XhoI and NdeI
restriction sites. Using digested SSO Est WT insert and the pET 22(b)+ vector,
ligation reactions were prepared using both a 2:1 and 1:1 ratio of vector to insert.
Control reactions were prepared using the SSO Est insert to ensure that no
undigested parent plasmid was present and using the pET 22(b)+ insert to
ensure that no recircularization of the parent plasmid occurred. Ligation reactions
and controls were plated on ampicillin plates. No growth was evident on either of
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the controls and colonies were evident on the plate using the 2:1 ratio of insert to
vector. To determine whether the SSO Est WT plasmid was successfully cloned
into the pET 22(b)+ plasmid, the ligation reaction was digested using SpeI, which
cuts inside the SSO Est plasmid. Successful digestion of the SSO Est plasmid
was confirmed via agarose gel electrophoresis, indicating the presence of the
SSO Est WT gene within the ligated plasmid. The SSO 191 mutant was then
cloned into the pET 22(b)+ plasmid using the same process.

Figure 5.8: Agarose gels displaying successful cloning of the SSO Est gene into a pET 22(b)+ plasmid.
Successful amplification of the SSO Est gene was confirmed by the bright band at approximately 1,000
bp (A). Successful digestion of the pET 22(b)+ plasmid was confirmed by the presence of a band at
approximately 6,000 bp after digestion compared to the 5,0000 bp band before digestion (B).
Successful cloning of the ligated plasmid was confirmed through digestion with SpeI, which cuts within
the SSO Est gene. The appearance of new band at approximately 8,000 bp indicates successful
digestion and the presence of the SSO Est gene in the ligated plasmid (C). Growth in the presence of
ampicillin indicates the presence of the pET 22(b)+ plasmid which has an ampicillin resistance tag.

Having successfully cloned the SSO WT and SSO 191 plasmids into pET
plasmids, we were able to prepare expressions for both WT and mutant enzyme.
A 20 mL expression was prepared for WT as described previously. Since the
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pREP4 plasmid was no longer necessary, cells were only grown in the presence
of ampicillin. Enzyme expression was induced with a 1:1000 ratio of IPTG.
Because the pET 22(b)+ plasmid contains a His-Tag, SSO Est could be purified
using a Ni column. To further
enhance the purity of the
enzyme, the cell lysate was
heated at 80 °C prior to
purification

using

the

Ni

column. The presence of
purified WT enzyme was
confirmed

through

the

presence of a 33 kDa band

Figure 5.9: SDS-PAGE analysis of WT and SSO 191
expressions with and without the addition of pAzF. Pure
WT and SSO 191 enzyme were obtained. Minimal
expression was seen in the absence of UAA as
expected. Slightly lower expression levels were seen in
mutant vs. WT enzyme.

via SDS-PAGE (Figure 5.9). SSO 191 was expressed and purified in a similar
manner by growing cells in the presence of ampicillin and chloramphenicol and
inducing with a 1:1000 ratio of IPTG and 20% arabinose and a 1:100 ratio of an
azide containing UAA, pAzF. A second expression was carried out to express
SSO 191 with a terminal alkyne containing UAA, pPrF. Negative control
expressions were prepared which were not induced with UAA. The presence of
SSO 191 was confirmed by via SDS-PAGE analysis. Only minimal levels of
enzyme expression occurred in the absence of UAA due to the incorporation of
tyrosine at the TAG mutation site. The 37 kDa impurity was no longer present in
either the WT or mutant samples. Fortunately, when subject to the esterase
assay, WT and SSO 191 in the presence of both UAAs showed enzymatic
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activity, with SSO 191 mutants displaying slightly more activity compared to WT.
The assay was carried out in triplicate to verify the reproducibility of these results
(Figure 5.10). These results confirmed that both WT and mutated SSO Est
enzyme containing UAAs were successfully expressed and were both active. It
was evident that introduction of UAAs did not lead to any significant reduction in
enzymatic activity.

Figure 5.10: A comparison of esterase assay results using WT and SSO 191 containing pAzF.
Results indicate enzymatic activity levels were maintained in mutant enzymes as can be seen by
comparable absorbance levels at 405 nm for WT and SSO 191 enzymes. The differences in
absorbance at 405 nm. is evident through the yellow color of both the WT and mutant samples
when compared to negative control (pictured). Error bars represent standard deviation.

With the UAA containing enzymes in hand, we next sought to immobilize
SSO Est onto a stabilizing resin. Previous studies involving the immobilization of
GFP have shown the Epoxy Sepharose 6B resin allows for the most efficient
immobilization of proteins. In order to immobilize protein onto the resin, the resin
must first be coupled with an alcohol containing a terminal alkyne, allowing
bioorthogonal reactions to occur between the resin and the UAA-containing
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protein (Figure 5.11).
A

1,3-dipolar

cycloaddition reaction
could

then

occur

between the terminal
alkyne of the resin and
the

azide

group

of

SSO 191 containing
pAzF. In addition, a
Glaser-Hay

reaction

could occur between
the terminal alkyne of

Figure 5.11: Immobilization reactions using Sepharose 6B resin.
Resin is first coupled with an alcohol containing a linker of varying
length (A). Bioorthogonal reactions can then occur allowing for
coupling between the terminal alkyne of the resin and the UAA
using either a Glaser-Hay coupling (B) or a 1,3dipolarcyloaddition (C).

the resin and the terminal alkyne of SSO 191 containing pPrF.

In order to

optimize the immobilization conditions, Sepharose resin was coupled with alkynyl
alcohols containing carbon linkers of various lengths. Resins were coupled with
propargyl alcohol, 5-hexyn-1-ol, and 10-undecyn-1-ol. Coupled resins were then
reacted with ethanolamine to prevent non-specific coupling of enzyme to the
resin. The use of bioorthogonal reactions ensures that the immobilization
reaction is specific, occurring only between the resin and the functional group of
the UAA incorporated at the specific residue on the enzyme.
SSO 191 containing pAzF was subjected to 1,3-dipolar cycloaddition
reactions with each of the three resins. Reactions were prepared using CuSO 4,
TBTA, and TCEP as the catalyst system at 4 °C for 14 hours. A control reaction
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was prepared using WT enzyme to ensure that non-specific coupling of SSO Est
did not occur. A separate control reaction was prepared using only resin and
PBS buffer in to eliminate any background absorbance caused by the resin when
performing the assay. Upon completion of the reaction, resins were washed 10
times using PBS buffer to wash away any unreacted enzyme. Washed resins
were then subject to the esterase assay. Assay reactions for SSO 191 and each
of the controls were performed in triplicate. No significant absorbance was
0.05
0.045
SSO 191

Absorbance at 405 nm

0.04

Wild Type

0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
Propargyl Alcohol

10-undecyn-1-ol

Figure 5.12: Esterase assay results for 1,3-dipolar cycloaddition immobilization reactions. It is
evident that site-specific immobilization occurred using both resins; however, more efficient
coupling was attained using propargyl alcohol. Activity levels were significantly reduced when
WT enzyme was utilized in the reaction. Error bars represent standard deviation.

observed for SSO 191 or any of the controls when 5-hexyn-1-ol was used as the
linker (results not shown). A significant difference in activity was evident between
SSO 191 and the WT control when propargyl alcohol was used as the linker
(Figure 5.12). A similar difference was seen between SSO 191 and WT when
using 10-undecyn-1-ol as the linker, but with less overall activity. These results
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indicate that shorter linker length allows for better immobilization, which
corroborated previous studies. For both resins, it was evident that the SSO 191
enzyme was site-specifically coupled to the resin; however, based off the activity
levels observed when using WT enzyme, some non-covalent association of the
WT enzyme also occurred.
Similar results were obtained when SSO 191 was subject to Glaser-Hay
reactions with each of the three resins. Reactions were carried out for 6 hours at
37 °C using a CuI and TMEDA catalyst system followed by 10 washes with PBS.
Control reactions were prepared as described previously. Assay results indicated
that SSO 191 showed increased activity when compared to the WT control for
both the propargyl alcohol and 10-undecyn-1-ol resins, with propargyl alcohol
resin showing slightly more activity. Interestingly, there was less of a difference
between propargyl alcohol and 10-undecyn-1-ol resins using the Glaser-Hay
reaction as opposed to the 1,3-dipolar cycloaddition reaction. Standard
deviations were significantly larger for each trial for these reactions; however,
which highlights the need further optimization of the assay protocol. In this
scenario it appears that the 1,3-dipolar cycloaddition lead to more enzymatic
immobilization. It was evident that site-specific immobilization occurred; however,
there was also some non-specific coupling as can be seen by the activity in the
WT control for both resins. Significant coupling was not obtained for SSO 191 or
the controls using hexyn-1-ol resin (results not shown). Overall, these results
indicate that SSO Est was site-specifically immobilized onto the Sepharose resin
using both 1,3-dipolar cycloaddition reactions and Glaser-Hay reactions with
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relatively equal efficiencies. In addition, it was evident that shorter linkers allow
for optimum immobilization.
In summary, both WT and SSO 191 enzyme were successfully cloned into
pET plasmids. Alkyne and azide-containing UAAs were successfully incorporated
into SSO 191 and activity levels were maintained. Using SSO 191,
immobilization reactions were carried out using resins containing carbon linkers
of various lengths through both 1,3-dipolar cycloadditions and Glaser-Hay
reactions. SSO 191 was successfully coupled to the resin using both reactions
and resins contained activity levels significantly larger than the WT controls.
More effective immobilization was achieved using shorter carbon linkers,
especially using the 1,3-dipolar cycloaddition reaction. Future work will involve
the cloning and expression of additional mutants, SSO 90 and SSO 116, to
determine if either of these sites allow for more effective immobilization. In
addition, studies will be conducted to non-specifically couple SSO Est to a
stabilizing resin using reactive amino acid residues, such as cysteine. It is
hypothesized that the activity levels of these resins will be significantly lower than
those obtained using the technique described herein, which will prove its utility.
This technique can then be translated to other proteins of therapeutic and
industrial significance. Studies will also be conducted involving resubjecting
resins to multiple assays to demonstrate the recyclability of the SSO Est enzyme
when immobilized on the resin. Using this technique, we will demonstrate that
UAA technology can be used to site-specifically immobilize enzymes onto
stabilizing resins, allowing for recyclability and an improvement in activity levels
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when compared to techniques that utilize non-specific coupling. This work will
also facilitate studies in nonaqueous solvents and enzymatic activation via
microwave irradiation.
III. Materials and Methods
General: Solvents and reagents were either obtained from Fisher Scientific or
Sigma-Aldrich and used without further purification unless otherwise noted.
Epoxy-activated 6B resin was obtained from GE Healthcare. The SSO P1
Carboxylesterase plasmid was obtained from the Kelley lab at NCSU. PCR was
performed using a Bio-RAD icycler and the Quick-Change II kit. All SSO proteins
were purified according to the manufacturer’s protocols using a Qiagen Ni-NTA
Spin Kit. The esterase assay was performed using a Synergy HT microplate
reader.
Quick-Change PCR Protocol: Three sites were selected for insertion of the
TAG mutation: Y90, Y116, and Y191. A pQE-30 plasmid harboring SSO P1
carboxylesterase was diluted to 24.7 ng/µL using sterilized deionized water. The
PCR reaction mixture was prepared by adding the diluted plasmid (5 µL) to 10
mM DNTPs (0.75 µL), KAPA Hi-Fi Polymerase (0.5 µL), forward primers (10 mM,
0.75 µL), reverse primer (10 mM, 0.75 µL), KAPA buffer (5 µL), and Milliq water
(12.25 µL). A negative control PCR mixture was prepared without the addition of
KAPA Hi-Fi polymerase. The reaction mixture was subjected to the following
heating protocol: 95 °C (1 min.), eighteen cycles of melting (95 °C, 30 s),
annealing (55 °C, 30 s), and, extension (68 °C, 6 min), followed by an additional
extension cycle (68 °C, 6 min) then an infinite hold at 4 °C. For both the reaction
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and control mixtures, the parent plasmid was digested and the mutant plasmid
was ligated by the addition of DPN1 (20,000 units/µL, 2 µL), 5x T4 Ligase buffer
(4 µL), and T4 Ligase (1 µL). The mixtures were then heated at 37 °C for 2 hours
followed by one cycle of heat deactivation at 80 °C for 15 minutes. The reaction
and control mixtures were cleaned and concentrated using a Zymo DNA Clean
and Concentrator kit. The reaction and control mixtures were transformed (5 µL)
into BL21 DE3 Escherichia coli cells by heat shock using an Eppendorf eporator
electroporator. The transformed cells were plated and cultured (500 µL) onto LB
agar containing ampicillin (50 µg/mL) and incubated at 37 °C overnight.
Differential growth between the reaction and control plates was observed. One
colony from the reaction plate was used to inoculate 10 mL of LB media
containing ampicillin (50 µg/mL). This culture was incubated and allowed to
shake at 37 °C overnight. The resulting cells were mini-prepped using an IBI
High Speed Plasmid Mini Kit to isolate the DNA. The isolated plasmids were
analyzed for successful insertion of the TAG mutation by sequencing at Genewiz.
The primers were obtained from IDT DNA Technologies Inc. and are as follows:
Y90TAG 5’-TGT AAT AGG CGA TGT GGA ATC TTA GGA CCC ATT ATG TAG
AG-3’ (forward) and 5’-CTC TAC ATA ATG GGT CCT AAG ATT CCA CAT CGC
CTA TTA CA-3’ (reverse), Y116TAG: 5’- CTA TAG GTT AGC TCC AGA ATA
GAA GTT TCC TTC TGC AGT-3’ (forward) and 5’-ACT GCA GAA GGA AAC
TTC TAT TCT GGA GCT AAC CTA TAG-3’ (reverse), Y191TAG 5’-CAA GAT
CCA TGA TAG AGT CTG ATG GGT TCT TCC T- 3’ (forward) and 5'-AGG AAG
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AAC CCA TCA GAC TAC TCT ATC ATG GAT CTT G-3’ (reverse). The
sequencing primer was 5’-TTC TGC TGA GCG GAT AAC-3’.
Cloning of SSO into a pET 22(b)+ Vector: SSO Est WT and each of the three
SSO Est TAG mutant plasmids were cloned into a pET 22(b)+ vector. Plasmids
were cut using the XhoI (forward) and NdeI (reverse) restriction sites. PCR
reactions were carried out on SSO Est WT and each of the three SSO Est TAG
mutant plasmids to amplify the SSO Est gene. Reaction mixtures were prepared
by adding SSO Est plasmid (2 µL) to 10 mM DNTPs (2 µL), KAPA Hi-Fi
Polymerase (1 µL), forward primer (10 mM, 2 µL), reverse primer (10 mM, 2 µL),
KAPA buffer (5 µL), and Milliq water (11 µL). The reaction mixture was subjected
to the following heating protocol: 95 °C (4 min.), thirty cycles of melting (95 °C, 30
s), annealing (51 °C, 30 s), and, extension (72 °C, 45 s), followed by an
additional extension cycle (72 °C, 5 min) then an infinite hold at 4 °C. Successful
amplification of the SSO Est gene was determined using agarose gels (1%)
stained with ethidium bromide. Gels were run for 1 hour at 80V in 1x TAE buffer
(diluted from a 5x stock containing 242 g Tris-base, 57.1 mL glacial acetic acid,
100 mL 0.5 M EDTA (pH 8.0), 842 mL deionized water). Gels were analyzed
using a Bio-Rad Molecular Imager (Gel Doc XR+) gel imager (Ethidium bromide
protocol). Double digestion of the PCR product was carried out by preparing a
reaction mixture containing 23 µL of the amplified SSO Est plasmid, 20 µL sterile
deionized water, 0.5 µL BSA, 5 µL 10x CutSmart buffer, 1 µL Xhol restriction
enzyme, and 1 µL NdeI restriction enzyme. The mixture was heated for 3 hours
at 37 °C followed by one cycle of heat deactivation at 80 °C for 15 minutes. The
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reaction mixture was cleaned and concentrated using a Zymo DNA Clean and
Concentrator kit. Successful digestion of the SSO Est plasmid at both restriction
sites was confirmed using an agarose gel (1%) as described previously. Double
digestion of the pET 22(b)+ plasmid was performed in an identical manner as the
SSO Est plasmid. Dephosphorylation of the digested pET 22(b)+ plasmid was
carried out by preparing a reaction mixture containing 20 µL of cut pET 22(b)+
plasmid, 5 µL Antarctic phosphodiesterase buffer, 2 µL phosphatase enzyme,
and 23 µL sterile deionized water. The reaction mixture was incubated for 1 hour
at 37 °C followed by one cycle of heat deactivation at 80 °C for 15 minutes. The
product was then cleaned and concentrated using a Zymo DNA Clean and
Concentrator kit. A ligation reaction was prepared using a 1:1 ratio of digested
SSO Est insert to digested pET 22(b)+ vector by mixing 2 µL digested SSO Est
plasmid, 2 µL digested pET 22(b)+ plasmid, 1 µL T4 ligase buffer, 1 µL T4 ligase,
and 4 µL sterile deionized H2O. A second ligation reaction was prepared using a
2:1 ratio of digested SSO Est insert to digested pET 22(b)+ vector by mixing 4 µL
digested SSO Est plasmid, 2 µL digested pET 22(b)+ plasmid, 1 µL T4 ligase
buffer, 1 µL T4 ligase, and 2 µL sterile deionized water. A control reaction was
prepared for the SSO Est insert by mixing 1 µL digested SSO Est vector, 1 µL T4
ligase buffer, 1 µL T4 ligase, and 7 µL sterile deionized water. A second control
reaction was prepared for the pET 22(b)+ insert by mixing 1 µL digested pET
22(b)+ plasmid, 1 µL T4 ligase buffer, 1 µL T4 ligase, and 7 µL sterile deionized
water. Ligation reactions were incubated overnight for approximately 16 hours at
4 °C. The reaction and control mixtures were transformed (4 µL) into BL21 DE3
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Escherichia coli cells by heat shock using an Eppendorf eporator electroporator.
The transformed cells were plated and cultured (500 µL) onto LB agar containing
ampicillin (50 µg/mL) and incubated at 37 °C overnight. Differential growth
between the reaction and control plates was observed. One colony from the
reaction plate was used to inoculate 10 mL of LB media containing ampicillin (50
µg/mL). This culture was incubated and allowed to shake at 37 °C overnight. The
resulting cells were mini-prepped using an IBI High Speed Plasmid Mini Kit to
extract the DNA. The isolated plasmids were analyzed for successful cloning
through reaction with a restriction enzyme that cuts within the SSO Est gene. The
reaction was prepared by mixing 20 µL of cloned plasmid with 0.5 µL BSA, 5 µL
CutSmart buffer, 1 µL SpeI restriction enzyme, and 24 µL sterile deionized water.
Successful digestion using the SpeI restriction site was confirmed using an
agarose gel (1%) as described previously. Primers were obtained from IDT DNA
Technologies Inc. and are as follows: 5’-GGT GGT GGT GCT CGA GAT GCC
CCT AGA TCC TAG A-3’ (forward) and 5’-AAG GAG ATA TAC ATA TGT TAA
ATT TTA TCA TAA AAT ACT CGT-3’.
Expression and Purification of SSO: A pET 22(b)+ plasmid harboring a
variable SSO Est TAG mutant (0.5 µL) was co-transformed with a pEVOL-pCNF
plasmid (0.5 µL) into BL21 DE3 E. coli cells by heat shock using an Eppendorf
eporator electroporator. The cells were then plated and cultured (300 µL) on LB
agar containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) at 37 °C in
an incubator overnight. One colony was then utilized to inoculate LB media (4
mL) containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This
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culture was then incubated and allowed to shake at 37 °C overnight. The
following day, this culture was then used to inoculate an expression culture
containing LB media (10 mL), ampicillin (50 µg/mL) and chloramphenicol (34
µg/mL) at a starting OD600 of 0.1. The cultures were incubated and allowed to
shake at 37 °C until an OD600 between 0.7 and 0.9 was reached. Protein
expression was then induced by the addition of pPrF or pAzF (100 µL, 100 mM),
20% arabinose (10 µL), and isopropyl β-D-1-thiogalactopyranoside (IPTG, 10 µL,
0.8 mM). The cultures were then incubated with and allowed to shake at 37 °C
for approximately 16 hours. The cells were then pelleted by centrifugation (5,000
rpm, 10 minutes) and then stored at -80 °C until purification.
Purified SSO Est was obtained by resuspending the cell pellet with 500 µL
Bugbuster (Novagen) containing lysozyme and 200 µL of lysis buffer. The
mixture was then incubated and allowed to shake at 37 °C for 20 minutes. The
mixture was then transferred to an Eppendorf tube and centrifuged at 13,200 rpm
for 10 minutes to pellet cellular debris. The supernatant was decanted into a
separate Eppendorf tube and incubated at 80 °C for 1 hour followed by
centrifugation at 13,200 rpm for 10 minutes. Purified SSO Est was obtained in
the supernatant and decanted into an equilibrated HisPur Ni-NTA spin (Qiagen)
column containing Nickel resin (200 µL) and SSO Est was purified according to
the manufacturer’s protocol. SDS-PAGE (BioRad 10% precise gels) was used to
analyze purified SSO Est. SDS-PAGE gels were run at 120V for approximately 2
hours, stained with Coomassie Brilliant Blue solution, and destained using a
solution containing 60% deionized water, 30% MeOH, and 10% glacial acetic
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acid. Gels were analyzed using a Bio-Rad Molecular Imager (Gel Doc XR+) gel
imager (Coomassie protocol) after 24 hours. Protein was used without further
purification.
Preparation of Epoxy Sepharose 6B Resin: Epoxy-activated 6B Sepharose
(GE Healthcare, 1 g) was added to a double filter syringe and washed with
deionized water (200 mL). The resin was dried via vacuum for 1 hour. Alkyn-ol (1
mL) and alcohol coupling buffer (5 mL, pH 13) were added to a vial. Dried resin
was added to the vial and the vial was shaken at 30 °C at 200 rpm for 16 hours.
The resin was transferred to a double filter syringe and washed 4 times with 5 mL
of alcohol coupling buffer. The resin was dried for 1 hour via vacuum. The
sepharose was transferred to a vial and capped with ethanolamine (2M, 844 µL)
and 7 mL of deionized water. The resin was shaken at 37 °C at 200 rpm
overnight then washed in a filter syringe with acetate buffer (0.1 M, pH 4) and
tris-HCl buffer (0.1 M, pH 8) using 3 alternating washes of 10 mL.
General Click Immobilization Conditions: The following reagents were added
to a sterile 1.5 mL eppendorf tube in the order listed: CuSO 4 (50 mM in H2O, 2
µL), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (5 mM in DMSO, TBTA, 20
µL), 20 µL SSO Est/pAzF, 30 mg derivatized Sepharose 6B resin (GE
Healthcare), tris(2-carboxyethyl)phosphine (50 mM in H2O, TCEP, 2 µL). The
reactions were then diluted in phosphate buffered saline solution at pH 7.4 (PBS,
6 µL). A control reaction was prepared using 20 µL SSO Est WT in place of SSO
Est/pAzF. A second control reaction was prepared using 20 µL SSO Est/pAzF,
30 mg derivatized Sepharose 6B resin (GE Healthcare), and 30 µL of PBS Buffer
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in place of the catalyst system. The reaction was incubated for 14 hours at 4 °C.
The reactions were then transferred to an empty spin column and washed with
1x PBS Buffer (10 x 200 µL) and centrifuged at 3,600 rpm for 1 minute. Resins
were then diluted in PBS Buffer (200 µL) and analyzed for protein activity via
assay.
General Glaser-Hay Immobilization Conditions: CuI (500 mM in H2O, 5 µL)
and tetramethylethylenediamine (500 mM, TMEDA, 5 µL) were added to a sterile
1.5 mL eppendorf tube and allowed to equilibrate for 10 minutes. Next, 30 mg
derivatized Sepharose 6B resin (GE Healthcare) was added and allowed to
equilibrate for an additional 10 minutes followed by the addition of 20 µL SSO
Est/pPrF. The reactions were then diluted in phosphate buffered saline solution
at pH 7.4 (PBS, 10 µL). A control reaction was prepared using 20 µL SSO Est
WT in place of SSO Est/pPrF. A second control reaction was prepared using 20
µL SSO Est/pAzF, 30 mg derivatized Sepharose 6B resin (GE Healthcare), and
10 µL of PBS Buffer in place of the catalyst system. The reaction was shaken at
200 rpm for 6 hours at 37 °C. The reactions were then transferred to an empty
spin column and washed with 1x PBS Buffer (10 x 200 µL) and centrifuged at
3,600 rpm for 1 minute. Resins were then diluted in PBS Buffer (200 µL) and
analyzed for protein activity via assay.
Arylesterase Assay: Prior to assay, purified SSO Est protein samples, were
concentrated using Corning Spin-X UF purification columns and diluted with 1x
PBS buffer to ensure uniform concentration between samples. Protein
concentrations were determined by UV-Vis absorbance at 280 nm. The reaction
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mixture was prepared in triplicate on ice by adding 2 µL of SSO Est TAG variant
protein to a mixture of 76 uL of 100 mM acetate buffer, 4 µL of 4-nitophenylhexanoate (0.114 g/mL), and 18 µL of 1x PBS (pH 7.4). A positive control mixture
was prepared in triplicate as described using 2 µL of SSO Est WT protein. A
negative control mixture was prepared in triplicate, containing an additional 2 µL
of 1x PBS and no protein. To analyze immobilization reactions, assay reactions
were prepared in triplicate as described previously with the exception of 15 µL of
diluted resin samples being used in place of a protein sample. Resins were
thoroughly resuspended by pipetting prior to transfer to ensure that equal
amounts of resin were analyzed in each trial. Control and reaction mixtures were
incubated at 80 °C for 30 minutes. The reaction was quenched using 100 µL of
distilled water saturated with Na2CO3. An absorbance reading was immediately
taken at 405 nm to measure product formation. A second absorbance reading
was taken at 405 nm after allowing the reactions to incubate at room temperature
for 1 hour.
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Chapter 6: Toward the Development of
Novel

UAAs

Containing

Silyl

and

Aldehyde Functional Groups
I. Introduction
Proteins are capable of a vast array of functions using the 20 natural
amino acids; however, they possess a relatively small range of functional groups,
limiting the number of possible chemical reactions that can occur using the
canonical amino acids.1 The genetic incorporation of amino acids containing
novel functional groups not found in the 20 canonical amino acids opens the door
for a wider variety of applications. The ability to encode novel functional groups
into the genetic code has allowed for modifications to be made to the structure
and function of proteins, which is applicable to several fields of study.1-4 The
addition of new amino acids to the genetic code has led to the development of
proteins with novel biological and pharmacological properties. 1 Furthermore, the
ability to incorporate UAAs has enabled researchers to improve their
understanding of processes within living systems in a nonintrusive manner.1,2
The incorporation of UAAs into proteins has allowed for a remarkable
number of applications.3 UAAs containing electron-withdrawing and electrondonating groups can alter the acid-base properties and redox potential of natural
amino acids, such as tyrosine, which can be useful in electron paramagnetic
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resonance (EPR) studies of radical chemistry.5,6 In addition, crosslinking UAAs
can be used to map protein interactions.7,8 Fluorescent UAAs can be used for
both the in vitro and in vivo labeling of proteins in a site-specific manner that
does not interfere with protein function.9 In addition, UAAs have been used as
both infrared and NMR probes.10,11 UAAs capable of interacting with certain
analytes have also been shown to play an important role as sensors by changing
properties of proteins, such as fluorescence, upon interaction with a specific
analyte.12 As previously described, chemically reactive UAAs can undergo
bioorthogonal chemical reactions to chemically link proteins to a synthetic moiety
in a site-specific manner.13,14 UAAs have also been used to encode posttranslationally modified UAAs, allowing researchers to understand and
characterize these PTMs.15 UAAs have been used for the development of
therapeutics owing to the ability to precisely control protein structure and
function. These techniques have been applied to cytokines, growth factors, and
antibodies to create bioconjugates, such as PEGylated proteins and antibodydrug conjugates, in which researchers are able to control the stoichiometry and
site of the reaction.4,16,17 UAAs can also be utilized to design proteins containing
enhanced or novel functions, which has been demonstrated through the use of
bipyridyl containing UAAs to design metal binding sites on proteins.18 The ability
to incorporate UAAs containing novel functional groups has greatly aided our
ability to understand and enhance protein structure and function in addition to
allowing for significant advances in therapeutics and diagnostics. The continued
development of new applications using UAAs underscores the need for
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continued exploration and development of UAAs containing novel functional
groups and their subsequent incorporation into proteins.
Trimethylsilyl (TMS) groups consist of three methyl groups bound to a
central silicon atom (Figure 6.1). These groups are relatively inert and have a
large molecular volume.19,20 TMS groups
have several applications making them
useful to chemists. They have been
applied within organic synthesis, serving
as protecting groups during chemical
Figure 6.1: The general structure of a
TMS group.

reactions

when

attached

to

reactant

molecules.19 They can later be removed using fluorinated compounds or HCl. 19
In addition, TMS groups can be added to phenols, carboxylic acids, and alcohols
allowing them to be more easily analyzed via mass spectrometry or gas
chromatography.20 Due to their large size TMS-containing UAAs may also serve
an important role in examining structure-function relationships in proteins. For
example, a key residue in the active site of a protein can be replaced with a
TMS-containing UAA to determine the impact of the residue on catalytic function.
In a similar manner, a TMS-containing UAA could be used to replace key
residues involved in protein folding to determine the role of specific residues in
protein folding patterns. TMS installation may block protein activity initially, but
function can be restored at a specific timepoint through removal of the TMS
group, which can occur relatively easily. To our knowledge, no TMS-containing
UAAs have been successfully synthesized and incorporated into proteins.
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A different approach to temporal control of protein function can be
achieved with a different UAA. Proteins can be manipulated exogenously using
stimuli such as light. Given the ability to control the wavelength and intensity of
light and its ability to be used in both a temporal and spatial manner, precise
control over protein function is possible when using light as a stimulus. 21 Protein
function can be regulated with light through the use of photochemical caging
groups.21 These caging groups inactivate the protein; however, their removal via
light irradiation can restore the function of the protein (Figure 6.2). 21 Onitrobenzyl groups are the
most

commonly

groups.21,22

photocaging
They

can

utilized

be

added

to

hydroxy, carboxy, thio, and
amino groups.21-23 Irradiation
using

UV

light

causes

Figure 6.2: Protein activation by UV light-induced
removal of a photocaging group.24

cleavage of these groups. Previous research has demonstrated the ability to
control protein activity in vivo using caged UAAs.21 In one example, a caged
tyrosine UAA, ONBY, was successfully incorporated into β-galactosidase. It was
shown that the replacement of a key tyrosine residue with ONBY reduced protein
activity to 5% of wild type levels; however, upon irradiation with 365-nm light,
protein activity was restored to nearly 67% of wild type levels.22 Several
applications have developed from this research including studies involving
phosphorylation, gene regulation, and perturbation of ion channels. 21 More
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recently, a UAA containing an alkyne modified dimethoxy-ortho-nitrobenzyl
caging group has been incorporated into E. coli.21 In addition to being
photocleavable, the UAA is able to undergo conjugation reactions to form a
bioconjugate, which can then be released upon irradiation. 21 This can be applied
to the delivery of cytotoxic drugs using antibody targeting agents.21 In this case, a
bioconjugate can be formed between the delivery agent and the small molecule.
Once the bioconjugate has been delivered to the cell, it can be photocleaved and
the drug can be released.21
Herein, the initial steps toward the synthesis of novel UAAs containing
TMS and caged aldehyde functional groups are described. First, several different
synthetic routes were explored to obtain TMS-containing UAAs. Upon
determination of the optimum synthetic route, we then made attempts to
incorporate this UAA into GFP utilizing aminoacyl-tRNA synthetases (aaRSs)
currently available in our laboratory. Several aaRSs with known promiscuity
which are able to
encode

multiple

UAAs were tested
first to eliminate
the need to evolve
a
Figure 6.3: Incorporation of the caged aldehyde UAA into GFP. Upon
incorporation, the caging group can be removed with UV light to
activate the protein.26

new

This
the

aaRS.25

represents
first

such

attempt to incorporate TMS-containing UAAs into proteins. In addition, the initial
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steps toward the development of a caged aldehyde UAA are described. Attempts
to incorporate the non-caged aldehyde UAA into GFP led to the discovery of two
synthetases which may have potential to be used for the incorporation of the
caged aldehyde UAA (Figure 6.3). Upon successful synthesis and incorporation
of these novel UAAs, their applications will then be explored.
II. Results and Discussion
A. Synthesis of the Silyl UAA
Several different starting materials and synthetic routes were explored for
the development of a novel UAA containing a TMS group. The first attempt
involved the use of trimethyl-p-tolylsilane (1) as the starting material. This starting
material already contains the desired silyl group; therefore, the synthetic route
used to obtain the desired product was aimed at synthesizing the amino acid
back bone followed by deprotection (Scheme 6.1). The first step involves allylic
bromination using NBS to obtain 2. The reaction involved heating at 110 °C for
approximately 1.5 hours. 2 was obtained in high purity, but a low yield of
approximately 30%.

The

next

step

involved

the

alkylation

of

diethyl

acetamidomalonate in the presence of a base to give 3, which was obtained in
relatively high purity, but a low yield of approximately 25%. Diethyl
acetamidomalonate is commonly used for synthesis of the general amino acid
backbone as it can be deprotected in the presence of acid or base. Initial
attempts to give 5 involved hydrolysis and decarboxylation of 3 using HCl to yield
the amino acid backbone; however, the addition of HCl also led to the removal of
the desired TMS group from the product. As a result, it was necessary to utilize
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NaOH for the deprotection of 3. Using this method, a mixture of 4 and 5 was
formed, primarily consisting of 4, which contains an acetamide group as opposed
to the desired amine found in amino acids. Because 4 and 5 were similar in
structure, differing only by the presence of an acyl group in 4, they were unable
to be effectively separated by column chromatography. As a result of this
difficulty, an acylase enzyme was utilized to remove the acyl group from 4 to
produce 5. The reaction was performed in potassium phosphate buffer at a pH of
8.0 by shaking the reaction at 215 rpm at 37 °C overnight. Based off the obtained
NMR spectra following this reaction, the acylase enzyme did not effectively
remove the acyl group as a mixture of 4 and 5 was still present. Because of the
inability to obtain 5, we sought to obtain a TMS-containing UAA through a different
methodology.

Scheme 6.1: The synthetic route used to obtain 5.
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The starting material for the next reaction was Boc-4-iodo-L-phenylalanine
(6), which is a derivative of the amino acid phenylalanine. Unlike the previous
synthesis, this starting material does not have the TMS group attached;
therefore, this synthesis involved the addition of the TMS protecting group,
followed by removal of the Boc and methyl protecting groups to form the amino
acid backbone (Scheme 6.2). Prior to addition of the TMS group, the carboxylic
acid of the starting material must first be protected. Methylation was carried out
using iodomethane in the presence sodium bicarbonate at 60 °C. The successful
addition of the methyl group was confirmed using NMR and 7 was obtained in a
moderate yield of 27.8%. The next step involved addition of the silyl group, which
was accomplished through the reaction of TMS acetylene with 7. The
Sonogashira reaction was catalyzed by CuI and Bis(triphenylphosphine)
palladium(II) dichloride and was carried out at room temperature. The product, 8,
was obtained in a moderate yield of 59% and the presence of the desired TMS
protecting group was confirmed using NMR. To obtain the deprotected product
(10), methyl deprotection was carried out using LiOH to obtain 9 followed
immediately by Boc deprotection using TFA. The NMR spectra revealed that the
silyl group was removed from the product resulting from the sensitivity of TMS
groups to acids, which were involved in the Boc deprotection step. Due to the
lack of a feasible method to remove the Boc group without the use of acid, an
alternative method for synthesis of the TMS-containing UAA was warranted using
a starting material containing different protecting groups.
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Scheme 6.2: The first synthetic route used to obtain 10.

It was hypothesized that the utilization of different protecting groups, which
do not require the addition of acid to be removed may facilitate the production of
the TMS-containing UAA. Fmoc-4-iodo-L-phenylalanine (11) was chosen as the
starting material for this reaction as the Fmoc group can be removed using a
base. Like the previous reaction, this starting material is a derivative of
phenylalanine. Because this starting material does not contain the desired silyl
group, the synthetic route for this reaction necessitates the addition of the silyl
group followed by deprotection of the Fmoc and methyl protecting groups to
obtain the amino acid. The first step of the reaction involves protection of the
carboxylic acid through methylation. The first attempt at methylation involving
sodium bicarbonate and iodomethane was unsuccessful as this reaction utilizes
a base, which caused removal of the Fmoc protecting group. As a result,
methylation involving thionyl chloride and methanol was utilized. Thionyl chloride
converts carboxylic acids into an acid chloride. The acid chloride then reacts with
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methanol to form the desired methyl ester protecting group. This reaction yielded
a white solid after 24 hours, and 12 was obtained in 99% yield. The next step
involved the addition of the TMS group using the addition of TMS acetylene to
12. The Sonogashira reaction was catalyzed by CuI and Bis(triphenylphosphine)
palladium(II) dichloride and carried out at room temperature for 24 hours. After
purification via column chromatography, 13 was obtained with a 93% yield.
Methyl and Fmoc deprotection of 13 can be carried out using 1 M LiOH and
dioxanes to yield 10.

Scheme 6.3: The second synthetic route used to obtain 10.

B. Synthesis of the Caged Aldehyde UAA
Synthesis of the caged aldehyde UAA was initiated using a similar
strategy initially attempted with the silyl UAA. The reaction scheme first
generated the aldehyde functionality followed by the coupling with the amino acid
backbone. This was then followed by addition of a photocleavable caging group
to the aldehyde and subsequent deprotection (Scheme 6.4). The starting material
for this reaction was 4-cyanobenzylbromide (14). The first step of the reaction
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involved reduction of 4-cyanobenzylbromide using DIBAL to obtain 15, which
was obtained in a moderate yield of 64% and high purity. The next step of this
reaction used 15 to alkylate diethyl acetamidomalonate in the presence of a base
to afford 16, which was obtained in relatively high purity, and very high yield of
approximately 85%. A portion of 16 was deprotected using 6M HCl to give 17
with an 80% yield. The remaining portion of 17 was then utilized for the caging
step. This step involved the addition of 1-(2-nitrophenyl)-1,2-ethanediol catalyzed
by pyridium-p-toluene sulfonate to give 18 with a yield of 37%. The low yield
most likely resulted from the fact that the reaction had not gone to completion.
This product was then deprotected using HCl; however, upon addition of HCl the
caging group was removed as was evident by the reappearance of the aldehyde
peak at 10 ppm on the NMR spectra indicating that 19 was not obtained.

Scheme 6.4: The synthetic route used to obtain 19.
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A Portion of 17 was diluted to 100 mM using deionized water. Various
aaRSs were assayed to determine if they could be used to successfully
incorporate 17 and eventually 19 into protein. pEVOL-pCNF, pEVOL-pAcF,
pEVOL-pCN 32, and pEVOL-pCN 32-65 aaRS plasmids were co-transformed
with a pET-GFP-TAG plasmid to determine their ability to incorporate 17 into
protein. Each of these plasmids encodes an orthogonal aaRS/tRNA pair which is
used to incorporate UAAs into proteins. These aaRSs contain mutations in
different locations, causing changes in their structure, which gives them different
recognition abilities toward different UAAs. Because this is a new UAA, relatively
promiscuous aaRSs were selected for these trials due to their ability to
incorporate multiple UAAs with varying structures. In order to test the
effectiveness of each synthetase for incorporation of 17, expressions were
carried out in which protein expression was induced using 100 µL and 200 µL of
a 100 mM solution of 17. An additional expression was carried out in which 17
was not added. In theory, truncated protein should result due to the lack of UAA

Figure 6.4: SDS-PAGE analysis of GFP 151 expression using pCN 32 and pCN 32-65 aaRSs
in the absence and presence of 100 µL and 200 µL of 17 (left) and fluorescence images of
GFP 151 in the absence and presence of 100 µL and 200 µL of 17 using pCN 32-65 (right).
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present, meaning that the aaRS cannot recognize and incorporate an amino acid
in response to the TAG mutation. Due to the promiscuity of some of the
synthetases being tested, tyrosine may be incorporated resulting in low levels of
protein expression. Proteins were analyzed via SDS-PAGE for differences in the
protein expression levels in the presence and absence of 17. Additionally,
proteins were examined for differences in fluorescence intensity. The pCN 32
and pCN 32-65 synthetases showed the greatest differences in band intensity
between expressions in the presence absence of 17 in SDS-PAGE gels. In
addition, these samples had a significant difference in fluorescence intensity
(Figure 6.4). It did not appear that addition of higher concentrations of 17
improved the ability of the synthetase to incorporate 17; therefore, the traditional
100 mM addition of UAA is sufficient.
Both the pCNF-aaRS and pAcF-aaRS
showed

nearly

identical

expression

levels in the presence and absence of 17
as

well

as

identical

fluorescence

intensities indicating that the UAA was
Figure 6.5: SDS-PAGE analysis of GFP
151 expressed in the absence and
presence of 100 µl and 200 µl of 17 using
the pEVOL pCNF aaRS.

not successfully incorporated (Figure
6.5). The protein expression obtained

using these synthetases most likely resulted from the incorporation of tyrosine as
opposed to 17 at the location of the TAG mutation.
In summary, three different synthetic routes have been employed toward
the development of a silyl-containing UAA. In the first two cases, the use of acid
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during deprotection to yield the amino acid backbone led to removal of the TMS
group. The third route appears to be the most promising option as it relies only
on base for the removal of protecting groups. Future work will involve
optimization of the deprotection of the methyl and Fmoc groups to obtain 10 and
the subsequent incorporation of 10 into protein. An aldehyde-containing UAA
was successfully synthesized and initial steps toward the incorporation of this
UAA have pointed toward the use of the pCN 32 aaRS and the pCN 32-65 aaRS
for the incorporation of 19 into protein. Attempts to add the caging group to 17
resulted in successful caging; however, upon deprotection using HCl, the caging
group was removed. In addition, the caged product was obtained in low yields.
Further work is required to optimize a decaging mechanism that is less harsh and
allows the caging group to remain attached.
III. Materials and Methods
General: Solvents and reagents were obtained from Sigma Aldrich, Alfa Aesar,
or Fischer Scientific and used without further purification. Reactions were
performed under ambient conditions with non-distilled solvents. NMR data was
acquired using a Varian Gemini 400 MHz NMR.
(4-(bromomethyl)phenyl)trimethylsilane (2): Trimethyl-p-tolylsilane (1) (500
mg, 1 eq., 3.00 mmol) was added to a flame-dried vial along with nbromosuccinimide (534 mg, 1 eq., 3.00 mmol), azobisisobutyronitrile (50 mg, 0.1
eq., 0.30 mmol), and chlorobenzene (10 mL). The reaction was stirred in a 110
°C oil bath for approximately 1.5 hours until a light orange color appeared. The
reaction was monitored by TLC. Upon completion, the reaction was quenched by
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placing the vial in an ice bath and adding 10 mL of ice water. The reaction was
washed 3 times using hexanes (30 mL). The organic layer was then washed 3
times using brine (20 mL). The organic layer was dried using anhydrous
magnesium sulfate, filtered, and solvent was evaporated under reduced pressure
to yield a solid (224 mg, 0.92 mmol, 30.3% yield). 1H NMR (CDCl3, 400 MHz): δ
7.60 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 4.55 (s, 2H), 0.36 (s, 9H).

Figure 6.6: 1H NMR of 2 in CDCl3.

Diethyl 2-acetamido-2-(4-(trimethylsilyl)benzyl)malonate (3): A portion of 2
was added to a flame dried vial (100 mg, 1 eq., 0.41 mmol) along with potassium
carbonate (113 mg, 2 eq., 0.82 mmol), potassium iodide (68 mg, 1 eq., 0.41
mmol), and diethyl acetamidomalonate (80 mg, 0.9 eq., 0.37 mmol). The mixture
was dissolved acetonitrile (8.5 mL) and stirred at 80 °C overnight. The reaction
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was monitored by TLC. The reaction was quenched by the addition of brine (5
mL). The reaction was extracted 3 times with ethyl acetate (15 mL) then the
organic layer was washed 3 times using brine (15 mL). The organic layer was
then dried using anhydrous magnesium sulfate, filtered, and solvent was
evaporated under reduced pressure to yield a solid. The product was then
purified using column chromatography (silica gel, 4:1 Hexanes/ethyl acetate) to
obtain a light brown solid (38.3 mg, 0.10 mmol, 24.6% yield). 1H NMR (CDCl3,
400 MHz): δ 7.40-7.36 (m, 2H), 6.97 (d, J = 7.6 Hz, 2H), 4.28-4.21 (m, 4H), 3.62
(s, 2H), 2.03 (s, 3H), 1.33-1.23 (m, 6H), 0.25-0.23 (m, 9H).

Figure 6.7: 1H NMR of 3 in CDCl3.
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2-acetamido-3-(4-trimethylsilyl)phenyl)propanoic acid (4): A small portion of
3 (10 mg, 1 eq., 0.033 mmol) was added to a flame-dried vial and dissolved in
acetone (2 mL) then mixed with 2M NaOH (2 mL). The reaction was stirred at 40
°C overnight. Acetone and NaOH were evaporated under reduced pressure to
yield a solid (7 mg). An impure mixture of 4 and 5 was obtained. NMR data is not
reported for this compound as pure product was not successfully obtained.

Figure 6.8: 1H NMR of the mixture of 4 and 5 in d-MeOH.

2-amino-3-(4-(trimethylsilyl)phenyl)propanoic acid (5): A portion of a mixture
of 4 and 5 (15 mg) was added to a flame-dried vial containing 100 mM (5 mL)
potassium phosphate buffer (pH 8.0). A catalytic amount of acylase enzyme was
added and the reaction was shaken at 215 rpm at 37 °C overnight. Potassium
phosphate buffer was evaporated under reduced pressure to yield a brown solid.
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The product was then dissolved in methanol (5 mL) and filtered to remove traces
of acylase enzyme. Methanol was evaporated under reduced pressure to yield a
light brown solid (14 mg). An impure mixture of 4 and 5 remained. NMR data is
not reported for this compound as pure product was not successfully obtained.

Figure 6.9: 1H NMR of the mixture of 4 and 5 in d-MeOH.

methyl 2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate (7): Boc4-iodo-L-phenylalanine (6) (500 mg, 1 eq., 1.28 mmol) was added to a flamedried round-bottom flask and dissolved in DMF (20 mL). Sodium bicarbonate
(323 mg, 3 eq., 3.85 mmol) and iodomethane (97 µL, 1.2 eq., 1.56 mmol) were
added. The reaction was stirred at 60 °C in an oil bath overnight. The reaction
was quenched using 10 mL brine. The product was extracted 3 times using ethyl
acetate (60 mL). The organic layer was washed 3 times using brine (40 mL),
dried using anhydrous magnesium sulfate, filtered, and solvent was evaporated
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under reduced pressure to yield an oil (144 mg, 0.36 mmol, 27.8% yield). 1H
NMR (CDCl3, 400 MHz): δ 7.57 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.0 Hz, 2H), 4.67
(q, J = 8.0 Hz, 1H), 3.67 (s, 3H), 2.92 (s, 2H), 1.37 (s, 9H).

Figure 6.10: 1H NMR of 7 in CDCl3.

methyl 2-((tert-butoxycarbonyl)amino)-3-(4-((trimethylsilyl)ethynyl)phenyl)
propanoate (8): A round-bottom flask and vial were flame-dried and flushed with
argon for 10 minutes. A portion of 7 (144 mg, 0.36 mmol, 1 eq.) was added to the
vial and dissolved in TEA (20 mL). The solution was flushed with argon for 10
minutes. A catalytic amount of CuI (20 mg) and Bis(triphenylphosphine)
palladium(II) dichloride (30 mg) were added to the round-bottom flask under
argon. The solution of 7 dissolved in TEA was transferred to the round-bottom
flask under argon. Trimethylsilylacetylene (100 µL, 2 eq., 0.71 mmol) was added
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dropwise to the reaction. The reaction was stirred at room temperature overnight.
The reaction was quenched with 10 mL brine and extracted 3 times in ether (30
mL). The organic layer was washed 3 times with brine (20 mL), dried using
anhydrous magnesium sulfate, filtered, and solvent was evaporated under
reduced pressure to yield a solid (138 mg, 0.37 mmol, 58.7% yield). 1H NMR
(CDCl3, 400 MHz): δ 7.38 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 4.60 (q, J
= 7.6 Hz, 1H), 3.69 (s, 3H), 3.10 (d, J = 8.0 Hz, 2H), 1.42 (s, 9H), 0.20 (s, 9H).

Figure 6.11: 1H NMR of 8 in CDCl3.

methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-iodophenyl)
propanoate (12): Fmoc-4-iodo-L-phenylalanine (11) (500 mg, 1 eq., 0.97 mmol)
was added to a flame-dried vial and dissolved in 5 mL methanol. Thionyl chloride
(141.5 µL, 2 eq., 1.95 mmol) was added dropwise. The reaction was stirred at
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room temperature overnight forming a white solid. The solid was dissolved in
ethyl acetate (15 mL). This solution was washed 2 times with brine (20 mL) and
once with saturated sodium bicarbonate (10 mL). The organic layer was dried
using anhydrous sodium sulfate, filtered, and solvent was evaporated under
reduced pressure to give a white solid (510 mg, 0.97 mmol, 99.4% yield). 1H
NMR (CDCl3, 400 MHz): δ 7.79 (d, J = 7.6 Hz, 2H), 7.62-7.58 (d, J = 8.0 Hz, 4H),
7.43 (t, J = 6.8 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H), 6.84 (d, J = 7.2 Hz, 2H), 4.744.65 (m, 3H), 4.47 (d, J = 7.2 Hz, 1H), 3.73 (s, 3H), 3.09 (d, J = 4.8, 2H)

Figure 6.12: 1H NMR of 12 in CDCl3.

methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-((trimethylsilyl)
ethynyl)phenyl)propanoate (13): A round-bottom flask and vial were flamedried and flushed with argon for 10 minutes. A portion of 12 (144 mg, 0.36 mmol,
1 eq.) was added to the vial and dissolved in TEA (20 mL) and DCM (20 mL).
The solution was flushed with argon for 10 minutes. A catalytic amount of CuI (20
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mg) and Bis(triphenylphosphine) palladium(II) dichloride (30 mg) were added to
the round-bottom flask under argon. The solution of 12 dissolved in TEA/DCM
was transferred to the round-bottom flask under argon. Trimethylsilylacetylene
(100 µL, 2 eq., 0.71 mmol) was added dropwise to the reaction. The reaction was
stirred at room temperature overnight. The reaction was quenched with brine (10
mL) and extracted 3 times in ether (30 mL). The organic layer was washed 3
times with brine (20 mL), dried using anhydrous magnesium sulfate, filtered, and
solvent was evaporated under reduced pressure to yield a solid. The product was
further purified using column chromatography (silica gel, 4:1 Hexanes/ethyl
acetate) to give a brown oil (0.448 mg, 0.981 mmol, 93.1 % yield). NMR data is
not reported as pure product was not successfully obtained.

Figure 6.13: 1H NMR of 13 in CDCl3.
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2-amino-3-(4-((trimethylsilyl)ethynyl)phenyl)propanoic acid (14): A portion of
13 (271 mg, 1 eq., 0.51 mmol) was mixed with LiOH (2 mL) and dioxanes (2 mL).
The reaction was stirred at 40 °C for 2 hours. Solvent was evaporated under
reduced pressure to yield a white solid (200 mg, 0.40 mmol, 78.0% yield). NMR
data and spectra are not reported as pure product was not successfully obtained.
4-(bromomethyl)benzaldehyde (15): 4-cyanobenzylbromide (14) (1.021 g, 1
eq., 5.08 mmol) was added to a flame-dried round-bottom flask. The flask was
then flushed with argon for 25 minutes. A second round-bottom flask was flamedried and toluene (25 mL) was added. The toluene was flushed with argon for 25
minutes. The toluene was then transferred to the first round-bottom flask under
argon. The reaction was flushed for an additional 5 minutes. Diisobutylaluminum
(7.2 mL, 0.008 eq., 0.040 mmol) was added dropwise. The reaction was stirred at
room temperature under argon for 2 hours followed by the addition of 10% HCl
(40 mL) and chloroform (13.2 mL). The reaction was stirred for an additional hour
at room temperature under argon. The reaction was extracted 3 times using brine
(75 mL), dried using anhydrous magnesium sulfate, filtered, and solvent was
evaporated under reduced pressure to yield a solid (650 mg, 3.27 mmol, 64.3%
yield). 1H NMR (CDCl3, 400 MHz): δ 10.01 (s, 1H), 7.87 (d, J = 6.4 Hz, 2H), 7.56
(d, J = 8.4 Hz, 2H), 4.51 (s, 2H).
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Figure 6.14: 1H NMR of 15 in CDCl3.

Diethyl 2-acetamido-2-(4-formylbenzyl)malonate (16): A portion of 15 (650
mg, 1 eq., 3.27 mmol) was added to a flame-dried round-bottom flask and
dissolved in acetonitrile (25 mL). Potassium carbonate (904 mg, 2 eq., 6.54
mmol),

potassium

iodide

(543

mg,

1

eq.,

3.27

mmol),

and

diethyl

acetamidomalonate (639 mg, 0.9 eq., 2.94 mmol) were added to the reaction.
The reaction was stirred at 80 °C overnight. The reaction was quenched with
deionized water (20 mL) then the product was extracted three times using ethyl
acetate (75 mL). The organic layer was washed 3 times using brine (60 mL),
dried using anhydrous magnesium sulfate, filtered, and solvent was evaporated
under reduced pressure. The product was then purified using column
chromatography (silica gel, 1:1 Hexanes/ethyl acetate) and solvent was
evaporated under reduced pressure to yield a white solid (937 mg, 2.79 mmol,
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85.6% yield). 1H NMR (CDCl3, 400 MHz): δ 9.98 (s, 1H), 7.78 (d, J = 8.4 Hz, 2H),
7.22 (d, J = 8.4 Hz, 2H), 4.29-4.25 (m, 4H), 3.74 (s, 2H), 2.04 (s, 3H), 1.30-1.25
(m, 6H).

Figure 6.15: 1H NMR of 16 in CDCl3.

2-amino-3-(4-formylphenyl)propanoic acid (17): A portion of 16 was added to
a flame-dried round-bottom flask and mixed with 6M HCl (15 mL). The reaction
was stirred at 90 °C overnight. HCl was evaporated under reduced pressure to
yield a brown solid (0.431 mg, 2.23 mmol, 79.8% yield). The resulting solid was
diluted to a concentration of 100 mM using deionized water. 1H NMR (d-MeOH,
400 MHz): δ 9.99 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.0, 2H), 4.82 (s,
1H), 3.41-3.29 (m, 2H).
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Figure 6.16: 1H NMR of 17 in d-MeOH.

2-amino-3-(4-(4-(2-nitrophenyl)-1,3-dioxolan-2-yl)benzyl)malonate (18): Two
vials were flame-dried and flushed with argon for 10 minutes. 1-(2-nitrophenyl)1,2-ethanediol (19 mg, 1 eq., 0.085 mmol), pyridium- p-toluene sulfonate (0.021
mg, 1 eq., 0.085 mmol), and anhydrous magnesium sulfate (20 mg) were added
to one of the vials. A portion of 17 (50 mg, 2 eq., 0.17 mmol) was dissolved in
anhydrous THF (2 mL) then transferred to the first vial under argon. The reaction
was protected from light and stirred at 40 °C in an oil bath for 24 hours. THF was
evaporated under reduced pressure. The product was then purified using column
chromatography (silica gel, 1:1 Hexanes/ethyl acetate) and solvent was
evaporated under reduced pressure to yield a solid (12 mg, 0.024 mmol, 37.2 %
yield). 1H NMR (CDCl3, 400 MHz): δ 8.13 (d, J = 8.0 Hz, 1H), 7.89 (t, J = 8.0, 1H),
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7.68-7.64 (m, J = 6.0, 2H), 7.49 (d, J = 6.8 Hz, 2H), 7.10 (d, J = 6.8 Hz, 2H), 6.54
(s, 1H), 4.32-4.25 (m, 5H), 4.04-4.00 (m, 2H), 3.71 (s, 2H), 2.04 (s, 3H), 1.331.29 (m, 6H).

Figure 6.17: 1H NMR of 18 in CDCl3.

Expression and Purification of GFP containing 17: A pET-GFP-TAG plasmid
(0.50 µL) was co-transformed with a pCN 32-65 plasmid (0.50 µL) into
Escherichia Coli BL21 (DE3) competent cells by heat shock using an Eppendorf
eporator electroporator. The cells were then plated (250 µL) on LB agar
containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL) and incubated
at 37 °C overnight. One colony was then used to inoculate LB media (4 mL)
containing ampicillin (50 µg/mL) and chloramphenicol (34 µg/mL). This culture
was then incubated and allowed to shake at 37 °C overnight. The following day,
this culture was used to inoculate an expression culture containing LB media (10
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mL), ampicillin (50 µg/mL), and chloramphenicol (34 µg/mL) at a starting OD600 of
0.1. The cultures were incubated and allowed to shake at 37 °C until an OD600 of
0.7 was reached. Protein expression was then induced by the addition of 20%
arabinose (10 µL), and isopropyl β-D-1-thiogalactopyranoside (IPTG, 10 µL, 0.8
mM), and 17 (100 µL, 100 mM). A negative control expression was set up by
inducing the expression in the absence of 17 and with the addition 20%
arabinose and IPTG as previously described. The cultures were then incubated
and allowed to shake at 30 °C for 16 hours. The cells were then pelleted by
centrifugation (5,000 rpm, 10 minutes) and stored at -80 °C until purification.
Purified GFP was obtained by resuspending the cell pellet in 500 µL of
Bug Buster (Novagen) containing lysozyme and 200 µL lysis buffer. The mixture
was incubated with shaking at 37 °C for 20 minutes. The mixture was then
transferred to an Eppendorf tube and centrifuged at 13,200 rpm for 10 minutes to
pellet out cellular debris. The supernatant was decanted into an equilibrated
HisPur Ni-NTA spin (Qiagen) column containing Nickel resin (200 µL) and GFP
was purified according to the manufacturer’s protocol. Purified GFP was
analyzed by SDS-PAGE (BioRad 10% precast gels, 120V, 2 hours). Gels were
stained with Coomassie Brilliant Blue solution, and destained using a destain
solution containing 60% deionized water, 30% MeOH, and 10% glacial acetic
acid. Gels were analyzed using a BioRad Molecular Imager (Gel Doc XR+) gel
imager (Coomassie protocol) after 24 hours. Protein was then concentrated and
buffer exchanged into PBS buffer at a pH of 7.4 using Corning Spin-X UF
purification columns. Protein was used without further purification.
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Chapter 7: Application of the SolidSupported Glaser-Hay reaction to
Natural Product Synthesis
I. Introduction
Polyyne core structures are prevalent in various natural products and
consist of a series of conjugated acetylenic units.1−3 Over 1,000 of these
naturally occurring molecules have been isolated from organisms such as
plants, fungi, and coral.2 These structures exhibit numerous biological activities
including antibacterial, antifungal, anti-HIV, and anticancer properties.3−7
Therefore, synthetic routes to the preparation of these structures are necessary
to further study their benefits and develop novel therapeutic analogs.
One approach to access these conjugated alkyne cores involves the
Glaser−Hay reaction. This reaction involves the coupling of two terminal alkynes
and was developed in the
1800s.8 The reaction was later
optimized

to

lower

the

temperature and increase the
rate of the reaction; however,
the lack of chemoselectivity
precluded

its

use,

as

a

Figure 7.1: Glaser−Hay coupling of terminal alkynes. (A)
Traditional Glaser−Hay reactions result in three diynes.
(B) Solid-supported Glaser−Hay reaction yields only the
heterodimeric product after resin cleavage.
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mixture of three coupling products could be obtained when using two unique
terminal alkyne reagents (Figure 7.1).9,10 This has been synthetically addressed
via the transition to the Cadiot−Chodkiewicz reaction between a halo-alkyne and
a terminal alkyne to differentiate the reaction partners.11,12 While this approach
does proffer a degree of chemoselectivity, homocoupling is still observed and
additional synthetic effort must be employed to prepare the halo-alkynes.13−15
Based on the asymmetrical nature of many of these natural product derivatives,
a more efficient mechanism to address chemoselectivity issues is required.
Recently, we reported the solid-supported Glaser−Hay reaction as a mechanism
to address several key pitfalls associated with the Glaser−Hay reaction.16−18
The solid-supported Glaser−Hay coupling requires the immobilization of
one terminal alkyne on a polystyrene resin. Subsequent reaction with another
soluble alkyne affords the asymmetrical diyne in high yield and purity.
Homodimerization of the immobilized alkyne is precluded by the pseudo-high
dilution conditions of the solid support, and homodimerization of the soluble
alkyne (used in excess) can simply be washed away from the solid support.
Moreover, we developed a methodology to perform these solid-supported
couplings with TMS-acetylene to sequentially add alkyne units, yielding highly
conjugated asymmetrical polyynes.16 Based on the success of this methodology,
we became interested in employing the solid-supported Glaser−Hay reaction
toward the synthesis of biologically relevant natural products. Herein, we report
the application of the reaction to the preparation of four natural products and their
subsequent screening for antibacterial activity.
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II. Results and Discussion
Many corals have been found to be rich in natural products that contain
antibacterial, antifungal, and cytotoxic properties. Specifically, numerous
acetylenic polyynes have been isolated from the genus Montipora, a velvet
coral.19 The most directly accessible natural product that lends itself to this
technology is 2,4-dodecadinyl alcohol (3), an asymmetrical diyne shown to
exhibit cytotoxicity against human tumor lines.2 Numerous research groups have
described the synthesis of this natural product.20−24 For example, Stefani et al.
report this synthesis via a Cadiot-Chodkiewicz coupling with a reported yield of
76%.24 However, this reported synthesis requires hazardous reagents and
requires a preliminary synthetic step to synthesize a halogenated alkyne.
Another synthesis reported by Fiandanese et al. requires numerous and
sometimes harsh reagents, six synthetic steps, and has a 42% yield. 23 Both
syntheses

also

required

tedious

purification

steps

postreaction.

We

hypothesized that the solid-supported Glaser−Hay reaction would be optimal to
obtain this product in fewer steps using milder conditions while affording higher
yields.
Immobilization of propargyl alcohol on a trityl chloride polystyrene resin (1)
at ∼0.7 mmol/g, as previously described,17 facilitated the subsequent Glaser−Hay
reaction with 1-nonyne (2) in the presence of a CuI/TMEDA catalyst system
(Scheme 7.1). Following successive DCM/MeOH washes of the resin, 3 was
cleaved from the resin using 2% TFA in DCM in 1 h. After a silica plug, 3 was
obtained in a 75% yield in high purity after essentially a single synthetic step.
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Analysis via 1H NMR,

13C

NMR, and GC/MS confirmed its identity and was in

accordance with previously reported literature values.23 Overall, utilizing the solidsupported Glaser−Hay methodology to synthesize this product eliminated harsh
reagents, halogenated precursor compounds, and synthetic steps required in
previously reported syntheses and produced the product in a better or
comparable yield.
A derivative of 3, Montiporic Acid A (5) is another common polyyne
isolated from this velvet coral species.2 Montiporic Acid A has been isolated from
the eggs of this coral and was shown to possess significant cytotoxicity against
P-338 murine leukemia cells. It has also been proven to be an efficient
antibacterial agent against E. coli.23 Conveniently, 5 can be accessed directly
from 3 via an SN2 reaction with 2-bromoacetate (4) followed by an ester

Scheme 7.1: The synthetic route used to obtain 5 from trityl chloride polystyrene resin (1) and
1-nonyne (2).

hydrolysis (Scheme 7.1) as previously reported. Synthesis of 5 was achieved in
good yield (49%) and analyzed via 1H NMR,
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13C

NMR, and GC/MS to confirm its

purity and identity. Thus, our methodology allowed us to prepare 5 in three
synthetic steps and in comparable yield to the previously reported synthesis that
required six steps.
This methodology can also readily be employed toward triyne natural
products. Toward this end, we initially targeted the preparation of octatriyn-1-ol
(8), originally isolated from a fungus, Kuehneromyces mutabilis, in 1973.25 This
compound and similar derivatives were shown to possess antibacterial
activities. Previous syntheses have utilized a Fritsch−Buttenberg−Wiechell
rearrangement to prepare the triyne core.26 Overall, this synthesis requires eight
synthetic steps to generate 8. This reported methodology also requires
numerous reagents, including some that are hazardous, and careful reaction
temperature control leading to an overall yield of only 3%.26
Building on our previously reported methodology for extending the
acetylenic scaffold,16 we developed a synthetic route toward octatriyn-1-ol
(Scheme 7.2), decreasing the synthetic steps and number of reagents used from
previous reports as well as increasing yield. Beginning with the previously
described propargyl alcohol polystyrene resin (1), TMS-acetylene (6) was
coupled using the Glaser−Hay conditions. The TMS group was then removed
using a TBAF/DCM solution, regenerating the terminal alkyne. Propyne (7) was
then coupled to the resin using the Glaser− Hay reaction and the product was
cleaved with a 2% TFA solution, affording the desired asymmetrical triyne natural
product, 8. Following a silica plug purification, 8 was obtained in a 68% yield and
analyzed by NMR and MS, which corresponded to previously reported values.
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This is a dramatic increase over the current literature synthesis, which was
performed with only a 3% overall yield and with an additional four steps.26

Scheme 7.2: The synthetic route used to obtain 8.

Finally, another triyne natural product is readily accessible using a similar
methodology to the preparation of octariyn-1-ol. Phenylhepta-2,4,6-trinyl acetate
(10) was originally isolated from several species of Bidens in the Aster family of
plants and has shown antibacterial properties.2 A previously reported synthesis
was utilized starting from 1,4-butynediol, and following the addition of a TBDPS
protecting group, it is reacted with a lithiated phenylacetylene and undergoes a
Fritch−Butenberg−Wiechell rearrangement to produce the triyne core.26 This
synthetic strategy requires eight total steps and the use of harsh chemical

Scheme 7.3: The Synthetic Route used to obtain 10.
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conditions, affording 10 in a 14% yield. Utilizing our previously described solidsupported strategy the triyne core is readily accessible in minimal steps and can
be further elaborated to generate the acetate (Scheme 7.3).
The previously described Glaser−Hay coupling with TMS followed by
TBAF-induced TMS deprotection was employed to prepare the immobilized
polyyne core, followed by the capping of the polyyne with phenylacetylene (9).
The solid support was then cleaved to afford the triynol product. The alcohol was
acetylated with acetic anhydride in the presence of DMAP to afford the desired
product. Upon acetylation, the reaction was extracted and washed with DCM/H2O
and dried with MgSO4. The triyne 10 was then purified on a silica column,
affording the desired natural product in a 46% yield, a marked improvement. The
product was then analyzed via NMR and MS and matched to previously reported
spectra. Utilizing the solid supported Glaser−Hay methodology we were able to
eliminate synthetic steps, as well as harsh and excessive reagents, and
drastically improve the yield of this natural product.
With the natural products in hand, we wanted to quickly assess their
antibacterial properties. Some have already been classified as antibacterial, while
others exhibited other biological relevance, but all harbor a similar alkynyl core.
Each of the products was dissolved in DMSO to generate stock solutions at 50
mg/mL. The compounds were then introduced in triplicate at various
concentrations to E. coli cultures at different cellular densities to assess if the
compounds either prevented bacterial growth (assay at low density) or simply
induced cell death (assay at high density). The cellular density of the bacteria
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was then observed over a 48-h period. When added to dense cultures (OD600 ≈
1), no decrease in cell density was observed with any of the natural products,
even at 5 mM concentrations (Figure 7.2).

Figure 7.2. E. coli screens with natural products prepared via the solid-supported Glaser−Hay
methodology. Compounds were added at varying concentrations up to 5 mM to cultures at
OD600 ≈ 1 (high-density assay) or OD600 ≈ 0.1 (low-density assay) in a 96 well plate.
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Chloramphenicol, a well-documented antibiotic, was used as a positive
control, and a significant decrease in bacterial density was observed at much
lower concentrations of 0.05 mM. However, when the natural products were
introduced to newly
inoculated E. coli
cultures, 5 and 8
prevented bacterial
growth at 2 μM
concentrations, and
10
Figure 7.3. E. coli screens with natural products prepared via the
solid-supported Glaser−Hay methodology. Cultures were inoculated
at an OD600 of 0.1 and grown in the presence of the compounds at
approximately 2 μM in a 96 well plate. The bacterial growth was
monitored at 6, 8, and 12 h. A DMSO control exhibited significant
culture growth, while a positive control of chloramphenicol at 0.05 mM
exhibited no growth. All cultures were grown in triplicate to establish
experimental error.

at

3

mM

concentrations. No
growth

inhibition

was observed for 3
at

even

higher

concentrations (Figure 7.3). This suggests that these natural products do indeed
possess antibacterial properties and can be easily prepared with the solidsupported Glaser−Hay methodology. Future work includes the use of more
sophisticated bacterial assays to determine their mechanism of action and their
investigation for other biological activity. Moreover, due to the modular synthesis,
various analogs can be rapidly generated to conduct an extensive SAR study to
further optimize their antibacterial properties. The application of the solid support
also facilitates a wide range of combinatorial strategies to be employed toward
the facile generation of large and varied polyyne libraries.
200

Overall, we have demonstrated that the solid-supported Glaser−Hay
reaction is a useful methodology in the synthesis of natural products. The
methodology has been employed to access four key natural products in fewer
synthetic steps, higher yields, and with less purification. These natural products
have been assessed for their antibacterial properties and found to be comparable
in efficacy to traditional antibacterials such as chloramphenicol.
III. Materials and Methods
General. Solvents and reagents were obtained from commercial sources and
used without further purification, unless noted. Tritylchloride resin, 100-200 mesh,
1% DVB crosslinking, was purchased from Advanced Chemtech. Reactions were
conducted under ambient atmosphere with non-distilled solvents. NMR data was
acquired on a Varian Gemini 400 MHz NMR. An Agilent J&W GC capillary
column (30 m length, 0.32 mm diameter, 0.25 nm film) was employed with a
splitless injection (250 ˚C inlet, 8.8 psi) with an initial 70 ˚C hold (2 minutes) and
ramped for 15 minutes to 230 ˚C. BL21(DE3) E. coli were obtained from Novagen
and cell growth was monitored using a microplate reader with a regulated
temperature.
Immobilization of Alcohol onto Trityl Chloride Resin in Low Loading
Conditions: Trityl chloride resin (200 mg, 0.36 mmol, 1 eq.) was added to a
flame-dried vial charged with dichloromethane (5 mL). The resin was swelled at
room temperature with gentle stirring for 15 minutes. Alcohol (25.0 μL, ∼1.2 eq.)
was added to reaction, followed by triethylamine (10.0 μL, 0.072 mmol, 0.2 eq.).
The mixture was stirred at room temperature for 16 hours. The resin was
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transferred to a syringe filter and washed with DCM and MeOH (5 alternating
rinses with 5 mL each). The resin was swelled in CH2Cl2 and dried under vacuum
for 45 minutes before further use.
Polyyne Extension Protocol: Trimethylsilylacetylene (160 μL, 1.05 mmol, 15
eq.) was added to a flame-dried vial containing the alcohol derivatized trityl resin
(100 mg, 0.070 mmol, 1 eq.) and tetrahydrofuran (2.0 mL). The CuI (20 mg, 1.06
mmol) and tetramethylethylenediamine (20 μL, 0.132 mmol) were added to a
separate flame-dried vial and then dissolved in tetrahydrofuran (2.0 mL). The
catalyst mixture was then added to the resin in one portion and stirred at 60 °C
for 16 hours. The resin was transferred to a syringe filter and washed with DCM
and MeOH (5 alternating rinses with 5 mL each). The TMS group was then
cleaved by incubation in 1 M tetra-n-butylammonium fluoride trihydrate in DCM
(TBAF, 1 mL, 1 hour). Then the reaction was again transferred to a syringe filter
and washed with DCM and MeOH (5 alternating rinses with 5 mL each) and dried
under vacuum for 45 minutes. Product was weighed and transferred to flamedried vial for future use.
Dodeca-2,4-diyn-1-ol (3):23 1-Nonyne (115 μL, 0.70 mmol, 10 eq.) was added to
a flame-dried vial containing the propargyl alcohol derivatized trityl resin (100 mg,
0.070 mmol, 1 eq.), and tetrahydrofuran (2 mL). CuI (10 mg, 0.053 mmol, ∼0.7
eq.) and tetramethylethylenediamine (30 μL) were added to a separate flamedried vial and then dissolved in tetrahydrofuran (2 mL). The catalyst mixture was
then added to the resin in one portion and stirred at 60 °C for 16 hours. The resin
was transferred to a syringe filter and washed with DCM and MeOH (5 alternating
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rinses with 5 mL each). The product was then cleaved from the resin by
treatment with 1 mL of 2% TFA (DCM, 1 h) and filtered into a vial. A short silica
plug was utilized to remove unreacted starting material (1:1 EtOAc/Hex), and
pure product was obtained (0.010 g, 0.052 mmol, 75% yield). 1H NMR (CDCl3,
400 MHz): δ 4.27 (s, 2H), 2.24 (t, J = 7.2 Hz, 2H), 1.55 (quint, J = 7.2 Hz, 2H),
1.39−1.31 (m, 2H), 1.30−1.19 (m, 6H), 0.90 (t, J = 6.9 Hz, 3H).

13C

NMR (CDCl3,

400 MHz): δ = 51.7, 31.8, 29.5, 28.7, 28.1, 22.4, 19.2, 14.0. GC: tR = 10.43 min;
MS: m/z calculated for C12H18O [M+]: 178.136; found: 178.092.

CDCl3

HO
3

H2O

3

Figure 7.4: 1H NMR of 3 in CDCl3.
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HO
3

CDCL

3

Figure 7.5: 13C NMR of 3 in CDCl3.

Figure 7.6: GC trace of 3.

Montiporic Acid A (5):23 Ethyl bromoacetate (10 μL, 0.10 mmol, 2 eq.) was
added at 10 °C to a vial containing 3 (0.010 g, 0.052 mmol, 1 eq.) dissolved in
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toluene (1 mL), 50% KOH (200 μL), and tetrabutyl ammonium sulfate (10 mg,
0.030 mmol, ∼0.5 eq.). The reaction was then vigorously stirred at 10 °C for 3
hours. Upon completion, the reaction was quenched with dilute HCl (5 mL),
extracted with EtOAc, and washed with water (3 × 5 mL). The product was then
dried over anhydrous MgSO4, and solvent was removed in vacuo. Purification
was performed via column chromatography (hexanes/EtOAc 10:1 to 1:3) to yield
the desired product (8 mg, 0.039 mmol, 49% yield). 1H NMR (CDCl3: δ 4.38 (s,
2H), 4.21 (s, 2H), 2.24 (t, J = 7.2 Hz, 2H), 1.49 (quint, J = 7.2 Hz, 2H), 1.34−1.31
(m, 2H), 1.29−1.19 (m, 6H), 0.84 (t, J = 6.9 Hz, 3H);

13C

NMR (CDCl3, 400 MHz):

δ 74.5, 71.1, 64.8, 64.6, 58.0, 51.5, 4.8; GC: tR = 11.02 min; MS: m/z calculated
for C14H20O3 [M+]: 236.141; found: 236.172.

Figure 7.7: 1H NMR of 5 in CDCl3.
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Figure 7.8: 13C NMR of 5 in CDCl3.

Figure 7.9: GC trace of 5.

Octatriyn-1-ol (8):26 The described polyyne extension protocol was used to
obtain the immobilized terminal alkyne diyne. 1-Propyne (53 μL, 0.70 mmol, 10
eq.) was added to a flame-dried vial containing the immobilized resin (100 mg,
0.070 mmol, 1 eq.) and tetrahydrofuran (2 mL). The copper catalyst (10 mg,
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0.053 mmol, ∼0.7 eq.) and tetramethylethylenediamine (30 μL) were added to a
separate flame-dried vial then dissolved in tetrahydrofuran (2 mL). The catalyst
mixture was then added to the resin reaction in one portion and stirred at 60 °C
for 16 hours. The resin was transferred to a syringe filter and washed with DCM
and MeOH (5 alternating rinses with 3 mL each). The product was then cleaved
from the resin by treatment with 1 mL 2% TFA (DCM, 1 hour) and filtered into a
vial. A short silica plug was performed to remove unreacted starting material (5:1
EtOAc/Hex), affording product 8 (4 mg, 0.040 mmol, 68% yield). 1H NMR (CDCl3,
400 MHz) δ 4.70 (s, 1H), 4.34 (s, 2H), 1.96 (s, 3H);

13C

NMR (CDCl3, 400 MHz):

δ 74.2, 71.1, 65.0, 64.8, 58.4, 51.7, 4.5; GC: tR = 10.99 min; MS: m/z calculated
for C8H6O [M+]: 118.042; found: 118.051.

CH 3
HO

8

CDCL 3

Figure 7.10: 1H NMR of 8 in CDCl3.
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CH
HO

CDCL

3

Figure 7.11: 13C NMR of 8 in CDCl3.

Figure 7.12: GC trace of 8.
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8

3

Phenylhepta-2,4,6-triynyl Acetate (10):26 The described polyyne extension
protocol

was

used

to

obtain

the

immobilized

terminal

alkyne

diyne.

Phenylacetlyene (0.70 mmol, 10 eq.) was added to a flame-dried vial containing
the starting material (100 mg, 0.070 mmol, 1 eq.) and tetrahydrofuran (2 mL).
The CuI (10 mg, 0.053 mmol) and tetramethylethylenediamine (30 μL) were
added to a separate flame-dried vial and then dissolved in tetrahydrofuran (2
mL). The catalyst mixture was then added to the resin reaction in one portion and
stirred at 60 °C for 16 hours. The resin was transferred to a syringe filter and
washed with DCM and MeOH (5 alternating rinses with 5 mL each). The product
was then cleaved from the resin by treatment with 1 mL of 2% TFA (DCM, 1
hour) and filtered into a vial. Solvent was removed in vacuo to afford the free
alcohol (10 mg, 0.056 mmol, 80% yield). Acetic anhydride (1 mL) and a catalytic
amount of DMAP were added and dissolved in 1 mL of DCM. The reaction was
allowed to stir at room temperature for 3 hours, followed by an extraction using
DCM/H2O (3 × 5 mL) and drying with MgSO4. The product was then purified on a
silica gel column using 5:1 Hex/EtOAc yielding 10 (9 mg, 0.041 mmol, 46%
yield), which was then analyzed via 1H NMR (CDCl3, 400 MHz): δ 7.70−7.61 (m,
2H), 7.56−7.32 (m, 3H), 4.85 (s, 2H), 2.16 (s, 3H);

13C

NMR (CDCl3, 400 MHz): δ

171.0, 134.5, 131.5, 129.9, 121.2, 78.5, 76.3, 74.3, 70.8, 66.2, 63.8, 53.1, 20.9;
GC: tR = 9.89 min; MS: m/z calculated for C15H10O2 [M+]: 222.068; found:
222.079.
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O
10

CDCL3

Figure 7.13: 1H NMR of 10 in CDCl3.

Figure 7.14: 13C NMR of 10 in CDCl3.
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H2O
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10

Figure 7.15: GC trace of 10.

Preparation of Stock Solutions. Following synthesis, each natural product
analog was transferred to a pre-weighed, flame dried vial. The mass of each
product was noted and dimethyl sulfoxide (DMSO) was added (between 40 to
180 µL) to create 50 mg/mL stock solutions of each product. Each solution was
then transferred to eppendorf tubes and stored at -26 °C.
Preparation of Working Plate. A serial dilution of the stock solution for each
product was performed in order to produce working solutions with concentrations
of 5, 0.5, 0.05, and 0.005 mg/mL. For each product, the stock solution was
transferred (15 µL) into the well of a 96 well microplate (Greiner Bio- One).
DMSO (135 µL) was subsequently added to the well to create a 5 mg/mL solution
of the product. The 5mg/mL solution (15 µL) was then pipetted into a neighboring
well and DMSO (135 µL) was added to create a 0.5 mg/mL solution. This
process was repeated to form the 0.05 mg/ml and 0.005 mg/mL solutions,
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respectively. Similarly, a serial dilution of chloramphenicol (34 mg/mL) was plated
as well as DMSO controls. The completed plate was stored at -26°C.
Low Cell Density Absorbance Assay: Luria−Bertani (LB) media (10 mL) was
inoculated with the Escherichia coli Novagen BL21(DE3) strain of cells and then
incubated for 16 hours at 37 °C. Optical density measurements on a
spectrophotometer at 600 nm (OD

600)

were used to assess the density of the

starter culture. The culture was diluted to an OD600 of 0.1 (low density) by addition
of fresh LB media. In a new 96 well microplate (Greiner Bio-One), the solutions of
varying concentration for each product from the working plate were plated
including chloramphenicol and DMSO (20 μL). Subsequently, the low-density cell
solution was added to each well in which solution had been previously added. An
initial absorbance was read using a Synergy HT Microplate Reader set to shake
the plate for 10 seconds prior to reading the OD600. An absorbance reading was
taken again at 2, 4, 6, 8, 12, and 24 hours. Between OD600 readings the
microplate was allowed to shake at 37 °C.
High Cell Density Absorbance Assay. Luria-Bertani (LB) media (10 mL) was
inoculated with Escherichia coli Novagen BL21(DE3) strain of cells and then
incubated for 16 hours at 37 °C. Optical density measurements taken on a
spectrophotometer at 600nm (OD600) were used to assess the density of the
starter culture. The culture was diluted to an OD600 of 1 (high-density) by addition
of fresh LB media. In a new 96 well microplate (Greiner Bio- One), the solutions
of varying concentration for each product from the working plate were plated
including chloramphenicol and DMSO (20 µL). Subsequently, the high-density
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cell solution was added to each well in which solution had been previously
added. An initial absorbance was read using a Synergy HT Microplate Reader
set to shake the plate for 10 seconds prior to reading the OD 600. An absorbance
reading was taken again at 2, 4, 6, 8, 12, 24 hours. Between OD600 readings the
microplate was allowed to shake at 37 °C.
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